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ABSTRACT 
             Bovine herpesvirus (BoHV-1) is an important bovine pathogen. The ul47 gene-encoded 
VP8 is the most abundant protein of the BoHV-1 virion. VP8 is indispensable for BoHV-1 
infection in cattle and a UL47-deleted virus exhibits drastic reduction in replication in tissue 
culture. The reason for the inability of UL47-deleted virus to replicate in cattle is unknown. 
Interferons (IFNs) secreted in response to viral infection trigger translocation of signal transducer 
and activator of transcription (STAT1) to the nucleus for induction of IFN-stimulated genes. We 
observed that VP8 interacts with STAT1 through two regions, amino acids 259-482 and 632-741. 
IFN-β production was significantly reduced in BoHV-1- but not in BoHV-1ΔUL47-infected cells. 
VP8 did not alter STAT1 phosphorylation or degrade STAT1, but inhibited nuclear translocation 
of STAT1 to reduce IFN-β production. Thus, VP8 plays a vital role in inhibition of IFN-β 
signaling via interaction and sequestration of STAT1 in the cytoplasm.  
  VP8 also interacted with Ataxia telangiectasia mutated (ATM) and Nijmegen breakage 
syndrome-1 (NBS1), which are critical components in the DNA damage response. Association of 
VP8 with ATM and NBS1 did not affect ATM, but inhibited NBS1 activation. Consequently, 
phosphorylation of structural maintenance of chromosome-1 (SMC1), the downstream regulator 
of the ATM/NBS1 pathway, was abolished. BoHV-1 but not BoHV-1ΔUL47 infection inhibited 
NBS1 and SMC1 phosphorylation. In addition, VP8 induced apoptosis through caspase-3 
activation. Hence, VP8 blocks the ATM/NBS1/SMC1 pathway resulting in induction of 
apoptosis, which reveals a role of VP8 in the modulation of the DNA damage response. 
  We identified heat shock protein-60 (HSP60) as a mitochondrial interacting partner of 
VP8. VP8 co-localized with HSP60 in the mitochondria. Association of VP8 with mitochondria 
reduced mitochondrial membrane potential (MMP) and adenosine triphosphate (ATP) 
production. Mitochondrial functions were impaired in BoHV-1- but not in BoHV-1ΔUL47-
infected cells. Thus, VP8 might contribute to the deregulation of mitochondrial functions.  
 These results demonstrate that VP8 plays a crucial role during BoHV-1 infection by 
down-regulating IFN-β signaling, inhibiting the DDR pathway and deregulating mitochondrial 
functions. These functional characteristics of VP8 provide a (partial) explanation for the defective 
replication of BoHV-1ΔUL47 in cell culture and its lack of virulence in cattle.  
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CHAPTER 1 	
LITERATURE REVIEW 
1.1          Introduction. 
1.1.1       Classification of BoHV-1. 
  Bovine herpesvirus-1 (BoHV-1) is an important bovine pathogen. BoHV-1 belongs to 
the family herpesviridae, the subfamily alphaherpesvirinae, and the genus varicellovirus. To 
date, all isolated BoHV-1 strains are differentiated into the following subtypes: 1.1, 1.2a, 1.2b 
and 1.3 (1).  The BoHV-1 subtype 1.1 is associated with the clinical manifestation of respiratory 
diseases, whereas the subtype 1.2a is predominantly responsible for respiratory and genital 
infections (2). Subtype 1.1 strains are more pathogenic than subtype 1.2b strains (3). The subtype 
1.3 strains are frequently associated with the respiratory infections (2, 4). Although different 
BoHV-1 subtypes are involved in a similar range of infections, a definitive identification of the 
strains depends on viral DNA analysis (5, 6). The most common strain is subtype BoHV-1.1 that 
tends to cause a variety of clinical manifestations in cattle. 
 
1.1.2      Clinical Manifestations and Economic Importance. 
 BoHV-1 is a causative agent of severe contagious diseases in cattle. It is responsible for 
multiple clinical symptoms ranging from immune suppression, respiratory tract infections genital 
disorders, and vulvovaginitis to abortions in cattle (7). The most severe form of the disease is 
infectious bovine rhinotracheitis (IBR) (7, 8). BoHV-1 transmission is facilitated through either 
direct contact with the infected animal or exposure of mucosal surfaces to virus. In some cases, 
airborne transmission also occurs in susceptible animals (9). Other transmission routes include 
mating and artificial insemination within and from infected cattle, respectively (2). Therefore, 
genital disorders and abortions are more prevalent in breeding cattle. Primary infection with 
BoHV-1 starts with the association of virus at mucosal surfaces followed by a 1-6 day incubation 
period (10). Following incubation, infected animals develop clinical symptoms of respiratory 
disorders including nasal discharge, high fever, salivation and coughing (11). Occasionally, 
abortion is coupled with acute respiratory infection, although it can be triggered by BoHV-1 
reactivation within 100 days of primary infection. BoHV-1 subtype 2a and 2b sometimes cause 
genital infections with increased urination symptoms (10).  
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 Primary infection of BoHV-1 is frequently associated with secondary infections that 
extend the severity of disease. BoHV-1 infection results in immune suppression in the infected 
cattle. The impaired immune system together with BoHV-1 infection provides an environment 
suitable for infection with secondary pathogens including bovine viral diarrhea virus (BVDV), 
bovine parainfluenza virus-3 (BPIV-3), bovine respiratory virus (BRSV) and bacterial causative 
agents, such as Mannheimia haemolytica, Mycoplasma bovis, and Pasteurella multocida (12), 
leading to bovine respiratory diseases complex (BRDC) or shipping fever (7). BRDC symptoms 
include anorexia, excessive salivation, high fever, and nasal discharge. BoHV-1-induced BRDC 
is facilitated by down-regulation of major histocompatibility complex (MHC) class I (13, 14) and 
induction of apoptosis of infected cells (15). 
 The severity of BoHV-1 infection and secondary infections results in significant losses 
to the cattle industry (16, 17). Infection with BoHV-1 introduces IBR, BRDC, and other genital 
disorders, causes a significant reduction in animal productivity including weight loss and a 
decrease in milk production (7, 18). A recent report indicated a significant decrease in average 
daily milk production in BoHV-1-infected animals compared to non-infected animals (19). Due 
to BoHV-1-associated genital disorders, the abortion rate is increased in BoHV-1-positive 
animals (20). Genital disorders can result in infertility. During early pregnancy, BoHV-1 
infection may also cause early embryonic death. Experimentally, BoHV-1-associated abortion 
has been observed anytime during gestation. However, in field conditions, BoHV-1-associated 
abortions were detected in the second half of gestation (21, 22). In Western Turkey, more than 
50% of abortions in cattle is caused by BoHV-1 infection (23). A recent study from India 
reported that BoHV-1 was responsible for causing 21.4% abortion in the state of Punjab. In 
addition, in North-Africa the majority of the abortions, 42%, were attributed to BoHV-1 infection 
(24). Moreover, BoHV-1 infection is associated with other economic issues including reduced 
show value due to bilateral conjunctivitis, restlessness and restriction in international livestock 
trading (18). 
                      
1.1.3       Host Range of BoHV-1.           
  The host range of BoHV-1 is limited. Although herpes simplex virus-1 (HSV-1) and 
BoHV-1 belong to the same alphaherpesvirus family, BoHV-1 is restricted to hosts cattle and 
buffalo (25). The host and viral factors determine the ranges of virus infection in the host. 
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Successful virus infection is closely associated with viral attachment and penetration into host 
cells followed by viral DNA replication and export of virus particles (26). BoHV-1 naturally 
infects cattle and buffalo. However, BoHV-1 also infects and causes diseases in goats and sheep 
(27). In addition, BoHV-1-specific antibodies have been detected in Asian elephants (Elephus 
maximus) with no clinical symptoms (6). In some cases, this virus has also been isolated from 
ferrets, antelope, and wildebeest without causing disease (28). BoHV-1 is not infectious to mice, 
rats, guinea pigs or chick embryos. However, immunocompromised mice lacking interferon 
receptors can be infected with BoHV-1 (29). Rabbits can be infected experimentally if BoHV-1 is 
introduced into the conjunctival sac of a rabbit’s eye (30). There are no reports of BoHV-1 
infection either in human or in human cell lines.  
 
1.1.4	 Pathogenesis	of	BoHV-1.																				BoHV-1 starts a productive infection at the mucosal surfaces. It primarily infects 
epithelial cells in the upper respiratory airway and genital tract mucosa. Viral entry into the cell is 
mediated through interaction between viral glycoproteins and host cell receptors (31). The lytic 
replication cycle of virus initiates with the entrance of the virus followed by subsequent viral 
gene expression and leads to the production of new progeny viruses. The progeny viruses are 
released into the extracellular environment. Subsequently, the extracellular viruses are spread 
throughout the infected host either by local dissemination or by systemic spread  (viremia) (1). 
Viral spread through viremia or blood circulation gains access to distant organs or tissues causing 
clinical symptoms including abortion (32). Besides primary infection at the mucosal surfaces, 
BoHV-1 neuroinvasion occurs by cell-to-cell spread (11). The virus also establishes a latent 
infection in the sensory neurons of the peripheral nervous system. Reactivation from latency 
occurs when the latently infected animal is under stress or during transport from one place to 
another (33). Stress increases corticosteroid levels that trigger latency reactivation. Once 
reactivated, the BoHV-1 lytic replication cycle starts, which leads to production of infectious 
virus particles. Following reactivation infected cell protein 0 (ICP0) promoter activation triggers 
lytic gene expression (34). 
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1.2.  Structural composition of BoHV-1. 		The BoHV-1 virion is composed of four different components.  The double-stranded 
DNA genome is enclosed within a capsid; the nucleocapsid is surrounded by a thick layer 
containing inner and outer tegument proteins, and an outer lipid envelope with glycoproteins. A 
schematic diagram of the BoHV-1 structure is presented in Figure 1.1. 
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Figure. 1.1 A schematic diagram of BoHV-1 virion structure demonstrating enveloped 
glycoproteins, tegument proteins and nucleocapsid including DNA.   
The BoHV-1 virion consists of four different compartments, the lipid envelope containing 
glycoproteins, tegument proteins, capsid, and double-stranded DNA. 																		
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1.2.1 BoHV-1 Genome.  
  BoHV-1 is an enveloped double-stranded DNA virus with approximately 135 kilobase 
pair (kbp) genome (35). Based on the presence of inverted or directly repeated sequences, the 
herpesviruses genomes are categorized as A-F genomes. The BoHV-1 genome belongs to the 
class D genome. Class D herpesviruses include varicella-zoster virus (VZV), pseudorabies virus 
(PRV) and equine herpesvirus 1 (EHV-1). The BoHV-1 genome consists of two unique 
sequences, a unique long (UL) and a unique short (US) sequence. The L segment is fixed in a 
single orientation or prototype (P) orientation, whereas the S segment is flanked by large inverted 
repeats (36). During packaging of the virus, the long linear double-stranded DNA or concatemer 
is cleaved into individual genomes. During packaging the concatemer DNA is cleaved, and the 
orientation of the L segment is altered to form inverted L genome. The DNA is then packaged 
into the virion. Thus, the concatemeric DNA contains a large number of L segments, while the 
virion DNA consists of a low level of inverted L segments (36). The BoHV-1 genome is 
composed of 73 open reading frames (ORF) (37). Among them, 33 ORFs are essential and 36 are 
identified as non-essential. Based on in vitro replication characteristics the importance of the 
remaining two dual copy ORFs is yet to be determined (38).  
 
1.2.2 Envelope glycoproteins of BoHV-1. 
  The envelope of BoHV-1 contains 11 glycoproteins. These glycoproteins are involved in 
several steps of virus infection. Glycoproteins are responsible for initial attachment of the virus to 
the host cell, subsequent penetration, and virus spread between cells (39, 40). Thus, glycoproteins 
determine the viral tropism for tissues and organs. The identified BoHV-1 glycoproteins are gB 
(UL27), gD (US6), gC (UL44), gD (US6), gE (US28), gG (US4), gH (UL22), gI (US7), gK (UL53), 
gL (UL1), gM (UL10) and gN (UL49.5)(7). According to a recent study the BoHV-1 virion 
contains nine glycoproteins, gB, gC, gD, gE, gG, gH, gI, gM, and gL, whereas the other two, gN 
and gK, were found in the infected cells but were not present in the virion (41). However, the 
absence of gN and gK in the BoHV-1 virion has been shown in one study only, so further 
confirmation is needed. The functions of these glycoproteins will be discussed below. 
 The three major glycoproteins of BoHV-1 are associated with various functions. The 
major glycoproteins of BoHV-1 are gB, gC, and gD, which can contribute to the virus attachment 
(39) and can induce immune protection (42). gB is a major component of the virion envelope and 
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one of the essential proteins of BoHV-1 (39). gB plays a crucial role in viral entry including 
attachment and penetration of the virus and subsequent virus spread. During viral entry, gB and 
gC initially bind to the cell surface heparan sulfate (43). Following the initial binding, gD and gB 
bind strongly to cell surface receptors, non-heparan sulfate (HS) and HS component, respectively 
(44). gB and gD are responsible for membrane fusion during viral entry (44, 45). gC is not 
essential for viral entry into the host cells, although deletion of gC attenuates the virus (39). 
Moreover, intramuscular immunization of gB, gC, and gD generates a high level of neutralizing 
antibodies, which protects cattle from the disease (42). This demonstrates that these proteins have 
antigenic properties (46). Thus, these glycoproteins are involved in multiple functions including 
virus attachment, entry, and spread. 
 Glycoproteins gE and gI are conserved in all alphaherpesviruses. gE and gI are not 
essential for virus growth in tissue culture (47). gE and gI are known to form a functional 
complex that is required for cell-to-cell spread as gE and gI deletion mutant viruses generate 
smaller plaques (48). Although gE and gI form complexes, a single deletion of either gene 
demonstrated some distinct characteristics. Incorporation of gE into the virion is not dependent 
on gI expression, but gE is essential for the integration of both gE and gI into the BoHV-1 virion 
(48). In a gE-negative virus, the gI is produced and released into the extracellular medium 
without being incorporated into the virion. A gE deletion mutant contributes to viral attenuation 
(49). Moreover, gE is relatively immunogenic and suitable as an antigenic marker (50). A gE-
negative strain also elicits protective immunity and allows serological differentiation, indicating 
the potential use of a gE-deleted virus as a vaccine (50, 51).  
              The glycoprotein gG of BoHV-1 is secreted into the medium, interacts with chemokines 
and inhibits chemokine activity by blocking their interaction with their receptors (52). A gG-
deletion mutant is less virulent indicating that the gG gene has immune evasion properties (53). 
gG facilitates junctional adherence among BoHV-1-infected cells and thus mediates cell-to-cell 
spread (40).  Furthermore, BoHV-1 gG is an anti-apoptotic viral factor and contributes to the 
establishment of infection (54). 
 BoHV-1 gH is necessary for virus entry into the target cells (55). For proper 
antigenicity, processing, and transport, gH forms a complex with another glycoprotein, gL (56). 
Moreover, the gH-gL complex induces a neutralizing antibody response and mediates anchoring 
of gL to the plasma membrane (56). This complex contributes to cell penetration but not 
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attachment (57). BoHV-1 gK is another essential glycoprotein with a molecular mass of 36 kDa.  
gK is comprised of four transmembrane domains with an N-terminal cleavable signal (56). gK 
interacts with UL20 and is essential for virus production and spread (58).  
  Glycoprotein gM is encoded by the UL10 gene and is associated with the virion and 
plasma membrane. gM plays a role in membrane penetration as well as cell-to-cell fusion. 
Deletion of gM in most herpesviruses suggests that it is dispensable for viral replication in vivo or 
in vitro (59-61). During BoHV-1 infection gM forms a complex with gN that is necessary for gM 
processing (62). In addition, PrV (pseudorabies virus) gM is involved in secondary envelopment 
(63) (64).  
 
1.2.3      Role of alphaherpesvirus tegument proteins. 
1.2.3.1   Role of tegument proteins in virion dissociation. 
 The space between the capsid and envelope of an extracellular virion is termed the 
tegument and contains several proteins that are called tegument proteins. The tegument of 
Alphaherpesvirinae consists of ~ 23 proteins (65). A growing range of functions is attributed to 
these tegument proteins throughout the course of a viral infection. Immediately after entering into 
the host cells, the virus releases its outer tegument proteins into the cytoplasm of the infected cell 
while some inner tegument proteins remain attached to the capsid (66). Virion tegument protein-
mediated functions include but are not limited to: virus entry (67), transporting virion 
components to the nucleus, regulation of host or viral gene expression, immediate early gene 
transactivation (68), initiation of viral replication, and immune evasion (69).   
 During viral entry, attachment is not dependent on the tegument proteins but on the 
interaction of viral glycoproteins with host cell receptors. HSV-1 viral entry is often 
accomplished by the pH-independent endocytic pathway (70) or pH-dependent pathway (71). 
Immediately after entry, tegument dissociation depends on an energy consumption reaction such 
as phosphorylation that involves adenosine triphosphate (ATP), enzymes and ions (Mg+) (72). 
Since inactivation of virion-associated kinase activity by heat treatment completely blocks virion 
dissociation, phosphorylation is suggested as a mechanism of virion tegument proteins 
dissociation (72). Thus, different tegument proteins become the substrates of cellular kinases to 
facilitate tegument protein dissociation (72). For instance, cellular kinase-2 (CK2)-mediated 
phosphorylation of VP22 (viral protein) triggers the dissociation of VP22 from the HSV-1 virion. 
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Some viral kinases, such as US3 (73) and UL13 (74) are incorporated into the virion to 
phosphorylate themselves or others to promote tegument dissociation (72). 
 Tegument protein dissociation from the incoming virion is correlated to the sequence of 
tegument protein incorporation during viral packaging. For instance, proteins that are 
incorporated into the tegument earlier during the infection cycle dissociate from the virion later 
than those incorporated later (75). Following entry, most of the tegument proteins leave the 
nucleocapsid, while a few remain associated with the capsid (66, 76). Inner tegument proteins 
such as US3, UL36 and UL37 are associated with the nucleocapsid during its transport to the 
nucleus (77), whereas outer tegument proteins UL41, UL11, UL48, UL47 and UL49 are lost in the 
cytoplasm immediately after entry (66). A BoHV-1 virion demonstrating the inner and outer 
tegument proteins is illustrated in Figure. 1.1. 
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Table 1.1 Functions of HSV-1 tegument proteins. 
 
Tegument protein Functions References 
Roles in Dissociation 
US3 
 
Phosphorylates tegument proteins to be disassembled 
 
(72) 
UL13 Triggers viral tegument dissociation by    
phosphorylating other tegument proteins 
(72) 
UL49 
 
Promotes dissociation of other tegument proteins  (72) 
Role in transporting capsid 
             US11 Promotes anterograde transport of capsid (78) 
ICP0 Delivers viral capsid to the nuclear periphery through   
ubiquitin ligase activity 
(79) 
UL14 Targets capsid to the nucleus (80) 
UL35 
 
Interacts with dynein to transport capsid to the nucleus 
 
(81) 
 
UL36 Promotes nuclear translocation of incoming capsid, 
co-ordinates with UL37 for maximal viral DNA 
delivery, 
promotes retrograde capsid transport toward the soma 
of neurons, and 
discharges viral DNA from capsid 
(82-84) 
UL37 Translocates incoming virus capsid to the nucleus, 
 and promotes maximum delivery of viral DNA 
(85) 
Roles in gene expression 
ICP0 Counteracts antiviral responses, leads transition from α 
to β gene transcription 
(86-88) 
ICP4 Functions as both transcriptional activator and repressor (89, 90) 
ICP34.5 Activates cellular translation initiation factor 2 (91, 92) 
		
	 11	
UL14 Promotes nuclear localization of UL48 to indirectly 
regulate IE or α gene transcription 
(80) 
UL37 Influences transcriptional activation of IE genes (93, 94) 
UL41 Degrades mRNA to promote viral mRNA turnover (69, 95) 
UL46 Enhances UL48-mediated gene transcription (96) 
UL47   Facilitates UL48-mediated transcriptional activity (96) 
UL48 Initiates immediate early gene transcription (97, 98) 
UL49 Virion incorporated UL49 RNA influences gene 
expression 
(99) 
    Roles in assembly and egress 
              US2 
 
Involves in trafficking of virion to apical surface (100) 
US3 Phosphorylates UL31 and UL34 for maximal egress 
efficiency and phosphorylates gB at outer nuclear 
membrane 
(101-103) 
UL11 Forms tripartite complex with UL16 and UL48, 
establishes connection between tegument and 
membrane 
(104-106) 
UL16 Interacts with UL21 and UL11 to promote 
tegumentation of capsid, and 
secondary development and cell to cell spread 
(104, 105) 
UL21 Interacts with UL16 and UL11, facilitates additional 
tegumentation, promotes virus egress 
(106) 
UL31 Forms complex with UL34 to facilitate nuclear egress of 
nucleocapsid 
 
(107-109) 
UL34 Interacts with UL31 to promote nuclear egress of 
nucleocapsid 
(109, 110) 
UL36 Facilitates capsid maturation, contributes to the 
tegumentation of capsid, promotes incorporation of 
UL48 into the capsid 
(106, 111, 
112) 
UL37 Promotes virus maturation, facilitates tegumentation of (106, 113) 
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capsid 
UL48 Forms complex with UL41, UL46, UL47, and UL49, 
links envelope and capsid during virion formation 
(114-116) 
UL49 Facilitates complete virion formation (117-119) 
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1.2.3.2   The role of tegument proteins in transporting capsid to the nucleus. 
 Tegument proteins facilitate transport of capsid to the nucleus. Following the 
dissociation of outer tegument proteins, the capsid is transported to the nucleus through 
microtubule-dependent interaction of inner tegument proteins with a cytoplasmic dynein/dynactin 
complex (81, 120). HSV-1 UL35 has been found to interact with dynein suggesting that it might 
contribute to the transport of the nucleocapsid to the nucleus (81). Moreover, the two inner 
tegument proteins, UL36 and UL37 tightly control the movement of capsid toward the nucleus. 
Although no interaction of UL36 or UL37 with dynein has been observed as yet, they are likely to 
bind dynein and to play a role in navigating the incoming nucleocapsid toward the nucleus (82, 
121).  
 UL36 is essential for delivering viral DNA into the nucleus (122). The importance of 
UL36 has been demonstrated by the fact that a UL36-deletion mutant capsid migrated to the 
nuclear pore, but did not deliver its DNA into the nucleus (83). The N-terminus of UL36 might 
play a role in releasing viral DNA to the nucleus (122, 123). To inject viral DNA from the 
nucleocapsid into the nucleus, UL36 interacts with the nuclear pore complex (83, 84). Once UL36 
binds to the nuclear pore complex, it triggers the cleavage of the N-terminus of UL36. The 
cleavage of UL36 is crucial for discharging viral DNA from the nucleocapsid (122, 124). UL25 
also interacts with UL36 and facilitates release of viral DNA into the nucleus (116, 125). 
Although UL37 is not essential for capsid trafficking to the nucleus (85), incoming capsid 
transport is delayed in the absence of UL37 (121). In addition, UL37 is a strong interacting partner 
of UL36. Structural analysis of UL37 revealed that its N-terminus shares structural similarity with 
the components of cellular multi-subunit tethering complexes (MTCs), which control vesicular 
trafficking to the destination organelles by tethering transport vesicles (126).  Thus, UL36 and 
UL37 contribute to navigate the nucleocapsid to the nucleus. 
 ICP0, an immediate early protein and an inner tegument protein of HSV-1, possesses 
ubiquitin ligase activity and interacts with the proteasome. ICP0 is tightly associated with the 
capsid through a really interesting new gene (RING) finger domain (127). Thus, virion ICP0 
delivers the viral capsid to the nuclear periphery by proteasome-dependent degradation of virion 
or host proteins (79).   
 Following lytic infection of HSV-1, the amplified virus enters neurons to establish latent 
infection (128). Inner tegument proteins, UL36 and UL37, interact with the host transport 
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machinery, for instance the dynein-dynactin complex, to facilitate retrograde transport of the 
capsid toward the soma (cell body) or nucleus of a neuron (129). Following reactivation the lytic 
replication cycle leads to the formation of new virus particles (130)(131). Newly assembled virus 
particles then migrate through anterograde transport to infect epithelial cells (130).		
1.2.3.3     Effect of tegument proteins on gene expression.	
1.2.3.3.1  Herpes Simplex Virus (HSV-1) gene expression.																		Once inside the nucleus, the viral genome is transcribed in a tightly regulated manner. 
Three groups of viral polypeptides denoted as immediate-early (IE), early (E), and late (L) are 
synthesized in a coordinated and sequential fashion during infection (132). The sequential 
expression of these genes is correlated because IE proteins are required for the expression of E 
proteins and subsequently, the E proteins functions are necessary for genome replication and late 
protein synthesis (132, 133).  IE genes are first synthesized. IE gene expression occur in the 
absence of de novo protein synthesis (reviewed in (134)). To date, five IE genes have been 
identified, ICP4, ICP0, ICP22, ICP24, and ICP47. Although IE gene expression is not dependent 
on viral protein synthesis, its transactivation is dependent on VP16 (135). ICP0 and ICP27 play 
critical regulatory roles in gene regulation throughout the infection. These four IE proteins, ICP0, 
ICP4, ICP22 and ICP27, also function as transcriptional and translational regulators of early and 
late proteins. In spite of being a positive regulator of IE and late protein transcription, ICP4 also 
functions as a negative regulator for ICP0 (reviewed in (134)). After initial stages of virus 
infection, ICP4 halts ICP0 expression to block the inhibitory function of ICP0. ICP0 and ICP4 
co-ordinately trigger the expression of E genes (134). These E proteins are required for DNA 
replication. The identified E gene products include scavenger enzymes including viral thymidine 
kinase and ribonucleotide reductase, and some enzymes, for instances viral DNA polymerase and 
DNA helicase, which are directly involved in DNA replication (reviewed in (134)). Finally, 
following DNA replication, the L genes are synthesized, and early gene expression wanes 
(reviewed in (134, 136)). The L genes encode mainly structural proteins to produce a complete 
virion including tegument proteins. Following protein synthesis, pro-capsids are formed and viral 
DNA is incorporated into the capsid. The capsid is assembled in the nucleus followed by the 
association of tegument proteins with the capsid (137). The virion then leaves the nucleus by 
primary envelopment in the perinuclear space and de-envelopment (138). Tegument protein 
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incorporation also occurs in the cytoplasm. The virion then acquires its final envelope through 
budding into post-Golgi compartment derived membranes, the process known as secondary 
envelopment (139). Enveloped virus -containing vesicles then migrate towards the cellular 
plasma membrane to fuse and release the infectious virion into the extracellular environment 
(140).  	
1.2.3.3.2  Role of tegument proteins on gene expression. 
  HSV-1 UL48 (also denoted as VP16 or α-transducing factor (α-TIF)) is an outer 
tegument protein and is conserved in the Alphaherpesvirinae subfamily (106). HSV-1 UL48 is 
crucial for lytic viral infection (68, 141). Immediately after viral entry, UL48 dissociates from the 
viral capsid and forms an UL48-induced transcription complex with host cell factor-1 (HCF-1) 
and octamer binding protein-1 (Oct-1). This complex formation is required for initiation of 
immediate early gene transcription (97, 98). The complex then binds to the IE promoters to 
trigger transcription of immediate early proteins, including ICP0, ICP4, ICP22, and ICP27, which 
in turn leads to the transcription of the first viral α, and β genes (142). Moreover, the expression 
of ICP0 and ICP4 is directly dependent on UL48 (106). During reactivation from latency in the 
neuron, UL48 also initiates immediate early gene transcription (143). Tegument protein UL46 and 
UL47 enhance UL48-mediated transcriptional activity (96). Another tegument protein, UL14, 
induces nuclear localization of UL48 to regulate immediate early gene transcription indirectly 
(80). Importantly, the UL14 homolog of the murine gammaherpesvirus-68 (MHV-68) ORF34 is 
essential for viral late gene expression (144).    
 HSV-1 ICP0 acts directly in the resistance of HSV-1 to interferon (IFN). This 
observation was supported by the fact that in IFN α/β knock-out mice a ICP0-deletion mutant 
replicated like wild type HSV-1 (86). This protein also plays a role in leading the transition from 
α to β viral gene expression (145). The shift from α to β viral gene expression depends on the 
RING finger domain of ICP0 (88). ICP0 forms a transcriptional complex with various viral gene 
promoters to facilitate transcriptional activation or repression (90, 146). Another tegument 
protein, ICP4, functions as both a transcriptional transactivator and repressor (89). In addition, 
ICP4-mediated transcription activation is regulated through binding with DNA and DNA-
dependent oligomerization (147). The transition from β to γ genes transcription depends on DNA 
replication. ICP4 has been demonstrated to be necessary for the activation of γ genes (134). 
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 HSV-1 tegument protein, UL37 activates the NF-κβ signaling pathway by interacting 
with TNF-receptor-associated factor 6 (TRAF6) (93, 94). The NF-κβ activity influences the 
transcriptional activation of IE genes such as ICP0 (94). UL37 also binds to the HSV-1 DNA 
binding protein, infected cell protein (ICP8), indicating another possible mechanism of regulation 
of IE gene transcription (148). Other HSV-1 tegument proteins, such as UL47, UL49, and US11 
bind to the viral and cellular RNA before packaging into the virion (99). In newly infected cells, 
the virion-incorporated RNA influences gene expression and facilitates a condition suitable for 
initial infection (99). The UL41 tegument protein, also called virion host shut-off (vhs) protein, 
suppresses viral and host cell protein synthesis by degrading mRNA’s during early infection (69, 
95). ICP34.5, another HSV-1 tegument protein, dephosphorylates cellular translation initiation 
factor 2 to preclude protein kinase R (PKR)-activated host protein shut-off functions (91, 92).     
 Some other tegument proteins such as HSV-1 thymidine kinase, UL23 and a dUTPase 
enzyme UL50 contribute to viral DNA replication through the nucleotide metabolism in neuronal 
cells; for instance, it prevents misincorporation of bases by the viral polymerase (149, 150). In 
addition, ICP34.5 has been found to be necessary for regulating viral DNA replication by 
interacting with proliferating cell nuclear antigens (151, 152).    
  
1.2.3.4   Role of tegument proteins during viral assembly and egress. 
 Following completion of DNA replication, the virion assembly and egress from the 
nucleus to the cytoplasm are described by the widely accepted envelopment-de-envelopment-re-
envelopment pathway (153). An overall pathway of herpesvirus assembly and egress describing 
the envelopment - de-envelopment - re-envelopment pathway is illustrated in Figure 1.2. During 
primary envelopment, from nucleus the capsid buds into the perinulcear region to obtain an 
envelope from the inner nuclear membrane. The fusion of the primary-enveloped membrane with 
the outer nuclear membrane is called de-envelopment. Finally, the re-envelopment includes the 
gaining of the final glycoprotein containing envelope before egress (105). The nuclear egress of 
the nucleocapsid is accomplished by the UL31 and UL34 protein complex. UL31-UL34 forms a 
complex through the interaction of multiple regions on the surface of each protein (107-109, 154) 
Protein complex formation is required for efficient budding of the nucleocapsid from the inner 
nuclear membrane (155). Formation of this protein complex causes the membrane to curve 
inwards to form a budding vesicle that encompasses the viral nucleocapsid (156). Thus, the 
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connection between the nuclear membrane and viral capsid is established through an interaction 
of the C-terminal region of UL31. The N-terminal region of UL31 facilitates the activation of 
nuclear egress (107). Another tegument protein, US3, regulates the primary envelopment at the 
inner nuclear membrane by phosphorylation of inner nuclear membrane proteins lamin A/C and 
emerin. Phosphorylation of lamin A/C results in increased permeability of the nuclear membrane 
(157-160). In addition, US3 phosphorylates UL31 and UL34 and this phosphorylation is required 
to evenly distribute UL31 and UL34 around the nuclear rim of HSV-1 infected cells (101, 102). 
HSV-1 VP13/14 also associates with UL31-UL34 complex to promote nuclear egress (161). 
 The tegument protein US3 is also involved in the de-envelopment of primary enveloped 
virions at the outer nuclear membrane.  In HSV and PrV US3-deletion mutants the enveloped 
primary virions were accumulated at the nuclear membrane invaginations suggesting the 
importance of the function of US3 in de-envelopment at the outer nuclear membrane (101, 102, 
162). Moreover, gB and gH also have a role in de-envelopement at the outer nuclear membrane 
(119). A gB and gH deletion mutant revealed the accumulation of primary virions in the 
perinuclear region, a similar phenotype to the US3-deletion mutant (163). The fusion of gB with 
the outer nuclear membrane is enhanced by US3-mediated phosphorylation of gB (103).   
 The re-envelopment or secondary envelopment is accomplished via incorporation of 
inner and outer tegument proteins onto the primary virion. The inner tegument proteins, UL36 and 
UL37 are vital for capsid maturation (106) and have been found to be associated with the 
intranuclear capsid (164, 165). Final tegumentation of the capsid was blocked in UL36- and 
UL37-deletion mutants resulting in accumulation of unenveloped capsids in the cytoplasm (106, 
111, 113). UL36 contains a capsid-binding domain that is crucial for direct interaction with 
capsid-associated protein UL25 (166). During secondary envelopment, the molecular interaction 
of some outer tegument proteins such as UL16 (tegument)-UL11 (membrane), UL48 (tegument)-
gH (membrane), and UL49 (tegument)-gE (membrane) makes the connection between viral 
capsid, tegument, and membrane (104, 105). UL16 also interacts with capsid-binding tegument 
proteins, UL21 and membrane-associated UL11, for maximal incorporation of UL16 into the 
mature virion. Thus additional anchoring of teguments to the membrane is achieved by the 
tripartite complex UL11-UL16-UL21. UL48 also interacts with outer tegument proteins such as 
UL41, UL46, UL47, and UL49 to link envelope and capsid during virion formation (114-116). 
Some tegument proteins also interact with different glycoproteins to facilitate the formation of a 
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complete virion. For example, the cytoplasmic tail of UL49 interacts with HSV-1 gD and gE 
(117-119).  
 Navigation of the de-enveloped nucleocapsid to the secondary envelopment or re-
envelopment site is facilitated by interaction of some tegument proteins and microtubule-
dependent molecular motor proteins. For instance, HSV-1 tegument protein US11 interacts with 
both kinesin-1 and PAT, a kinesin-related protein (78, 167). UL21, another HSV-1 tegument 
protein, associates with microtubules possibly to transport capsids to the trans-Golgi network 
(TGN)-derived vesicles, where the interaction of UL21, UL16 and UL11 establishes a connection 
between capsid and membrane to facilitate the budding process (168, 169). HSV-1 UL36 is also 
involved in transporting enveloped virions (170). Several other HSV-1 tegument proteins, such as 
UL21 and UL49, have been found to interact with microtubules (168, 171). However, the 
functions of UL21 and UL49 interactions remain to be determined. Another tegument protein of 
HSV-1, UL37, binds with a cytoskeleton cross-linker dystonin, which is involved in microtubule-
based transport (172). UL37 and dystonin interaction might function as a linker between the 
capsids and molecular motor and thus, contributes to capsid transport (172). The virion 
nucleocapsid buds into a TGN-derived vesicle, and acquires an envelope together with an outer 
vesicular membrane (173). The virus-containing vesicles then migrate to the plasma membrane, 
and fuse with the plasma membrane to release mature virion (174). In neuronal cells, the 
glycoprotein gK is essential for viral egress (175).  
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Figure. 1.2 An overall pathway of herpesvirus assembly and egress.  
During herpesvirus assembly and egress the envelopment - de-envelopment -re-envelopment 
pathway is illustrated here. 
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1.2.3.5   VP8, the major tegument protein of BoHV-1.  
 The ul47 gene product, VP8, is the most abundant tegument protein in BoHV-1 virions, 
and is conserved among different alphaherpesviruses (176-178). VP13/14, the ul47 gene product 
of HSV-1, and pUL47 of pseudorabies virus (PRV) are homologues of VP8 (176, 177). In VP8-
deleted BoHV-1, incorporation of tegument and other viral proteins was disrupted, resulting in 
dramatic changes in the morphology of the mature virion (179).   
 VP8 has been found to shuttle between cytoplasm and nucleus. VP8 is observed in the 
nucleus early during BoHV-1 infection (180, 181). This nucleocytoplasmic shuttling is attributed 
to the fact that VP8 contains two nuclear localization signals (NLS) at its N-terminus. NLS1 
(11RPRR15) of VP8 is crucial for nuclear localization (182). However, the optimal nuclear 
localization of the entire VP8 protein requires a 9 amino acid peptide (180). NLS2 
(R48PRVRRPRP54) is required for the proper function of NLS1 (180). Later during infection, 
nuclear VP8 is exported into the cytoplasm (180, 183). Nuclear export of VP8 is facilitated by a 
nuclear export signal (NES) containing largely hydrophobic and leucine-rich sequences. NES1, 
located within residues 600-609  (600GVGLIAQRL609), is found to be important (182). However, 
NES1 possesses weak nuclear export activity suggesting the presence of another possible NES 
within VP8. The second NES2 is located from amino acid 95 to 123 of VP8.  Interestingly, NES2 
is more efficient in transporting a fusion protein into the cytoplasm. Nevertheless, in the absence 
of NES1 and NES2, VP8 is still transported to the cytoplasm indicating another possible 
mechanism of nuclear export of this tegument protein (182).   
 VP8 is a multifunctional protein and is involved in interactions with multiple proteins 
throughout BoHV-1 infection. It interacts with cellular kinase CK2 and viral kinase US3 (184). 
Recently, it has been demonstrated that phosphorylated VP8 is involved in redistributing 
promyelocytic leukemia (PML) (185) and also facilitates optimal viral DNA encapsidation and 
virion incorporation (186). VP8 also associates with DNA damage-binding protein 1 (DDB1) 
possibly to modulate the DNA damage response (187). Moreover, VP8 associates with mRNA’s 
of some glycoproteins, such as gB, gC and gD (188). In the context of BoHV-1 infection, a 
RNA-binding activity of VP8 has also been reported (188, 189).  
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1.2.3.6.  Homologs of ul47 gene product. 
 The HSV-1 ul47-encoded protein denoted as VP13/14 is homologous to BoHV-1 VP8. 
VP13/14 is involved in the regulation of alpha-transducing factor (alpha-TIF or VP16)-mediated 
transactivation of immediate early genes. Importantly, immediate early protein, ICP8 coordinates 
expression of VP13/14 (190). HSV-1 VP13/14 is posttranslationally modified by glycosylation 
and phosphorylation. Phosphorylated VP13/14 was observed in the virus-infected cells but not in 
the purified virion (178). In HSV-1-infected cells, VP13/14 is predominantly localized to the 
nucleus. Nuclear localization of VP13/14 is governed by the N-terminally localized NLS (191). 
Nuclear translocation is also associated with the US3-mediated phosphorylation of VP13/14 
(192). Later during HSV-1 infection, two NES’s drive the cytoplasmic localization of VP13/14. 
The NES functions through the chromosomal region maintenance (CRM1)-dependent or -
independent pathway to navigate VP13/14 into the cytoplasm (183, 191).  Moreover, nuclear 
egress of HSV-1 is facilitated through the interaction of VP13/14 with the transmembrane UL31-
UL34 protein complex (161).. However, whether BoHV-1 VP8 forms a complex with UL31-UL34 
to facilitate nuclear egress is not known. 
 VP13/14 possesses RNA binding activity and associates with polyadenylated RNA 
(189). VP13/14 expressed in Escherichia coli (E. coli) bound to RNA, while BoHV-1 VP8 did 
not (189). Thus, RNA binding activity of VP13/14 is independent of posttranslational 
modifications, whereas BoHV-1 VP8’s RNA binding activity is dependent upon this 
modification (188, 189). VP13/14 associates with ICP27 to maintain the stability of mRNA 
without affecting the efficacy of reporter RNA translation (193, 194).  
 Another BoHV-1 VP8 homologous protein is encoded by the ul47 gene of Marek’s 
diseases virus-1 (MDV-1), a chicken herpesvirus. Although MDV-1 UL47 is not essential for 
virus growth, a ul47-deleted MDV-1 mutant virus exhibited impaired growth properties (195). 
The ul47 gene-encoded protein from another avian alphaherpesvirus, infectious laryngotracheitis 
virus (ILTV), is also not essential for in vitro replication, but required for virulence (196). 
Moreover, a PRV ul47-deletion mutant demonstrated impaired virion morphogenesis and a 
reduction in virus titer suggesting a role in virion assembly (177). In all cases, the ul47 gene 
product was required for virulence. However, the detailed virulence mechanism of BoHV-1 VP8 
or other homologous proteins is unknown. 
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1.3.         Innate antiviral responses to Herpes Simplex Virus (HSV-1) infection.  
 Virus infections are detrimental to host cells. Host cells trigger innate cellular defenses 
in response to virus infection. Innate immune responses restrict viral replication, rendering the 
cells less permissive to virus infection. Largely pre-existing pattern recognition receptors (PRRs) 
such as Toll-like receptors (TLRs) of cells recognize viral components or pathogen-associated 
molecular pattern (PAMPs) (197). Recognition of PAMPs by PRRs triggers activation of 
intracellular signaling pathways to induce cellular cytokine, chemokine and interferon (IFN) 
production (197). Soon after virus infection, the recognition of PAMPS triggers the IFN signaling 
pathway.  
 
1.3.1.     Interferons and classification of interferons.  
 Interferons are cytokines secreted by the host cells in response to virus infection. IFNs 
are multifunctional cytokines that function as major components of innate immunity. The IFN 
response is one of the barriers that a virus has to overcome to establish infection. IFN possesses a 
unique ability to trigger the expression of IFN-stimulated genes (ISGs) and develop an antiviral 
state in neighbouring virus-infected cells.  
 IFNs can be categorized into two major groups based on their primary structure: type I 
and type II. Type I IFNs are secreted directly in response to virus infection and includes IFN-α, 
IFN- β, IFN-ε, IFN-κ and IFN-ω (198). IFN-γ belongs to the type II IFNs (199). The best-
characterized IFNs are IFN-α and IFN-β synthesized by most cells in response to virus infection, 
while IFN-γ is secreted by activated T-lymphocytes and natural killer cells (199). All type I IFNs 
generally bind to the same cell surface receptor denoted as a type-I IFN receptor, whereas type II 
IFN binds to the type II IFN receptor (199). In vertebrates, type I interferon is crucial for 
controlling virus infection. Researchers reported that type I IFN receptor knockout mice are more 
susceptible to virus infection despite the presence of a normal adaptive immune system (200).  
On the other hand, type II IFN is involved in immune regulation. In spite of structural 
dissimilarities between these two types of IFN, the signaling cascades that activate these IFNs are 
occasionally overlapping. However, in many cases, the non-redundancy of these two systems 
elicits an efficient immune response against specific virus infections. 
 Another novel recently identified IFN, IFN-λ, denoted as type III IFN, consists of IFN-
λ1, IFN-λ2, and IFN-λ3. Type III IFNs are structurally similar to the type I IFN, while the 
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receptor is different. Type III IFNs are induced by virus infection or double-stranded RNA 
(dsRNA) rendering cells less permissive to virus infection.   
 
1.3.2.      Modulation of IFN response by herpes simplex virus-1 (HSV-1) proteins. 
 Immediately after virus infection, viral constituents are recognized by surface, or 
intracellular receptors denoted as PRRs. PRRs are activated following recognition of PAMPs. 
PRR activation leads to the expression of genes with pro-inflammatory activities such as 
cytokines and type I IFN (reviewed in (201)). Cytosolic PRRs include an essential family of 
receptors such as Toll-like receptors (TLRs) or DNA or RNA sensors. TLRs bind to microbial 
elements leading to the activation of intracellular signaling cascades that promote an antiviral 
cellular response. Nevertheless, to evade host antiviral responses, HSV-1 has multiple viral 
evasion mechanisms to attenuate the host anti-viral response and to expedite virus infection 
(202). Therefore, inhibition of the innate antiviral immune response is crucial for the 
establishment of HSV-1 infection. Here we will discuss some of the HSV-1 proteins that function 
in modulating the type I IFN response. 
 
1.3.2.1   Immediate early protein-0 (ICP0). 
  Inhibition of downstream IFN signaling is controlled by viral evasion mechanisms. All 
herpesviruses target Interferon Regulatory Factor-IFN, (IRF-IFN) pathways at different levels 
(165). The immediate early protein, ICP0, is involved in subverting type I IFN signaling 
pathways. During virus infection TLRs recognize PAMPS and recruit the downstream adaptor 
proteins such as myeloid differentiation primary response protein (MyD88), MyD88 adaptor-like 
protein (Mal) and Toll/interleukin 1 receptor domain-containing adaptor-inducing IFN-β (TRIF) 
leading to the activation of Interferon Regulatory Factors (IRFs) including IRF-3, IRF-7, and NF-
κB (202, 203). This causes IRF3 hyperphosphorylation and translocation to the nucleus to 
activate the IFN-β promoter for initiation of the IFN response and IFN-β production (204). ICP0 
is a multifaceted protein and possesses E3 ubiquitin ligase activity. During HSV-1 infection ICP0 
blocks nuclear accumulation of IRF3 and thus, inhibits IFN production (205). Mechanistically, 
cytoplasmic localization of ICP0 is involved in degradation of IRF3 as well as in sequestration of 
IRF3 and CBP/300 (205-207). Cytoplasm-localized ICP0 is thought to be associated with the 
inhibition of IRF3 phosphorylation, dimerization and nuclear translocation. Another possible 
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mechanism of prohibiting IRF3-mediated IFN signaling includes either prevention or reversing 
the phosphorylation of IRF3, which is indispensable for nuclear translocation and dimerization of 
IRF3 (205, 206). 
 MyD88 consists of two domains, a death domain and a Toll-like receptor domain that 
functions as an adaptor molecule and is necessary for TLR-mediated inflammatory responses 
(208). ICP0 exerts its ubiquitin ligase activity, and its expression leads to a reduction in the level 
of TLR-adaptor proteins, MyD88 and Mal. Thus, it blocks the TLR-2 mediated IFN-signaling 
pathway (209).  In addition, ICP0 inhibits TLR-activated nuclear factor (NF-κβ). To prevent 
TLR-mediated NF-κβ activation, ICP0 delocalizes USP7 from the nucleus to the cytoplasm. 
Once in the cytoplasm, USP7 interacts with TNF receptor-associated factor (TRAF6) and IKK-γ 
to dissociate their polyubiquitin chains, impeding activation by TLRs and their degradation. 
TRAF6 and IKK-γ are required for nuclear translocation of NF-κβ and subsequent activation of 
NF-κβ target genes (209). Another study demonstrated that ICP0 also binds with NF-κβ subunits 
p65 and p50 to prohibit nuclear accumulation of p65 and to degrade p50 by using E3 ubiquitin 
ligase activity in the ubiquitin-proteasome pathway (210).   
 Another possible mechanism by which host cells exert or initiate antiviral responses is 
through nuclear sensors. IFN-inducible protein-16 (IFI16) is a nuclear and cytoplasmic sensor, 
and a DNA binding protein. Although this protein is predominantly nuclear, unlike other DNA 
sensors, it shuttles between the cytoplasm and the nucleus (211, 212). During HSV-1 infection, 
IFI16 recognizes viral DNA in the nucleus, which leads to IFI16 acetylation and subsequently, 
IRF-3 phosphorylation to induce IFN-β signaling (213). An IFI16-mediated type I IFN response 
has been demonstrated in response to DNA virus infection (214, 215). One study revealed that 
during HSV-1 infection, IF116 is degraded by proteasome-mediated degradation, and this 
degradation is dependent on the E3 ubiquitin ligase activity of ICP0.  Another report suggested 
that the degradation of IFI16 is not solely dependent on ICP0 as an ICP0-null mutant is able to 
degrade IFI16 (216). The discrepancy between the former and latter study has been explained by 
the fact that different cell types and different infection conditions were utilized. 
  
1.3.2.2.  ICP27.  
 Recent evidence indicates that ICP27 functions as a major modulator in down-regulation 
of IFN signaling during HSV-1 infection. ICP27 functions in multiple pathways to alter type I 
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IFN production. The NF-κB pathway triggers expression of genes involved in immune responses.  
In response to virus infection inhibitory kappa B (IκB) is phosphorylated and degraded by 
ubiquitination. NF-κB is released from IκB and translocates to the nucleus where it triggers 
transcription of the target genes (217). An ICP27-deletion mutant of HSV-1 produces a higher 
level of IFN-α/β in both HeLa cells and macrophages (136). Mechanistic studies revealed that 
ICP27 inhibits NF-κB and IRF3 activation to suppress IFN and cytokine induction during HSV-1 
infection (136). Other research demonstrates that ICP27 binds inhibitory kappa B alpha (IκBα) to 
block its phosphorylation and ubiquitination and thus, ICP0 stabilizes IκBα (218). As a 
consequence, IFN production is reduced.   
 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) 
signaling pathway is activated by binding of ligands, such as IFN to their receptors (219). 
Activated JAK phosphorylates its substrates including STAT1 and STAT2. Phosphorylated 
STAT1 and STAT2 heterodimerize and translocate to the nucleus. Once in the nucleus, STATs 
bind to the IFN-response element to trigger IFN production (219). HSV-1 infection interferes 
with JAK-STAT signaling pathway. The potential mechanisms of inhibition of the JAK-STAT 
signaling pathway by HSV-1 ICP27 include blocking of STAT1 phosphorylation as well as 
inhibition of STAT1 translocation into the nucleus (220). Thus, ICP27 plays a pivotal role in 
immune response escape at early stages during HSV-1 infection. 
 
1.3.2.3  ICP34.5. 
            TANK-binding kinase-1 (TBK1) functions as a critical player in both TLR-dependent and 
independent signaling pathways. Recognition of microbial components causes TBK1-mediated 
phosphorylation of IRF3 leading to cytokine expression. ICP34.5, a gamma protein of HSV-1, 
interacts with TBK1 and sequesters TBK1 to inhibit phosphorylation of IRF3 and its 
accumulation into the nucleus and thus, blocks induction of IFN-stimulated gene promoters (221, 
222). As a result, ICP34.5 inhibits IFN production. 
 Double stranded-RNA dependent protein kinase (PKR) is activated by virus infection. 
Upon activation, PKR phosphorylates its downstream target, eukaryotic translation initiation 
factor-2α (eIF2α). The inhibition of eIF2α leads to blocking of viral and cellular mRNA 
translation, which prevents virus production (223). However, during HSV-1 infection, although 
PKR is activated, ICP34.5 interacts with and redirects phosphatase 1 alpha, which 
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dephosphorylates eIF2α to enable protein synthesis (92, 224).    
 
1.3.2.4   US3. 
 Toll-like receptor 3- mediated type I IFN production is well characterized. It can induce 
the expression of type I IFN by detection of double-stranded RNA. Impaired TLR-3 signaling 
results in higher HSV-1 replications. Similarly, in TLR3-deficient cells, HSV-1 infection 
produces much less IFN (225, 226). The tegument protein US3 of HSV-1 can reduce TLR3 
expression and inhibit the TLR3-mediated IFN response. This finding was also supported by the 
fact that US3-deletion mutants exhibit stronger IRF3 activation and thus exerts a stronger type I 
IFN response (227). US3 also suppresses the TLR2 signaling pathway by inhibiting 
polyubiquitination of TRAF6. This inhibition was dependent on the kinase activity of US3 (228).  
 Activation of most of the PRRs including TLRs leads to the activation of the NF-κβ 
signaling pathway. This activation facilitates cytokine expression including type I IFN production 
(229). p65/RelA is a subunit of NF-κβ and functions as a crucial transcription factor in the innate 
immune response. Some DNA and RNA viruses antagonize innate immune responses by 
modulating the p65-mediated signaling pathway. Likewise, HSV-1 US3 hyperphosphorylates 
p65, inhibiting its nuclear translocation and thus abrogates NF-κβ activation to decrease IFN 
production (230).   
 IRF3 dimerization is associated with the activation of anti-viral responses particularly 
the production of type I IFN. US3, the serine/threonine kinase of HSV-1, can significantly down-
regulate type I IFN production. This inhibition is facilitated by US3-mediated 
hyperphosphorylation of IRF3 and inhibition of its dimerization and nuclear accumulation (231).  
 
1.3.2.5   US11.  
 RIG-I (retinoic acid-inducible gene)-like receptors (RLRs) include RIG-I and 
melanoma- differentiated-associated protein-5 (MDA5). These receptors are critical for initiating 
antiviral responses. RIG-I detects RNA containing 5’-triphosphate groups, while MDA5 
recognizes double-stranded RNA (dsRNA) and stimulates adaptor proteins to activate IRF3 and 
NF-κB (232, 233). This activation triggers expression of type I IFN. HSV-1 infection down-
regulates RLR signaling by interfering with multiple protein functions in this pathway. US11, 
one of the tegument proteins of HSV-1, is an RNA binding protein (234). US11 uses its carboxy-
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terminal binding domain to interact with RIG-I and MDA5. The association of US11 with RIG-I 
and MDA5 abrogates the formation of MDA5/ mitochondrial antiviral signaling protein (MAVS) 
and RIG-I/MAVS complexes and consequently inhibits IFN-β production (235). 
 US11 also functions to suppress type I interferon production through interacting with the 
double-stranded RNA binding protein, protein kinase R activated protein (PACT). RIG-I 
interacts with PACT and gets activated to be functional (236). US11 interacts with PACT and 
thus, blocks the association of PACT with RIG-I to inhibit type I IFN production (237). 
 
1.3.2.6   UL41. 
 The UL41 gene product, vhs, is known as a crucial determinant of HSV-1 virulence (69). 
vhs is an mRNA-specific RNase that is involved in triggering rapid shutoff of host mRNA 
degradation and host cell protein synthesis (reviewed in (238)). vhs, a multifunctional protein, is 
involved in various immunomodulatory mechanisms including the regulation of IFN-α/β 
production during HSV-1 infection (239, 240). The interference of vhs with IFN production is 
demonstrated by the fact that vhs deficiency in HSV-1 increases susceptibility to IFN-α/β (241). 
Vhs inhibits phosphorylation of STAT1 and thereby, suppresses the JAK/STAT signaling 
pathway. This suppression of JAK/STAT1 signaling results in impaired expression of IRF7 and 
subsequently reduces IFN-α production. IRF7-mediated functions are crucial for the 
establishment of effective antiviral responses against HSV-1 infection (242). Vhs also up-
regulates the suppressor of cytokine signaling (SOCS) expression that leads to the inhibition of 
IFN production. Thus, for the establishment of HSV-1 infection, vhs down-regulates the IFN 
signaling pathway. 
 
1.3.2.7   UL36. 
 TNF receptor-associated factor 3 (TRAF3) plays a critical role in the RLR signaling 
pathway by linking an upstream adaptor protein, MAVS, to TBK1 (243, 244). With the activation 
of TRAF3, lysine-63 (K-63) is polyubiquitinated. This is essential for the induction of the MAVS 
signaling pathway. MAVS recruits TBK1 to phosphorylate IRF3 for initiation of IFN production. 
UL36, the largest tegument protein of HSV-1, is conserved among the herpesviridae family and 
is indispensable for virus replication. The N-terminus of UL36 contains a deubiquitinase (DUB) 
motif denoted as UL36 ubiquitin-specific protease (UL36USP) (123, 245). UL36USP blocks IRF3 
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dimerization-mediated promoter activation and IFN-β transcription that are induced by Sendai 
virus (Sev) infection. In parallel, the DUB activity of UL36USP is responsible for 
deubiquitination of TRAF3 and for prevention of the recruitment of downstream adaptor 
molecule TBK1. Hence it blocks IFN production (246).  
 
1.3.3      Modulation of IFN responses by HSV-1 through DNA sensors.  
 Cytosolic DNA is detected by DNA sensors and triggers immune responses by inducing 
inflammatory gene expression. Thus, the DNA sensor can stimulate induction of antiviral 
responses, including IFN production, independent of RIG-I and TLRs (247). To date, a number 
of DNA sensors have been identified with potential roles in antiviral signaling pathways. 
Stimulation of IFN genes (STING) is predominantly expressed in T cells, epithelial cells, and 
endothelial cells, as well as in macrophages and dendritic cells, and is a crucial component for 
induction of type I IFN signaling by the detection of cytosolic DNA (248). STING functions by 
recruiting TBK1 and IRF3 for IRF3 phosphorylation and subsequent production of type I IFN. 
STING knockout mice showed increased susceptibility to HSV-1 infection, indicating the 
significance of STING in host restriction of HSV-1 infection (249). Researchers reported that 
viral proteins ICP0 or US3 are involved in altering the function and stability of STING in a cell 
type-dependent manner (250). However, HSV-1-facilitated immune evasion strategies of STING-
mediated responses are still being elucidated.   
 Another recently identified DNA sensor denoted as cyclic GMP-AMP synthase (cGAS) 
belongs to the nucleotidyltransferase family and shares enzymatic and structural features with 
dsRNA-sensing 2-5-oligoadenylate synthase (OAS) (251). cGAS, a major component of the 
cGAS-STING pathway, undergoes significant conformational changes with the detection of 
dsDNA. Upon DNA binding, it catalyzes GTP and ATP to form an endogenous second 
messenger, cyclic GMP-AMP (cGMP). cGMP then binds to STING, inducing its activation by 
causing dramatic conformational changes to STING. Activated STING triggers phosphorylation 
of IRF3 via TBK1 to promote nuclear translocation IRF3. Subsequently, this cascade triggers 
transcription of type I IFN (252). HSV-1 infection interferes with the cGAS-mediated IFN 
signaling pathway. This interference is supported by evidence that significantly increased 
susceptibility was observed against HSV-1 infection in cGAS knockout mice compared to wild-
type mice (215). The cGAS-mediated signaling pathway is dependent on STING. As a result, any 
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viral protein interfering with STING or its downstream component affects the cGAS pathway. 
Until now, only one HSV-1 protein, the UL41 gene product vhs, has been found to abrogate the 
cGAS-STING pathway (253). During HSV-1 infection, vhs reduces accumulation of cGAS to 
block viral DNA recognition by host cells as well as degrades cGAS via its RNAase activity to 
evade cGAS-STING mediated antiviral responses (253). In addition, recent research revealed that 
due to recognition of HSV-1 and Kaposi’s sarcoma-associated herpesvirus (KSHV) genome by 
histone-2B-IFI16 (H2B-IFI16), the complex IFI16-breast cancer-1-H2B (IFI16-BRCA1-H2B) 
interacts with cGAS and STING to induce IFN-β production (254).  	 
1.4         Modulation of DNA damage response by herpesviruses. 
1.4.1      DNA damage response. 
 Damaged DNA includes any breaks in the DNA strand, missing base pairs in the DNA, 
or chemical-induced rearrangements of the bases (255). Throughout the lifespan of a cell, the 
cellular genomic integrity is threatened by intrinsic or extrinsic stresses, such as replication 
errors, uncontrolled recombination, microbial infections, endogenously metabolized by-products, 
reactive oxygen species, and exposure to ultraviolet (UV) light or environmental mutagens (256). 
The most common DNA damages are DNA single-strand breaks (SSBs) and DNA double-strand 
breaks (DSBs) (reviewed in (257)). These DNA damages pose a severe threat to genomic DNA 
as they can lead to chromosomal aberration, abnormal amplification, and rearrangements finally 
leading to genomic instability. 
 To survive these detrimental situations, as well as to avoid the fundamental threat of 
genomic erosions, eukaryotic cells evolved a sophisticated and well-coordinated network denoted 
as DNA damage response (DDR) (258). The complex signaling network of DDR consists of 
recognition of DNA damage and transmission of signals to the regulators. The transmitted signals 
control the cell fate either by arresting the cell cycle, by triggering the DNA-repair pathway or by 
terminating cells by inducing apoptosis. The DDR pathway is orchestrated with two major 
kinases, ataxia-telangiectasia mutated (ATM) and ATM- and RAD-related (ATR) kinase. These 
kinases are the central regulator of DDR pathways and are activated in response to DNA damage 
(258). Over the past few decades, researchers revealed that virus infection and host cell DDR 
pathways are strongly inter-connected, and that the DDR pathway plays a pivotal role in the 
establishment of virus infection. As such, virus infection is associated with the activation or 
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repression of specific components of DDR pathways in a temporally coordinated manner to favor 
viral infection (259). In the following sections, the regulation of ATM- and ATR-mediated DDR 
pathways by different herpesviruses will be discussed. A schematic diagram demonstrating the 
modulation of DDR pathway by different herpesviruses, such as HSV-1, EBV, HCMV, and 
KSHV is presented in Figure 1.3. 
 
1.4.2.      Regulation of DDR pathways by different herpesviruses. 	 To	 date	 different	 herpesviruses	 are	 known	 to	 modulate	 the	 DDR	 pathways.	The 
DDR signaling pathway contains a major kinase cascade, which mediates phosphorylation of 
downstream targets to facilitate major cellular events, such as DNA repair or apoptosis. ATM is 
one of the kinases and plays a vital role upstream of the DDR pathway. ATM is expressed in 
most of the tissues and loss of ATM activity results in autosomal recessive disorder ataxia-
telangiectasia (260). ATM kinase functions as a master regulator of the DDR pathway. In 
response to DSBs or oxidative stress, the ATM-mediated DDR pathway coordinates cell-cycle 
checkpoint activation, DNA repair, and eventually decides the cell fate by inducing cell cycle 
arrest or apoptosis (reviewed in (261)). In resting cells, ATM is predominantly nuclear and exists 
in its inactive form as a homodimer. Upon DNA damage, ATM undergoes autophosphorylation 
at residue S1981. This autophosphorylation triggers the dissociation of ATM from its inactive 
homodimer form to generate an active monomer that facilitates phosphorylation of its various 
downstream targets (reviewed in (262)). A mutation in the S1981A of ATM fails to form active 
monomer and subsequently, loses the ability to activate ATM, highlighting the importance of 
ATM phosphorylation in ATM activation (263). Conversion of inactive ATM dimer to active 
ATM monomer has also been observed through the MRN (MRE11-RAD50-NBS1) complex 
(264). MRN complex unwinds the DNA ends, which are essential for ATM monomerization 
(265). Following DNA damage, one of the earliest events is the phosphorylation of a variant of 
histone, H2AX, by ATM kinase. This phosphorylated form of H2AX is known as γH2AX (266). 
γH2AX acts as a docking site for multiple DDR proteins. As a downstream regulator, the MRN 
complex also gets phosphorylated to carry out numerous functions including DNA recombination 
and DNA double-strand break repair. In the ATM/NBS1 pathway, upon DNA damage some 
proteins including NBS1 and breast cancer-1 (BRCA1) migrate to the DSB sites independent of 
the ATM activation. ATM is activated followed by recognition of DNA damage. Upon 
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activation, ATM phosphorylates multiple nucleoplasmic substrates including p53 and NBS1. 
Consequently, NBS1 phosphorylates SMC1 as a downstream target. Phosphorylation of SMC1 is 
critical for decreasing chromosomal aberrations and increasing cellular survival (267). Activated 
ATM also activates p53 to link the DNA damage response to cell cycle checkpoint pathways 
(268). p53 phosphorylation by ATM stabilizes p53. In addition, following DNA damage, ATM 
phosphorylates cellular checkpoint kinases CK1 and CK2, which subsequently phosphorylates 
p53, contributing further stabilization of p53 (269). Finally, p53 activation stimulates cell cycle 
checkpoint activation or induces apoptosis (270). In ATM-deficient cells, the level of DNA 
damage increases due to lack of DNA damage detection. Hence, the damaged DNA is sustained 
in the absence of DDR. Depending on the level of DNA damage, multiple pathways are 
activated. For instance, minor DNA damage activates sensor proteins to be recruited at the 
damaged site for DNA repair. However, if the damage is too extensive to repair, the DDR 
pathway gets activated to trigger some signal specialized transducer proteins (258). These 
effector proteins induce temporary cell cycle arrest or halt the cell cycle or trigger apoptotic 
pathways (258).  
 
 1.4.2.1  Modulation of DDR by HSV-1. 
 A contribution of the DDR pathway to HSV-1 DNA replication has been demonstrated. 
During HSV-1 infection several cellular factors including MRE11, RAD50, and NBS1 have been 
associated with homologous recombination (HR) (271). With sensing of DSB, HR is facilitated 
through MRN complex formation and ATM signaling. Following DNA damage, ubiquitination 
of histone-2A (H2A) by ring finger protein-8 (RNF8) and ring finger protein-168 (RNF168) 
facilitates recruitment of other downstream effectors such as p53-binding protein-1 (53BP1), 
RAD51 recombinase (RAD51), and breast cancer-1 (BRCA1) (reviewed in (272)). These 
effectors mediate homologous recombination to repair DSBs. HSV-1 manipulates the HR 
pathway during productive infection. Although HSV-1 requires HR cellular machinery 
components for efficient virus production, chromosomal integration assays reveal that it 
suppresses HR during infection (273). Besides, HSV-1 infection triggers ATM activation, which 
is demonstrated by the phosphorylation of ATM, NBS1, and checkpoint kinase-2 (CHK2) (271, 
274). Similarly, an ATM- or MRN-deficient cell lines the virus production was reduced (271, 
274, 275). However, the immediate early protein ICP0 of HSV-1 degrades RNF8 and RNF168 
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through ubiquitinase activity and thereby, inhibits the recruitment of BRCA1 and 53BP1 to the 
damaged foci (276). Thus, in spite of ATM activation during HSV-1 infection, HR is inhibited 
(273). Consequently, HSV-1 infection is suggested to block the HR to favor virus replication 
(271, 277). 
 ATR, another checkpoint kinase is also activated with the ATM substrates, and thus, 
ATR activation is related to ATM activation (278). ATR and ATR-interacting protein (ATRIP) 
are recruited to stretches of single-stranded DNA (ssDNA). The ATR signaling is initiated 
through ATR activation through recruitment of 9-1-1 (RAD9-RAD1-HUS1), which in turn 
recruits an ATR-activator, DNA topoisomerase 2 binding protein-1 (TopBP1).  Subsequently, 
TopBP1 phosphorylates checkpoint kinase-1 (CHK1) to activate ATR-CHK1 signaling pathway 
(reviewed in (279)). Although ATM activation is observed during HSV-1 infection, it abrogates 
the ATR-CHK1 signaling pathway (280). A mechanistic study revealed that HSV-ICP8 and three 
proteins of the helicase/primase complex bind to the substrates of cellular replication protein A 
(RPA) and ATR. Binding of viral proteins to these substrates blocks recruitment of 9-1-1 
complexes and therefore, prevents engagement of ToBP1. Subsequently, the ATR signaling is 
inhibited (281). The purpose of blocking the ATR pathway is not clear. However, since ATR 
signaling prevents DSB formation, it is anticipated that the DSB formation might be beneficial 
for HSV-1 replication (282). In spite of suppression of ATR signaling, HSV-1 infection has been 
found to recruit ATR pathway proteins to the virus replication compartment, which are vital for 
virus production. Thus, ATR-signaling proteins might function in favor of virus genome 
replication by inhibiting cellular DNA replication (279).   
 DNA-protein kinase (DNA-PK) signaling pathway responds to DSBs. Following 
detection of DSBs activated DNA-PK phosphorylates some effector protein to repair DSBs 
through nonhomologous end joining (NHEJ) (283). It is anticipated that during HSV-1 infection 
the presence of nicks and gaps in the HSV-1 genome will trigger the DNA-PK signaling 
pathway. However, during HSV-1 infection the DNA-PK signaling pathway is attenuated 
through an ICP0-mediated function (279, 284).  
 
1.4.2.2   Regulation of DDR by Epstein-Barr Virus (EBV). 
 Epstein-Barr Virus (EBV) infection is known to modulate DDR pathways. EBV is a 
ubiquitous human herpes virus. EBV infection causes mononucleosis and sometimes cancers, 
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such as Burkitt’s lymphoma and Hodgkin’s lymphoma. Thus, EBV is classified as human tumor 
virus (285). EBV contains a 170 kilobase double-stranded DNA. It infects both B-lymphocytes 
and epithelial cells. In EBV-infected cells, the episome exists in the host cell nuclei as an 
extrachromosomal DNA enclosed with the histones (286). With the entrance of virus into the 
cells, the lytic DNA replication starts with the synthesis of viral DNA replication proteins. The 
EBV genome is replicated through a rolling circle mechanism generating long linear DNA 
concatemers like other herpesviruese, which are cleaved into individual genomes before 
packaging into viral capsid (287). 
 Like other herpesviruses, EBV is also involved in modulation of the DDR pathway. 
EBV infection is correlated to the deregulation of the ATM signaling pathway in Hodgkin’s 
lymphoma. Down-regulation of ATM expression has been found to be associated with the EBV 
latent membrane protein-1 (LMP-1). In addition, suppression of DNA repair was observed in a 
LMP-1 expressing cell line through down-regulation of the ATM signaling pathway (288). 
Moreover, EBV-positive nasopharyngeal (NPC) cells had reduced levels of ATM transcripts and 
proteins (289). Similarly, upon exposure to γ radiation, EBV-infected cells demonstrated a 
defective DNA damage response. However, in one report, LMP1 has also been found to up-
regulate ATM signaling through activation of the NF-κB pathway (290). This discrepancy could 
be due to the action of different levels of LMP1 or ATM expression in different cell lines (291). 
Importantly, a high level of LMP1 expression leads to the induction of apoptosis (292).  
 Another EBV protein, EBV Nuclear antigen 3C (EBNA3C), disrupts the G2/M cell 
cycle checkpoints. EBNA3C-expressing cells are unable to arrest cells in the G2/M checkpoints. 
Besides, being a crucial effector of the ATM/ATR pathway, CHK2 interacts with EBNA3C, and 
this interaction is involved in inhibition of cell cycle arrest (293).  Importantly, ATM or CHK2 
inhibition significantly increases the B-cells transformation efficiency. Thus, EBNA3C-mediated 
attenuation of DDR in EBV-infected cells promotes primary B-cell hyperproliferation (294). 
Overall, EBV infection down-regulates ATM expression to attenuate the ATM-mediated DDR 
pathway and subsequently, impedes the downstream effector functions. This disruption of the 
ATM-mediated pathway may contribute to the genomic instability and tumorigenesis, as well 
(291). In addition, EBV immediate-early lytic protein, BZLF1, also mislocalizes the DDR 
proteins followed by EBV infection (295). However, during lytic reactivation, EBV replication is 
triggered by ATM activation. It has been reported that the induction of BZLF1 is dependent on 
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ATM activation (296). Likewise, ATM knockdown in epithelial cells infected with EBV resulted 
in reduced virus production (296). Thus, EBV infection modulates the DDR pathway in both 
latency establishment and lytic reactivation. These findings indicate that the host cells closely 
monitor the viral DNA replication and in parallel, EBV exhibits different strategies to establish 
infection. 
 The involvement of the DNA-PK signaling pathway during EBV infection is less 
studied compared to the ATM- and ATR-signaling pathways. However, according to recent 
research during EBV infection DNA-PK signaling is impaired, and this attenuation was 
associated with the function of viral oncoprotein, LMP1 (297). 
 
1.4.2.3   Regulation of DDR by human cytomegalovirus (HCMV). 
 Like other DNA viruses, HCMV infection also elicits DDR responses. The β 
herpesvirus, human cytomegalovirus (HCMV), is responsible for causing diseases in 
immunocompromised and immunosuppressed patients, including pneumonitis and retinitis (298). 
HCMV is an enveloped DNA virus with ~235 kilobase pair double-stranded DNA genome (299). 
Like HSV-1, HCMV DNA replication and gene expression are also coordinated in a tightly 
controlled manner, including immediate early (IE), early (E) and late (L) protein expression 
(300). The IE proteins coordinate expression of E and L proteins to initiate DNA replication. 
Some of these proteins are directly involved in viral DNA replication while others are associated 
with the modulation of cellular factors (301). The ATM or ATR signaling pathway is linked to 
the induction of cell cycle arrest or apoptosis. HCMV infection alters the cell cycle checkpoints 
to suppress cellular DNA synthesis, while favoring viral DNA replication. HCMV infection is 
known to both activate and inhibit the ATM-mediated DDR pathway. Induction of DDR by 
HCMV infection includes activation of ATM and its downstream targets such as H2AX, NBS1, 
CHK1, and CHK2. HCMV proteins IE1, IE2, pp71 and UL97 can induce DSBs and subsequently, 
activate ATM, H2AX, and P53. Thus, they contribute to HCMV replication (reviewed in (302)). 
UL35 is also involved in activation of DDR by inducing phosphorylation of H2AX and formation 
of 53BP1 foci to arrest the cell cycle. Thus, the ATM-mediated DDR pathway contributes to 
HCMV DNA replication.  
 However, although the ATM-mediated DDR pathway is activated during lytic infection, 
it has been reported that the downstream signaling components were blocked by HCMV infection 
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(303). For example, CHK2 activation was inhibited by HCMV infection. Following DNA 
damage, the DDR proteins migrate to the nucleus to coordinate the DNA repair proteins. 
However, later during HCMV infection, it alters the localization of ATM and CHK2 from the 
nucleus to the cytoplasm to interfere with their normal function. Thus, it is proposed that HCMV 
infection induces ATM-mediated checkpoint activation in response to DSBs, whereas the virus 
responds by mislocalization of checkpoint proteins to inhibit the signaling pathway (303). Luo et 
al, 2007 also reported the disruption of both ATM- and ATR-mediated signaling pathways by 
HCMV infection. At the initial stage of infection, phosphorylation of NBS1 was observed 
through ATM activation (304). However, the relocalization of NBS1 to the site of DNA damage 
was inhibited by HCMV infection (304). A relocalization of DDR proteins, such as P53, pATM, 
NBS1, RAD50, ATRIP, CHK1 and CHK2 to the replication compartment by HCMV infection 
was also reported (reviewed in (302). Thus, although HCMV infection activates the ATM-
mediated DDR, it manipulates the localization of DDR protein to subvert the full activation of the 
ATM signaling pathway (304). EBV infection is also involved in disrupting the ATR signaling 
pathway. Disruption of ATR-CHK1 signaling is mediated through impaired activation of STAT3, 
which facilitates ATR-mediated phosphorylation of STAT3 (305). 
 
1.4.2.4   Modulation of DDR by Kaposi’s sarcoma-associated herpesvirus (KSHV). 
 The DDR pathway is also modulated by KSHV. KSHV (also known as human 
herpesvirus-8) belongs to the family of gamma-herpesviruses. It contains a large double-stranded 
DNA. KSHV is etiologically associated with Kaposi sarcoma (KS), a form of malignancy in 
human skin (306, 307). Like other members of the herpesvirus family, the KSHV lifecycle also 
consists of both latent and lytic phases. This virus is also involved in the regulation of the DDR 
pathway to ensure evasion of host cell antiviral defenses.  KSHV encodes several homologs of 
host genes to modulate the host cell response. Such genes include viral interferon regulatory 
factor (vIRF1), viral interleukin-1 (vIL1), and viral Bcl2 (vBcl2) (reviewed in (308). Lytic 
replication of KSHV-1 results in sustained DDR in infected cells. The elevated level of γH2AX 
evidences the induction of DDR (309). This activation of DDR is induced before initiation of 
viral DNA replication. Researchers speculate that induction of DSBs can be the result of the 
action of viral mRNA export factor, ORF57 (310). Even though KSHV infection induces DDR 
activation, it suppresses ATM activation. Shin et al, 2006 demonstrated that the C-terminal 
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domain of vIRF1 interacts with ATM and reduced its phosphorylation (311). This, consequently, 
inhibits activation of the downstream proteins of the ATM pathway, such as P53, H2AX, and 
CHK2 (311). However, vIRF1 expression increases expression of the cell cycle regulatory 
protein CdC25, which is consistent with suppression of the ATM-mediated signaling pathway. 
vIRF1 also inhibits activation of p53, another downstream component of the ATM signaling 
pathway. vIRF1 interacts with p53, and this interaction is associated with suppression of 
acetylation and transcriptional activation of p53 (308, 312). Thus, KSHV infection alters 
downstream signaling of the DDR pathway.  
 
1.5         Purpose of reshaping the DNA damage response by DNA viruses. 
              With a limited coding capacity of the viral DNA genome, it exploits the cellular 
machineries to facilitate their genome replication and to generate progeny viruses. Consequently, 
in favor of completing their life cycles DNA viruses hijack and manipulate cellular repair and 
replication processes (reviewed in (257)). Upon release of virus genomes into the infected cells 
nuclear sensors recognize them (313). In response, host cell defensive complexes are 
accumulated at the site where incoming viral genomes are localized. For instance, the HSV-1 
genome containing nicks and single-strand gaps is delivered into the nucleus and thus, attract 
DNA repair factors (314).The initial purpose of this attraction is to inhibit virus replication by the 
host cells. Instead, viruses manipulate the DDR signaling to promote replication. Early DDR 
markers including γ-H2AX and MDC1 (mediator of DNA damage checkpoint protein-1) are 
localized to the incoming HSV-1 genome (276). However, the viral E3 ubiquitin ligase, ICP0 
antagonizes this host defense by degrading RNF8 and RNF168 to prevent recruitment of 
downstream repair protein, 53BP1 (276). Thus, the selective disarming indicates that the 
exploitation of upstream DDR factors may facilitate recombination-mediated replication, whereas 
elimination of the downstream proteins prevents processing and silencing of the viral genome by 
host cells (reviewed in (257)). Thus, the activation of upstream signaling favors virus replication, 
but the execution of downstream signaling to cell cycle checkpoint or apoptosis often negatively 
affects virus replication (261). Therefore, viruses developed strategies to block downstream 
signaling. Thus, viruses activate or inactivate the components with the most profound 
consequences to facilitate their replication (261).   
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         Although many DNA viruses activate the DDR pathways, whether it is beneficial or 
detrimental to the virus is still largely unknown. Depending on the type of the infection, such as 
latent or lytic infection, or on the structure of replicating DNA the role of the DDR varies (261). 
A common theme often reported is that during lytic replication by DNA viruses there is a 
requirement for DDR activation, signaling through PIKK (phosphatidylinositol 3-kinase like 
protein kinase) and specific subsets of DNA repair factors (reviewed in (261)). Additionally, to 
assure the cell survival during replication the downstream signalling leading to apoptosis or 
senescence is prevented by the viral proteins (reviewed in (261)). On the other hand, during 
latency the viral DNA persists without generating any progeny virus in specific cells, such as 
neuronal cells. It has been suggested that DDR might facilitate the establishment of latency and is 
exploited during reactivation (315). Prevention of ubiquitinylation of histone or recruitment of 
downstream repair factors by ICP0 contributes to virus genome silencing (276) leading to the 
establishment of latency. Thus, viruses harness the DDR machinery to optimize the signaling to 
be latent.  
          Oncogenic viruses, on the other hand, optimize the DDR signaling and utilize cell cycle 
regulatory proteins,	Such as Chk2 or p53 leading to cell proliferation (261). The expected outcome 
of attenuation of the DDR by oncogenic viruses is viral genome replication. However, it may 
result in unexpected consequences for the infected cells promoting uncontrolled cell proliferation 
and ultimately, tumorigenesis. Attenuation of the DDR by oncogenic viruses can be achieved by 
directly antagonizing the downstream components of the DDR pathway, such as checkpoint 
kinase p53 (reviewed in (261)). Herpesviruses, such as EBV and KSHV infection also impair 
DDR leading to cell proliferation. EBV and KSHV infection regulate S-phase entry to promote 
cell proliferation (294, 316). Hence, oncogenic herpesviruses alter the DDR signaling to bypass 
growth-suppressive effect and consequently, stimulate cell proliferation causing tumorigenesis 
(261). 
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Figure. 1.3 Modulation of the DDR pathways by different herpesviruses. 
Exposure of cells to DNA damage triggers activation of the major DDR pathways, the ATM, 
ATR, and DNA-PK pathways. Following DNA damage, ATM is activated by phosphorylation. 
ATM activation is associated with MRN complex recruitment. Activated ATM transmits DNA 
damage signals by activating histone 2AX (γH2AX). Activated ATM then transduces the signal 
to the downstream proteins by activating CHK2, 53BP1, and BRCA1. Activated CHK2 leads to 
the activation of P53. In the ATR pathway, exposure to damaged DNA triggers ATR kinase 
activation. Activated ATR interacts with ATRIP to recruit 9-1-1 complex (RAD9-HUS1-RAD1). 
RAD9, a subunit of 9-1-1 complex, binds to TOPBP1 to stimulate ATR kinase activity. 
Subsequently, activated ATR promotes activation of CHK1. Activated CHK1 mediates P53 
activation. P53 activation by both the ATM and ATR pathways facilitates multiple functions, 
such as DNA repair and cell cycle checkpoint activation. A growing body of evidence 
demonstrated that different herpesviruses modulate the DDR pathways by activating or blocking 
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DDR pathway proteins. HSV-1 triggers ATM activation, phosphorylation of NBS1 (a component 
of MRN complex), and CHK2 activation, while blocking the ATM pathway by inhibiting 
recruitment of BRCA1.  In addition, HSV-1 also abrogates DNA-PK to inhibit non-homologous 
end joining (NHEJ) repair. The ATR-CHK1 kinase pathway is also blocked by HSV-1 infection 
through preventing recruitment of the 9-1-1 complex and TOPBP1. Additionally, the DNA-PK 
signaling pathway is attenuated by HSV-1 infection. Similarly, EBV is also involved in both 
activation and prevention of ATM pathway. EBV induces phosphorylation of ATM, H2AX, and 
CHK2. Conversely, EBV-encoded oncoprotein, LMP-1 down-regulates the ATM signaling 
pathway. Moreover, EBV EBNA3C inhibits cell cycle arrest by interacting with CHK2. In 
addition, the ATR-CHK1 pathway, as well as P53 signaling is also inhibited by EBV infection. 
Moreover, EBV infection also blocks the DNA-PK signaling pathway. HCMV infection induces 
the DDR pathway by activating ATM, H2AX, CHK2, and p53, while also inhibiting the ATM-
mediated pathway by altering the localization of ATM and CHK2. ATM-mediated checkpoint 
activation is also inhibited by HCMV infection. Although KSHV infection induces ATM 
activation by increased phosphorylation of H2AX, it abrogates ATM/p53 signaling. 
Consequently, CHK2 activation is prevented by KSHV infection. 
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1.6         Modulation of apoptosis by HSV-1 and BoHV-1. 
1.6.1      Apoptosis. 
 Apoptosis, a prevalent form of cell death and a natural process, occurs in multicellular 
organisms for the development and maintenance of homeostasis. The apoptotic cells exhibit 
morphological and biochemical changes including DNA fragmentation, apoptotic body 
formation, plasma membrane blebbing, chromatin condensation and shrinkage of cells (317). 
These apoptotic morphological features are the results of the action of proteolytic enzymes 
triggered by the apoptotic stimuli. Apoptosis is also a necessary component of the responses to 
cellular injury (318). Induction of apoptotic pathways may occur by exposure of cells to 
endogenously synthesized  (tumor necrosis factor & reactive oxygen species, (ROS)) or external 
(retinoic acid & ricin) components (319). Some cells undergo apoptosis in response to the 
infection with microbial pathogens, such as virus infection. Thus, virus infection triggers 
induction of apoptosis (320). Therefore, it is not surprising that viruses adopt multiple 
mechanisms to modulate apoptotic responses. These evolutionary mechanisms confer survival 
advantages to either the host cell or to the virus.  
 
 1.6.2     Apoptosis mechanism. 
 The mechanism of apoptosis involves highly complex and energy-dependent sequences 
of events consisting of three subsequent parts, initiation, execution and termination (321). The 
apoptotic signaling can be initiated by different factors including ROS, alkylating agents, 
chemotherapeutic agents and Fas ligands. The major mechanism of apoptosis involves the 
activation of two distinct pathways: i) extrinsic and ii) intrinsic or mitochondria-dependent 
pathways (321, 322).  
 The extrinsic pathway-mediated apoptotic signaling involves transmembrane receptor-
associated interaction. These are classified as death receptors of the tumor necrosis factor (TNF) 
superfamily (323).  These death receptor proteins contain “death domains” that are responsible 
for transmitting the death signal from the cell surface to intracellular networks. TNF-α/TNFR1 
and first apoptosis signal ligand/receptor (FasL/FasR) are considered as death receptors and their 
corresponding ligands. The cascades of events involved in the extrinsic pathways are best 
characterized in TNF-α/TNFR1 and FasL/FasR systems (reviewed in (322). Binding of receptors 
with the corresponding homologous ligands triggers activation of death receptors. This results in 
		
	 41	
the recruitment of cellular adaptor proteins (322). For example, binding of Fas ligand to the Fas 
receptor causes engagement of the cytoplasmic adaptor protein (Fas-associated death domain) 
FADD. Similarly, anchoring of the TNF receptor to the TNF ligand triggers recruitment of the 
TNFR1-associated death domain (TRADD) (324, 325). Following recruitment, FADD interacts 
with procaspase-8, triggering activation of procaspase-8. With activation of procaspase-8, the 
execution phase of apoptosis is stimulated (326). The active procaspase-8 then facilitates the 
cleavage of its downstream executioners procaspase-3 to generate active caspase-3.  Finally, the 
active caspase-3 proceeds to the induction of apoptosis by initiating fragmentation of DNA (327).  
The termination phase of apoptosis involves the inhibitory function of the cellular FLICE-
inhibitory protein (cFLIP) that binds to the FADD or procaspase-8 to negatively regulate their 
activation (328). 
 In contrast, the intrinsic apoptotic-signaling pathway initiates apoptosis in response to 
intracellular signals. It involves an array of non-receptor-associated stimuli that directly act on 
intracellular targets and also includes mitochondria-dependent events (322). The intrinsic 
apoptotic pathway is also triggered by another set of stress stimuli within the cells such as DNA 
damage stress and ROS production (321). All of these intracellular stimulus events cause 
alterations in the inner mitochondrial membrane that results in an opening of mitochondrial 
permeability transition  (MPT) pores. Consequently, the mitochondrial transmembrane potential 
is lost, resulting in induction of mitochondrial outer membrane permeabilization. This triggers the 
sequestration of pro-apoptotic protein such as cytochrome-C, from the intermembrane space into 
the cytoplasm (329). Subsequently, the released cytochrome-C forms a complex with apoptotic 
protease activating factor-1 (Apaf-1) and caspase-9 denoted as “apoptosome” (330, 331). The 
formation of apoptosome then leads to the activation of caspase-9 (332). The activated caspase-9 
triggers activation of executioner caspases including caspase-3 (333).  Finally, caspase-3 induces 
apoptosis by fragmentation of nucleosomal DNA. Apoptotic signaling through the intrinsic 
pathway is also tightly regulated by the anti-apoptotic Bcl-2 family member proteins such as Bcl-
1 and Bcl-xL and by the pro-apoptotic Bcl-2 family proteins, for example, Bid (BH3-interacting 
domain death agonist), Bax (Bcl-2-associated X protein), and Bak (Bcl-2 homologous antagonist 
killer) (334). A schematic diagram representing the overall apoptosis mechanism and modulation 
of apoptosis by HSV-1 and BoHV-1 is shown in Figure 1.4. 
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1.6.3      Regulation of apoptosis by HSV-1. 
 To thwart viral infection, cells adopt innate anti-viral countermeasures that can delay 
virus replication and propagation. Apoptosis is one of the common anti-viral responses. In spite 
of inducing apoptosis, HSV-1 virus has strategies to promote HSV-1 infection and pathogenesis. 
For instance, HSV-1 encodes some anti-apoptotic virulence factors to counteract apoptotic 
responses. A HSV-1 regulatory protein immediate early protein, ICP24, blocks apoptotic cell 
death. ICP24 deletion mutant exhibits less apoptotic cell death as is evident based on reduced 
chromatin condensation, or DNA laddering compared to wild-type HSV-1 infection (335). 
Researchers demonstrated that HSV-1 gD prevents Fas-mediated apoptosis (336, 337). A 
mechanistic study indicated that HSV-1 entry is facilitated through binding of herpes virus entry 
mediator (HVEM), a gD receptor (338). Binding of HVEM to gD triggers NF-κB signaling 
cascades (339). NF-κB activation promotes anti-apoptotic functions of gD by reducing caspase-8 
activity and increasing expression of anti-apoptotic proteins (340). Furthermore, HSV-1 US3 is 
also involved in blocking apoptosis by phosphorylation of pro-apoptotic protein Bad and Bid, 
thereby inhibiting their apoptotic function (341). US3 also interacts with programmed cell death 
protein 4 (PDCD4) to block the apoptotic pathway (342). In addition, two R1 proteins, ICP6 and 
ICP10, contain ribonucleotide reductase (RNR) subunits, which also function as apoptotic 
inhibitors (343). Both of these proteins are responsible for inhibition of TNF-α- and Fas-mediated 
apoptosis. The RNR domain prohibits caspase-8 activation by directly binding with caspase-8 
(343). The serine-threonine protein kinase (PK) domain-mediated function is associated with the 
abrogation of apoptosis in neuronal cells (344, 345). The late protein of HSV-1 glycoprotein-J 
(gJ) is also involved in blocking caspase activation to interrupt Fas-mediated apoptosis (346). gJ 
abrogates activation of caspase-3, 6, 8 and 9 to halt the cellular apoptotic responses (346). 
Another late protein of HSV-1, UL14, also functions as viral apoptotic inhibitor since UL14-
deleted virus exhibits a reduced ability to suppress apoptosis (347). Furthermore, neuronal 
apoptotic cell death inhibition is associated with the function of HSV-1 latency-associated 
transcript (LAT). LAT expression abolishes both the intrinsic and extrinsic apoptotic pathway by 
interfering with caspase-8 and caspase-9 activation. Thus, the LAT expression contributes to the 
neuronal survival during latency (348, 349). 
 Despite multiple anti-apoptotic mechanisms of HSV-1, it encodes some immediate early 
proteins that induce apoptosis. HSV-1 ICP0 triggers induction of apoptosis. In the presence of 
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translational inhibitor, cyclohexamide (CHX), wild-type HSV-1 promotes apoptosis, while lack 
of ICP0 expression halts the induction of apoptosis. ICP0-medaited activation of the apoptotic 
pathway is associated with activation of caspase-3. Another immediate early protein of HSV-1, 
ICP27, stimulates the apoptotic cell death pathway by increasing intracellular reactive oxygen 
species (ROS) and Bax expression, as well (350). ICP27 also facilitates p38 mitogen-activated 
protein kinase signaling to stimulate apoptosis signaling pathway (351). However, ICP27 has also 
been demonstrated as an inhibitor of apoptosis (352). Thus, it is conceivable that HSV-1 infection 
causes apoptotic cell death. However, HSV-1 apoptosis inhibitor proteins such as, ICP24, gD, gJ, 
and UL14, eliminate the apoptotic signals to favor virus infection. 
 
1.6.4      Regulation of apoptosis by BoHV-1. 
 Viruses are ancient intracellular parasites that adopted various strategies to utilize the 
host cells to replicate and spread. Therefore, it is not surprising that BoHV-1 adopted multiple 
mechanisms to regulate apoptosis during productive infection. BoHV-1 infection in cattle or 
permissive bovine cell lines causes rapid cell death (15, 353). A growing body of evidence 
suggests that several proteins of BoHV-1 are involved in both induction and inhibition of 
apoptosis. BoHV-1 was found to induce apoptosis in peripheral blood mononuclear cells 
(PBMC) (354). In addition, BoHV-1 causes apoptotic cell death in large numbers of immune 
cells in vitro such as T-lymphocytes, B-lymphocytes, and monocytes/macrophages (355), 
lymphoid and epithelial cells.  
 Induction of apoptosis by BohV-1 is mediated by multiple mechanisms. Researchers 
reported that both live and inactivated BoHV-1 induces apoptosis in mitogen-stimulated PBMCs. 
Since triggering of apoptosis was observed with inactivated BoHV-1 virus particles, it was 
postulated that the mechanism of apoptosis induction might include the attachment or penetration 
or the effect of viral structural proteins, such as glycoproteins or tegument proteins (354, 356). 
gH of BoHV-1 is important for virus penetration but not for attachment. A gH-deleted mutant 
was able to induce apoptosis indicating that attachment but not penetration is required for 
apoptosis induction by BoHV-1 (356). Since a gD-deleted mutant was unable to trigger 
apoptosis, gD was concluded to be necessary for apoptotic cell death associated with virus 
attachment (357). In addition, BoHV-1 infection of Madin Darby Bovine Kidney (MDBK) cells 
leads to the activation of caspases and p53 resulting in apoptotic cell death (358). An immediate 
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early protein, ICP0 (bICP0) also functions as an apoptosis inducer (359, 360). bICP0 causes 
activation of caspase-3, a major hallmark of apoptosis, leading to apoptotic cell death (360). 
Furthermore, a tegument protein of BoHV-1, VP22, induces apoptosis through activation of 
caspase-3 and upregulation of Bax (361). Xu et al, 2012 also demonstrated the involvement of a 
mitochondria-dependent pathway in induction of apoptosis during BoHV-1 infection (362). They 
revealed that BoHV-1 infection activates both intrinsic and extrinsic pathways to activate 
caspase-8, cleavage of Bid and caspase-9. These events consequently trigger upregulation of Bax 
expression and caspase-3 activation, finally leading to apoptosis of BoHV-1-infected cells (362). 
A recent report also demonstrated that BoHV-1-induced oxidative stress promotes mitochondrial 
dysfunction by reducing ATP production and mitochondrial membrane potential (MMP) (363). 
Thus, ROS-mediated mitochondrial damage contributes to cell death. Moreover, the ORF8, 
located in the unique short (Us) segment of the BoHV-1 genome, plays a role in promoting 
apoptotic cell death. Cells infected with a BoHV-1 ORF8 deletion mutant exhibited significantly 
down-regulated apoptotic processes, suggesting the contribution of ORF8 in apoptosis induction. 
The importance of induction of apoptosis by ORF8 was demonstrated by the fact that loss of 
ORF8 markedly reduced the release of progeny viruses from the infected cells to the extracellular 
environment (364). Furthermore, increased expression of ORF8 leads to DNA laddering and 
chromatin condensation due to apoptotic cell death. Thus, BoHV-1 has developed various 
strategies to induce apoptosis in infected cells. 
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Figure. 1.4. Modulation of apoptosis by HSV-1 and BoHV-1.       
Apoptosis is triggered through activation of the extrinsic or intrinsic pathway. Binding of death 
receptor, TNFR1 or Fas R, to its corresponding ligand, TNF and FasL, leads to the formation of a 
complex containing TRADD and FADD. TRADD-associated complex triggers NF-κB activation 
followed by expression of anti-apoptotic genes, for example anti-apoptotic Bcl2 family proteins 
and cFLIP. These anti-apoptotic factors block both the intrinsic and extrinsic pathways. In the 
extrinsic pathway, a secondary complex, consisting of FADD, pro-caspase-3 and RIP1, is 
formed, which triggers caspase-8 activation. Activated caspase-8 promotes caspase-3 and 
caspase-7 activation leading to apoptosis. In the intrinsic pathway, activation of BAX promotes 
reduction of mitochondrial membrane potential (MMP) leading to the release of cytochrome C. 
In parallel, caspase-8 also triggers Bid and Bax activation leading to cytochrome C release. 
Cytochrome C activates caspase-9 leading to caspase-3 and caspase-7 activation. These 
executioner caspases induce apoptosis. The anti-apoptotic and pro-apoptotic proteins encoded by 
HSV-1 modulate apoptotic signaling. HSV-1 gJ, LAT and gD inhibits both intrinsic and extrinsic 
pathways. gD promotes anti-apoptotic gene expression  through NF-κB activation. US3 blocks 
the intrinsic pathway to inhibit apoptosis. ICP0 and ICP6 prohibit pro-caspase-8 activation. Other 
proteins, such as ICP24, ICP4, UL14 and ICP27 prevent apoptosis. However, ICP27 also 
functions as an apoptotic inducer. In addition, ICP0 triggers caspase activation to induce 
apoptosis. BoHV-1 is also known to activate both the intrinsic and extrinsic pathways. In the 
extrinsic pathway, BoHV-1 activates pro-caspase-8. Several BoHV-1 proteins, such as bICP0, 
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VP22 trigger caspase-3 activation. gD, ORF8, and US3 also induce apoptosis. However, US3 has 
also been found to block apoptosis. BoHV-1 activates the intrinsic pathway through reduced 
MMP, Bax and Bid activation, cytochrome C release, and caspase-9 activation.  Conversely, 
several anti-apoptotic proteins, such as gJ and ORF2, block BoHV-1-induced apoptosis. 
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 BoHV-1 also evolved apoptosis evasion mechanisms to counteract the apoptotic stimuli. 
As such, like most of the DNA viruses, BoHV-1 also encodes proteins responsible for inhibition 
of apoptosis. In contrast to apoptosis inducers, a tegument protein UL14 interferes with the 
apoptotic pathway (365). UL14 expression in transfected cells can inhibit caspase-3 and caspase-9 
activation and thereby increase cell survival in response to apoptotic stimuli (365). US3 of 
BoHV-1 is also involved in inhibition of apoptosis (366), although according to earlier reports 
US3 is not directly involved in blocking apoptosis (367).  Furthermore, during latency, a latency 
related-RNA (LR-RNA) is abundantly expressed. The LR-RNA-encoded protein, ORF2, 
negatively regulates apoptotic responses to promote survival of latently infected neuronal cells 
(368). Likewise, another glycoprotein, gG, is capable of postponing the apoptotic process and 
thus, contributes to cell survival and efficient production of virus (54). Overall, BoHV-1 encodes 
a number of proteins throughout the infection cycle, either to induce or to abrogate the apoptotic 
processes. Therefore, it is conceivable that, although BoHV-1 infection induces apoptosis, some 
virus-encoded anti-apoptotic proteins inhibit the lethal effects of apoptosis. As a result, a delicate 
balance between anti-apoptotic and pro-apoptotic activity promotes productive virus infection.  
 
Overall, since deletion of VP8 reduces BoHV-1 replication and egress, when grown in 
tissue culture, and prevents BoHV-1 replication in cattle (179), it was of interest to determine 
how VP8 contributes to BoHV-1 replication. Overcoming the cellular antiviral IFN response is a 
widely used strategy of viruses to promote infection. Hence, the first objective of this research 
was to determine the role of VP8 in regulation of IFN signaling during BoHV-1 infection. The 
DDR pathway also often functions as an antiviral response. Therefore, our second objective was 
to determine the effect of VP8 on the DDR pathway during BoHV-1 infection. Furthermore, 
HSP60 was identified as a new mitochondrial interacting partner of VP8. Hence, in our third 
objective we hypothesized that during BoHV-1 infection VP8 has an effect on mitochondrial 
functions. Overall, this research demonstrates various functions of VP8 during the life cycle of 
BoHV-1.			
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CHAPTER 2 	
HYPOTHESIS AND OBJECTIVES 
	
2.1         Rationale and hypothesis. 
 The major tegument protein of BoHV-1, VP8, is indispensable for virus replication in 
cattle, and a VP8-deleted mutant virus demonstrates defective virus replication in cell culture 
(179). In addition, VP8 is abundantly incorporated into the mature BoHV-1 virion (41), 
suggesting the importance of VP8 during the lytic replication cycle. Upon fusion of viral 
envelope with the host cell membrane, VP8 is dissociated from the virion, and detected in the 
cytoplasmic compartment at 2 h post infection (187). This might reflect the significance of the 
function of VP8 at early stages of BoHV-1 infection. We hypothesize that VP8 contributes to the 
modulation of cellular antiviral responses against invading BoHV-1 during early infection, and 
thus, promotes BoHV-1 replication.  
 In the absence of VP8, the mutant virus exhibited drastic reduction in virus replication, 
suggesting a pro-viral role of VP8 during BoHV-1 infection. In addition, since a VP8-deleted 
mutant was avirulent in vivo, VP8 might be a potential candidate for modulating strong anti-viral 
responses. Therefore, we hypothesized that VP8 functions through alteration of anti-viral 
responses during BoHV-1 infection.    
 
 
2.2          Objectives. 	
§  Identify a role of VP8 in the establishment of BoHV-1 infection through inhibition of IFN-
β signaling. 
§ Investigate the function of VP8 in the modulation of the DNA damage response pathway 
during BoHV-1 infection. 
§ Express and purify VP8, and investigate its role as mitochondrial interacting partner.  
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3.1         Abstract 
 The UL47 gene product, VP8, is the most abundant tegument protein of bovine 
herpesvirus 1 (BoHV-1). Previously, we demonstrated that a UL47-deleted BoHV-1 mutant 
(BoHV1-ΔUL47) exhibits 100-fold-reduced replication in vitro and is avirulent in vivo. In this 
study, we demonstrated that VP8 expression or BoHV-1 infection inhibits interferon beta (IFN-β) 
signaling by using an IFN-α/β-responsive plasmid in a luciferase assay. As transducer and 
activator of transcription (STAT) is an essential component in the IFN-signaling pathways, the 
effect of VP8 on STAT1 was investigated. An interaction between VP8 and STAT1 was 
established by coimmunoprecipitation assays in both VP8-transfected and BoHV-1-infected cells. 
Two domains of VP8, amino acids 259 to 482 and 632 to 686, were found to be responsible for 
its interaction with STAT1. The expression of VP8 did not induce STAT1 ubiquitination or 
degradation. Moreover, VP8 did not reduce STAT1 tyrosine phosphorylation to down-regulate 
IFN-β signaling. However, the expression of VP8 or a version of VP8 (amino acids 219 to 741) 
that contains the STAT1-interacting domains but not the nuclear localization signal prevented 
nuclear accumulation of STAT1. Inhibition of nuclear accumulation of STAT1 also occurred 
during BoHV-1 infection, while nuclear translocation of STAT1 was observed in BoHV1-
ΔUL47-infected cells. During BoHV-1 infection, VP8 was detected in the cytoplasm at 2 h post 
infection without any de novo protein synthesis, at which time STAT1 was already retained in the 
cytoplasm. These results suggest that viral VP8 down-regulates IFN-β signaling early during 
infection, thus playing a role in overcoming the antiviral response of BoHV-1-infected cells. 
 
3.2         Importance.  
Since VP8 is the most abundant protein in BoHV-1 virions and thus may be released in 
large amounts into the host cell immediately upon infection, we proposed that it might have a 
function in the establishment of conditions suitable for viral replication. Indeed, while 
nonessential in vitro, it is critical for BoHV-1 replication in vivo. In this study, we determined 
that VP8 plays a role in down-regulation of the antiviral host response by inhibiting IFN-β 
signaling. VP8 interacted with and prevented nuclear accumulation of STAT1 at 2 h post 
infection in the absence of de novo viral protein synthesis. Two domains of VP8, amino acids 259 
to 482 and 632 to 686, were found to be responsible for this interaction. These results provide a 
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new functional role for VP8 in BoHV-1 infection and a potential explanation for the lack of viral 
replication of the UL47 deletion mutant in cattle. 
 
Key words: BoHV-1, VP8, IFN signaling, STAT1 
 
3.3         Introduction. 
  Bovine herpesvirus-1 (BoHV-1) is responsible for several clinical manifestations, 
including rhinotracheitis, vulvovaginities and conjunctivitis, in cattle (26). BoHV-1 is composed 
of a double-stranded DNA surrounded by a nucleocapsid, a tegument and an envelope (369). 
Although the tegument is a major constituent in the BoHV-1 virion, it is the least studied. The 
tegument consists of at least 20 virus-encoded proteins (reviewed in (106)). Herpesvirus infection 
is mediated by the interaction of glycoproteins such as gB, gC and gD with cellular proteins 
(370). The majority of the tegument proteins is then released into the cytoplasm indicating that 
these proteins are the first to interact with the intracellular environment (66). Herpesvirus 
tegument proteins are involved in various functions including capsid transport, DNA replication, 
transcriptional and translational regulation, and viral assembly and egress (106). These functions 
suggest that tegument proteins contribute to the establishment of conditions suitable for viral 
replication.  
  The ul47 gene product, VP8, is a 97 kD tegument protein and the most abundant protein 
in BoHV-1 virions (176).  Although BoHV-1 VP8 is not essential for viral infection, a UL47-
deleted mutant (BoHV1-ΔUL47) exhibits a smaller tegument structure and impaired growth in 
cell culture, and is avirulent in cattle (179). In addition, BoHV-1 VP8 plays a role in induction of 
humoral and cellular immunity (181). VP8 is monoubiquitinated and interacts with DNA damage 
binding protein-1 (DDB1) (187), which is a component of the Cul4A-DDB1 E3 ubiquitin ligase 
complex (371). Furthermore, VP8 remodeled the distribution of promyelocytic leukemia (PML) 
nuclear bodies (NBs) (185).  
Viruses can establish an infection in the host cells by overcoming the antiviral defense 
mechanisms. The antiviral state is established by secretion of type I interferon (IFN), which is 
needed for the activation of other cellular genes. Interferons are categorized into type I (IFN-α, 
IFN-β, IFN-ω, IFN-κ and IFN-ε), type II (IFN-γ) and Type III (IFN-λ) depending on their 
primary structure [reviewed in (198, 372)]. IFN-α/β are synthesized by cells in response to viral 
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infections, whereas IFN-γ is secreted by activated T lymphocytes and natural killer cells in virus-
infected cells. These types of IFN are involved in limiting the growth of target cells and in 
influencing cell apoptosis, thereby arresting viral spread. The activity of these IFNs is initiated by 
the binding of IFN-α/β and IFN-γ to their cell surface receptors (373). Some IFN-mediated 
cascades are regulated by the Janus tyrosine kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway, whereas others are regulated by STATs to optimize 
transcription regulation of target genes (198). IFN-λs are induced by either interferon response 
factor (IRF3), IRF7 or NF-κB pathways (372). Recently, IFN-λ was identified as having antiviral 
properties against numerous viruses. 
The activation of the JAK/STAT signaling pathway is initiated by binding of IFN-α/β to 
their receptors, which are composed of IFNAR1 and IFNAR2 subunits. Upon binding of IFN-α/β 
to its receptors, the IFNAR1 and IFNAR2 complex activates tyrosine kinase 2 (Tyk2) and Janus 
kinase 1 (JAK1) by transphosphorylation. Activated Tyk2 phosphorylates IFNAR1 on tyrosine 
466, making a platform to bind STAT2. This facilitates phosphorylation of STAT2 by activated 
Tyk2, which in turn recruits STAT1. The newly recruited STAT1 is phosphorylated on tyrosine 
701 residue by JAK1. Phosphorylated STAT1 and STAT2 form a heterodimer, which dissociates 
from the receptor and then translocates to the nucleus to bind with IRF9 and form a 
heterotrimeric complex, the IFN stimulated gene factor-3 (ISGF3) complex. The ISGF3 complex 
binds to the IFN response element for the induction of IFN-stimulated genes [reviewed in (373)].  
  Most viruses have developed specific mechanisms to circumvent the IFN response, either by 
reducing IFN production or by down-regulating the IFN signaling cascade (373). For example, 
rabies virus P protein (374), simian virus 5 (SV5) V protein (375), respiratory syncytial virus 
(376), human parainfluenza virus type-1 virus V protein (377) and mumps virus V protein (378) 
inhibit IFN-β signaling by proteasome-mediated degradation of STAT1 or STAT2, by reducing 
phosphorylation of STAT1 or STAT2, or by inhibiting nuclear translocation of STAT1. During 
BoHV-1 infection, inhibition of IFN signaling by infected cell protein bICP0 through degradation 
of IRF3 was observed (207). In the absence of IRF3 expression, bICP0 inhibits the ability of 
IRF7 to trans-activate the IFN-β promoter (379). Furthermore, bICP27 inhibits transcriptional 
activity of two bovine IFN-β gene promoters (IFN-β1 and IFN-β3) during transient transfection 
(380).	However, no other protein of BoHV-1 has been reported to down-regulate IFN-β signaling.  
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  Since BoHV-1 VP8 is essential for viral replication in vivo, we examined its effect on 
the IFN signaling pathway. We determined that VP8 down-regulates the IFN response, both in 
VP8-transfected and in BoHV-1-infected cells. VP8 interacted with STAT1, and this interaction 
required two distinct domains of VP8. Furthermore, VP8 acted as an IFN antagonist by 
preventing nuclear translocation of STAT1. 
 
3.4         Materials and Methods. 
	
3.4.1	 Cell culture, virus infection and IFN treatment.  
               Madin-Darby bovine kidney (MDBK), embryonic bovine tracheal (EBTr), human 
embryonic kidney HEK293T, and Vero cells were grown in Eagle's minimum essential medium 
(MEM; Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco, Life Technologies, Burlington, ON, Canada), 1% 
antibiotic-antimycotic (Life Technologies), and 10 mM HEPES buffer (Life Technologies). Cells 
were cultured with 5% CO2 in a 37°C incubator. Wild-type BoHV-1 108, BoHV1-ΔUL47, and 
BoHV1-UL47R were propagated in MDBK cells (8). MDBK cells were infected with BoHV-1 at 
a multiplicity of infection (MOI) of 0.5 unless indicated otherwise. Recombinant human IFN-β 
was purchased from PeproTech Inc. (Rocky Hill, NJ, USA), and bovine IFN-β was purchased 
from Kingfisher (Saint Paul, MN, USA). 
 
3.4.2      Antibodies. 
VP8-specific mouse monoclonal antibody was used as previously described (181). 
Rabbit antibodies specific for bICP0 and bICP4 were made in-house and used as described 
previously (179) (188). Rabbit polyclonal anti-STAT1 (catalog no. sc-345), anti-STAT1 p84/91 
(catalog no. sc-346), anti-pSTAT1 (catalog no. sc-8394), anti-STAT2 (catalog no. sc-476), anti-
ubiquitin (catalog no. sc-8071) and anti-fibrillarin (H-140) antibodies were obtained from Santa 
Cruz Biotechnology Inc. (Dallas, Texas, USA). Mouse monoclonal anti-FLAG (catalog no. 
F3165-0.2MG), anti-actin (catalog no. A2228) and anti-tubulin (catalog. no T6199) antibodies 
were purchased from Sigma-Aldrich. SV5 V5-specific rabbit antibody was purchased from 
Invitrogen, Life Technologies.  
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Table 3.1 Primer list for plasmid constructions using PCR (5’ to 3’end) 
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3.4.3      Plasmids. 
The ul47 gene (GenBank accession no. AY530215.1) was cloned into pFLAG-CMV2 
(Sigma-Aldrich) as described previously (184). The VP8 ORF was sub-cloned with a N-terminal 
FLAG tag into an expression vector (named pCMV4.1k) downstream from a human CMV 
promoter with intron A. The resulting plasmid was then used as a template in PCR to generate 
truncated versions of the FLAG-VP8 ORF, using the primers listed in Table 3.1. PCR fragments 
were cloned back into the pCMV4.1k expression vector to create the constructs described in the 
text. Correct ORFs of all constructs were verified by DNA sequencing. The pFLAG-CMV-2 
plasmid was purchased from Sigma-Aldrich. The IFN-α/β responsive reporter plasmid, 
pISREluc, and pRL-TK have been described previously (375), and were kindly provided by Dr. 
Danielle Blondel, LVMS, CNRS, France. pISREluc contains the firefly luciferase gene fused 
with four tandem repeats of the IFN-inducible gene 9-27 ISRE. pRL-TK, which contains the 
herpes simplex virus thymidine kinase promoter region upstream of the Renilla luciferase gene, 
was used to normalize transfection. A Simian Virus 5 V expression plasmid, pSV5V, and pHis-
Ub plasmids were kindly provided by Dr. Richard Randall, University of St. Andrews, School of 
Biology, St, Andrews, Fife, United Kingdom. 
 
3.4.4      Luciferase assay. 
  Vero cells were used as IFN-deficient cells to demonstrate the effect of transient VP8 
expression on IFN-treated and nontreated cells. Vero cells were seeded at a concentration of 7 × 
104 cells per well in 24-well plates. The next day, the cells were transfected with pRL-TK and 
pISREluc together with pCMV4.1K (empty vector), pFLAG-EYFP, or pFLAG-VP8 by using 
Lipofectamine and Plus reagent (Invitrogen, Life Technologies). At 24 h posttransfection, cells 
were treated with 2,500 units/0.5 ml of human IFN-β or left untreated. While MDBK cells are 
routinely used for propagation of high-titer BoHV-1, they are very resistant to transfection. EBTr 
cells have a relatively good transfection efficiency and thus were used to determine the effects of 
VP8 on IFN during BoHV-1 infection. EBTr cells were transfected with pRL-TK and pISREluc 
plasmids, and 24 h later the cells were infected with BoHV-1 or BoHV-1-ΔUL47. At 24 h post 
infection, the cells were treated with 400 ng/0.5 ml of bovine IFN-β or left untreated. Cells were 
harvested 6 h after IFN treatment in lysis buffer. Firefly and Renilla luciferase activity were 
assayed in the cell lysates according to the manufacturer's protocol (dual-luciferase reporter assay 
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system; Promega, Madison, WI, USA). The relative expression levels were determined by 
dividing the firefly luciferase values by the Renilla luciferase values. Actinomycin D (ActD; 
Sigma-Aldrich) was used to treat cells before the luciferase assay. EBTr cells were transfected 
with pRL-TK and pISREluc for 20 h. The transfected cells were treated with ActD at a 
concentration of 10 µg/ml for 1 h before mock infection or infection with BoHV-1 or BoHV1-
UL47R at an MOI of 4 or with BoHV-1-ΔUL47 at an MOI of 10. ActD was maintained in the 
medium throughout the infection. One hour after addition of the virus ActD was removed, the 
medium was replaced with fresh medium, and cells were stimulated with bovine IFN-β for 1 h. 
Cell lysates were prepared and luciferase assays were performed as described above. 
  
3.4.5      Preparation of cell lysates.   
  HEK293T and EBTr cells at 80 to 90% confluence were transfected with different 
plasmids by using Lipofectamine and Plus reagent (Invitrogen, Life Technologies). HEK293T 
cells were used for coimmunoprecipitation experiments. Cells were incubated with MEM for 48 
h, washed with ice-cold PBS (pH 7.3), and lysed in lysis buffer (50 mM Tris, 150 mM NaCl, 1 
mM EDTA, 1% Triton X-100, pH 7.4) supplemented with 10 µl/ml mammalian cell and tissue 
extract protease inhibitor cocktail (Sigma-Aldrich). Cells were gently rocked on a nutator for 3 to 
4 min and then kept on ice for 30 min before centrifugation at 12,000 × g for 15 min at 4°C. The 
supernatant was collected in an Eppendorf tube and kept at −80°C for future use. EBTr cells were 
used for transfection and BoHV-1 infection. To prepare lysates, BoHV-1-infected cells were 
collected at 24 h post infection. 
 
3.4.6      Immunoprecipitation and Western blotting. 
              Cell lysates prepared as described above were incubated with ant-VP8, anti-STAT1, or 
anti-ubiquitin antibody overnight at 4°C followed by incubation with protein G-Sepharose Fast 
Flow beads (GE HealthCare, Niskayuna, NY, USA) for 3 h at 4°C; alternatively, anti-FLAG M2 
affinity gel (Sigma-Aldrich) was directly added to the cell lysates, and the mixtures were 
incubated at 4°C overnight. This was followed by three washes with buffer (50 mM Tris-HCl, 
250 mM NaCl, 2% Triton X-100, pH 7.4). For Western blotting, 15 to 25 µg of the immune 
complexes or cell lysates was boiled for 5 min after addition of SDS-PAGE sample buffer. 
Proteins were separated on 10% or 8 to 16% SDS-PAGE gels and then transferred to 
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nitrocellulose membranes. The nitrocellulose membranes were blocked with 5% skim milk in 
phosphate-buffered saline-Tween-20 (PBST; 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 
135 mM NaCl, 0.1% Tween 20, pH 7.4) for 2 h followed by incubation overnight at 4°C with 
anti-STAT1, anti-FLAG, anti-VP8, and/or anti-ubiquitin antibodies. The membranes were 
washed three times with PBST and incubated with IRDye680-conjugated anti-mouse IgG or 
IRDye-800CW-conjugated anti-rabbit IgG (LI-COR Bioscience, Lincoln, NE, USA). The 
proteins were detected with an Odyssey Infrared Imaging system (LI-COR Bioscience) followed 
by processing of images by Odyssey 3.0.16 application software (LI-COR Bioscience). 
 
3.4.7      Cell fractionation.  
Cytoplasmic and nuclear fractions were obtained as described previously (26). Cell 
fractionation was performed using Nuclei EZ Prep lysis buffer (Sigma). Briefly, cells were 
collected by trypsinization followed by lysis for 5 min on ice with the Nuclei EZ lysis buffer. The 
nuclei were collected by centrifugation at 500 × g for 5 min at 4°C. The incubation in lysis buffer 
and centrifugation were repeated five times to remove any loosely bound cytoskeletal 
components from the nuclei. The supernatants were pooled as cytoplasmic fraction and 
concentrated with an Amicon Ultra-15 Ultracel-10K filter unit (Millipore). For nuclear isolation, 
the nuclei were resuspended in 3 ml of 0.25 M sucrose, 10 mM MgCl2, and 1 mM 
phenylmethylsulfonyl fluoride (PMSF), layered over a 3-ml cushion of 0.88 M sucrose, 0.5 mM 
MgCl2, and 1 mM PMSF, and centrifuged at 2,800 × g for 10 min at 4°C. The nuclear pellet was 
resuspended in 200 µl of the Nuclei EZ storage buffer. The nuclei were counted with a 
hemocytometer, and equal numbers of nuclei were lysed by incubation with SDS at 100°C for 5 
min. The purity of the nuclei was determined by Western blotting with fibrillarin- and tubulin-
specific antibodies. 
 
3.4.8      Immunofluorescence and confocal microscopy. 
Vero cells were plated at a concentration of 2 × 105 cells per well in two-chamber 
Permanox slides (Lab-Tek, Naperville, IL, USA) and mock transfected or transfected with 
pFLAG-VP8 219-741 or pFLAG-VP8. At 24 h posttransfection, cells were fixed with 4% 
paraformaldehyde (Sigma-Aldrich) for 20 min at room temperature (RT) followed by 
permeabilization and blocking with 1% goat serum and 0.1% Triton X-100 in PBS. FLAG-
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tagged proteins and STAT1 were detected by incubating cells with mouse monoclonal anti-
FLAG (diluted 1:1,000) and rabbit anti-STAT1 (diluted 1:50) antibodies for 2 h at RT. MDBK 
cells were infected with BoHV-1 or BoHV1-UL47R at an MOI of 4 or with BoHV1-ΔUL47 at an 
MOI of 5 for 14 h and then fixed and stained as described above. For the time course experiment, 
MDBK cells were infected with BoHV-1 at an MOI of 4, and samples were fixed and blocked 
overnight. The next morning, cells were incubated with monoclonal anti-VP8 or anti-gB 
antibodies and rabbit anti-STAT1 antibodies for 2 h. Alexa Fluor 488 goat anti-mouse IgG and 
Alexa Fluor 633 goat anti-rabbit IgG (diluted 1:500; Invitrogen, Life Technologies) were used as 
secondary antibodies. Finally, mounting medium containing 4′,6-diamino-2-phenylindinole 
(DAPI) was added, and the slides were air dried for 24 h at RT. The cells were examined and 
images taken with a Leica SP5 confocal microscope (Leica Microsystems Inc., Concord, ON, 
Canada), using green laser excitation at 488 nm (Alexa 488), red laser excitation at 633 nm 
(Alexa 633), and 461 nm for DAPI. Final images were processed using the Image J browser. 
 
3.5         Results. 
3.5.1      VP8 inhibits IFN-β signaling. 
              While VP8 has been reported to be nonessential in vitro, it is critical for replication in 
cattle in vivo, which suggests that it might have a profound impact on the innate antiviral 
response. As type I IFN signaling constitutes one of the most powerful antiviral defense 
mechanisms, we examined whether VP8 plays a role in IFN down regulation by conducting 
luciferase reporter gene assays with Vero cells in the presence or absence of VP8 expression. 
Since Vero cells are IFN deficient, IFN-β responses were induced by addition of extracellular 
IFN-β. Vero cells were transfected with luciferase reporter plasmids pRL-TK and pISRE together 
with pCMV4.1K, pFLAG-EYFP, or pFLAG-VP8, and cells were stimulated with IFN-β at 24 h 
posttransfection or left untreated. IFN-β treatment of Vero cells resulted in induction of luciferase 
expression compared to untreated cells (Figure. 3.1A). When the cells were transfected with 
CMV4.1K or FLAG-EYFP, no inhibition of IFN-β signaling was observed. However, IFN 
signaling was reduced to 22% in VP8-expressing cells compared to cells transfected with 
pCMV4.1K or pFLAG-EYFP. This indicates transcriptional activation of the ISREs due to the 
formation of ISGF3 transcription complexes in the cells. Treatment of FLAG-VP8-transfected 
Vero cells with IFN-β demonstrated that the expression of VP8 inhibits IFN-β-responsive 
		
	 59	
transcription. The presence of VP8 in the cell lysates was confirmed by Western blotting with 
anti-VP8 antibody (Figure. 3.1B). 
             The IFN-β response was also investigated in the context of BoHV-1 infection. EBTr cells 
were transfected with luciferase reporter plasmids, and at 24 h posttransfection cells were mock 
infected or infected with BoHV-1 or BoHV1-ΔUL47. IFN-β treatment of mock-infected cells 
resulted in significant production of luciferase, in contrast to what was observed for nontreated 
cells. However, BoHV-1 infection reduced the induction of luciferase expression by IFN-β to 
∼20% compared to mock infection (Figure. 3.1C) indicating inhibition of IFN signaling. Some 
luciferase activity was also observed in cells not treated with IFN-β, which can be attributed to 
the fact that EBTr cells are not IFN deficient. In BoHV1-ΔUL47-infected cells, the luciferase 
activity was higher than that in BoHV-1-infected cells, further confirming the inhibitory effect of 
VP8 on the IFN response. These results suggest that VP8 functions as IFN-β antagonist during 
BoHV-1 infection. 
              Some residual down-regulation of the IFN response was observed in BoHV1-ΔUL47-
infected cells, which could be attributed to the presence of bICP0. To confirm the inhibition of 
IFN signaling by VP8 in the absence of any immediate early protein expression, ActD was used 
to inhibit transcription. EBTr cells were transfected with luciferase reporter plasmids, and at 20 h 
posttransfection cells were or were not pretreated with ActD before mock infection or infection 
with BoHV-1, BoHV1-ΔUL47, or BoHV1-UL47R. In BoHV-1- and BoHV-1-UL47R-infected 
cells, the luciferase signal was reduced to ∼20% without ActD treatment compared to mock-
infected cells (Figure. 3.1D), while infection with BoHV1-ΔUL47 reduced IFN signaling to 
∼70%. The expression of VP8 and two immediate early proteins, bICP0 and bICP4, is shown in  
 Figure 3.1E. Since ActD is a transcription inhibitor, no expression of immediate early protein 
was observed in ActD-treated cells as expected. However, VP8 was detected at 2 h post infection 
in BoHV-1- and BoHV-1-UL47R-infected cells regardless of ActD treatment (Figure. 3.1E & 
3.1G), representing VP8 released from the virions. In the presence of ActD, IFN signaling was 
again inhibited by BoHV-1 or BoHV1-UL47R infection to ∼20%, while the mock and BoHV1-
ΔUL47 infection did not cause down-regulation of IFN signaling (Figure 3.1F) These experiments 
demonstrate that the residual inhibition of IFN signaling induced by BoHV1-ΔUL47 was due to 
immediate early gene expression. Furthermore, inhibition IFN signaling was caused by VP8 
released from the incoming virions in the absence of any immediate early protein expression. 
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Figure. 3.1 Inhibition of IFN-β signaling by BoHV-1 VP8.   
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Vero cells were transfected with pISREluc and pRL-TK together with pCMV4.1K, pFLAG-
EYFP, or pFLAG-VP8. (A) At 24 h posttransfection, cells were stimulated with 2,500 units of 
human IFN-β in 0.5 ml or left untreated. After 6 h of incubation, cell lysates were made and 
reporter gene activity was measured. (B) Expression of VP8 and EYFP was confirmed by 
Western blotting with monoclonal anti-FLAG antibody. (C) EBTr cells were transfected with 
pISREluc and pRL-TK. At 24 h posttransfection cells were mock infected or infected with 
BoHV-1 or BoHV1-ΔUL47, and another 24 h later cells were treated with 400 ng of bovine IFN-
β in 0.5 ml or left untreated. After 6 h of incubation, cell lysates were made and reporter gene 
activity was measured. (D to G) EBTr cells were transfected with pISREluc and pRL-TK, and at 
20 h posttransfection cells were either left untreated (D and E) or were pretreated with ActD (F 
and G) before mock infection or infection with BoHV-1, BoHV1-ΔUL47, or BoHV1-UL47R. (D 
and F) At 1 h post infection, cells were stimulated with IFN-β for 1 h, and at 2 h post infection 
cell lysates were collected and reporter gene activity was measured. ActD was maintained in the 
medium throughout the infection. (E and G) Expression of VP8, bICP0, and bICP4 in untreated 
cells (E) but not in Act-treated cells (G) was confirmed by Western blotting with monoclonal 
anti-FLAG antibody and bICP0- and bICP4-specific rabbit antibodies, respectively. IFN-β-
induced firefly luciferase reporter values were normalized to the expression of Renilla luciferase. 
The values are presented as percentages of IFN-stimulated controls and are expressed as means ± 
standard deviations (SD) for six samples. Statistical significance is indicated by asterisks 
(***, P < 0.001). 
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3.5.2      Identification of STAT1 as an interacting target of BoHV-1 VP8.  
              Since STATs play a critical role in IFN signaling, we determined whether VP8 might 
interact with STAT1 or STAT2. HEK293T cells were transiently transfected with pFLAG-EYFP 
or pFLAG-VP8. At 48 h posttransfection, cell lysates were prepared and incubated with anti-
FLAG resin (Figure. 3.2A) and anti-STAT1 antibody followed by protein G-Sepharose	 (Figure. 
3.2B). STAT1 was precipitated from pFLAG-VP8-transfected cells but not from pFLAG-EYFP- 
or mock-transfected cells	(Figure. 3.2A). Anti-STAT1 antibody precipitated STAT1 from mock-, 
FLAG-EYFP-, and FLAG-VP8-transfected lysates	 (Figure. 3.2B), whereas it precipitated VP8 
from the FLAG-VP8-, but not from mock- or FLAG-EYFP-transfected cell lysates (Figure. 
3.2B). Expression of pFLAG-EYFP and pFLAG-VP8 in transfected cell lysates is confirmed in 
Figure. 3.2C. As further evidence of VP8 interaction with endogenous STAT1, MDBK cells were 
infected with BoHV-1 or BoHV1-ΔUL47. At 24 h post infection cells were lysed, and proteins 
were precipitated with anti-bovine STAT1 antibody followed by Protein G Sepharose, and 
analyzed by Western blotting. As shown in Figure. 3.2D, VP8 was precipitated with cellular 
STAT1 in BoHV-1-infected cells, whereas no VP8 was pulled down from mock- or BoHV1-
ΔUL47-infected cell lysates. The expression of VP8 and STAT1 in BoHV-1-infected cells is 
shown in Figure. 3.2F. To pull down endogenous STAT1 with BoHV-1 VP8, mock, BoHV-1 or 
BoHV1-ΔUL47-infected cell lysates were incubated with anti-VP8 antibody followed by Protein 
G Sepharose. STAT1 was precipitated with VP8-specific antibody in BoHV-1-infected cells but 
not in mock- or BoHV1-ΔUL47-infected cells (Figure. 3.2E). To identify interactions between 
VP8 and STAT2, mock, FLAG-EYFP and FLAG-VP8 transfected lysates (Figure. 3.2G) were 
subjected to immunoprecipitation with anti-FLAG resin. Input lysates are presented in Figure. 
3.2H. STAT2 was neither precipitated by FLAG-EYFP nor by FLAG-VP8. These results 
demonstrate that VP8 interacts with STAT1 in both transiently transfected and BoHV-1-infected 
cells. However, VP8 did not interact with STAT2. 
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Figure. 3.2 BoHV-1 VP8 interacts with STAT1.  
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HEK293T cells were transfected with pFLAG-EYFP or pFLAG-VP8. (A and B) At 48 h 
posttransfection, cell lysates were generated and incubated with anti-FLAG resin (A) or anti-
STAT1 antibody (B) followed by protein G-Sepharose. (C) Input lysates of mock-, pFLAG-
EYFP-, and pFLAG-VP8-transfected cells that were used in the immunoprecipitation assays 
illustrated in panels A and B. (D to F) MDBK cells were mock infected or infected with BoHV-1 
or BHV1-ΔUL47. (D and E) At 24 h post infection, cell lysates were made and incubated with 
anti-STAT1 antibody (D) and anti-VP8 antibody (E), followed by protein G-Sepharose. (F) 
Expression of VP8 in BoHV-1-infected cells and STAT1 in mock-, BoHV-1-, or BoHV1-ΔUL47-
infected cells. (G and H) HEK293T cells were transfected with pFLAG-EYFP or pFLAG-VP8. 
(G) At 48 h posttransfection, cell lysates were collected and incubated with anti-FLAG resin. (H) 
Input lysates of mock-, pFLAG-EYFP-, and pFLAG-VP8-transfected cells that were used in the 
immunoprecipitation assay illustrated in panel G. VP8, EYFP, STAT1, and STAT2 were detected 
by Western blotting with monoclonal anti-VP8 and anti-FLAG antibodies and rabbit anti-STAT1 
and anti-STAT2 antibodies, respectively. 
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3.5.3      Identification of interacting domains of VP8 with STAT1.  
Since the central and C-terminal parts of VP8 are conserved between herpesviruses 
while the N-terminal part is not (Figure. 3.3), it was of interest to determine which domain of 
VP8 interacts with STAT1. Nine different plasmids containing N-terminally and C-terminally 
truncated, FLAG-tagged VP8-coding sequences were generated. First, plasmids encoding N-
terminally truncated FLAG-tagged VP8 were used to investigate the role of the C-terminal 
domain of VP8 in the interaction with STAT1. Anti-STAT1 antibody precipitated all N-
terminally truncated versions of VP8 (VP8 121-741, VP8 219-741, VP8 343-741, VP8 538-741 
and VP8 632-741) as well as full-length VP8 (Figure. 3.4A) from transfected cells. As all of the 
N-terminally truncated VP8 versions contain amino acids 632-741, this suggests that a STAT1-
binding domain is located within this region of VP8. To investigate the involvement of the N-
terminal domain of VP8 in the interaction with STAT1, cell lysates with C-terminally truncated 
VP8 (VP8 1-120, VP8 1-258, VP8 1-482 and VP8 1-631) and full-length VP8 were analyzed by 
immunoprecipitation with anti-STAT1 antibody (Figure. 3.4C). This experiment demonstrated 
that VP8 was only precipitated by anti-STAT1 antibody when amino acids 259-482 were 
retained, and this occurred even though amino acids 632-741 were absent.  Input cell lysates are 
presented in Figure. 3.4B and 3.4D. These results indicate that the conserved central and C-
terminal parts of VP8 contain two domains, 259-483 and 632-741, that mediate its interaction 
with STAT1. To further define the interacting regions of VP8, four additional VP8 truncations 
consisting of amino acids 1-371, 372-483, 631-686 and 687-741, were generated. The latter four 
truncations also contained amino acids 1-258, a domain shown not to interact with STAT1, at the 
N-terminal region to facilitate expression. VP8 259-371, VP8 372-483 and VP8 631-686, but not 
VP8 687-741, were immunoprecipitated with anti-STAT1 antibody (Figure. 3.4E). Input lysates 
demonstrating expression of these truncated VP8 versions and STAT1 are shown in Figure. 3.4F. 
This result demonstrates that domains within the 259-482 and 632-686 regions of VP8 are 
required for its interaction with STAT1. A schematic presentation summarizing VP8-interacting 
domains with STAT1 is provided in Figure. 3.5. 
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Figure. 3.3 Comparison of the amino acid sequences of BoHV-1 UL47 and its homologues. 
The sequence labels are Bovine herpesvirus 1 (BoHV1), Human herpesvirus 1 (HHV1), Equine 
herpesvirus 1 (EHV1), Suid herpesvirus 1 (SHV1) and Gallid herpesvirus 3 (GHV3) UL47 
protein. The consensus secondary structure prediction for the UL47 family is shown above the 
sequences. The prediction was carried out using PROFphd software (381, 382).    Invariant 
residues are highlighted in bold letters with white boxes, and highly conserved residues in white 
bold text surrounded by black boxes. The alignment was generated using UniPro (citation) and 
the figure was generated using the ESPript server (382). 
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Figure. 3.4 Mapping of STAT1 interacting domains in BoHV-1 VP8.  
 
HEK293T cells were transfected with plasmids containing FLAG, FLAG-VP8, or different N-
terminally and C-terminally truncated FLAG-tagged VP8 versions as indicated. At 48 h 
posttransfection, cell lysates were made and incubated with anti-STAT1 antibodies (ab), followed 
by incubation with protein G-Sepharose. Immune complexes were separated by SDS-PAGE and 
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detected by Western blotting. Immunoprecipitation of N-terminally (A) and C-terminally (C) 
truncated FLAG-tagged VP8 with anti-STAT1 antibody. Input lysates of cells transfected with 
N-terminally (B) and C-terminally (D) truncated FLAG-tagged VP8. (E) Immunoprecipitation of 
VP8 259-371, 372-483, 631-686, and 687-741 with anti-STAT1 antibody. (F) Input lysates of 
cells transfected with VP8 259-371, 372-483, 631-686, or 687-741. Truncated and full-length 
VP8 and STAT1 were detected using antibodies specific for FLAG and STAT1, respectively. It 
should be noted that anti-STAT1 antibody detects both STAT1α and STAT1β. Molecular weight 
markers (× 10−3) are indicated in the left margins. 
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Figure. 3.5 Schematic representation of the interacting domains of VP8 with STAT1.  
 
The solid lines represent the presence of VP8 amino acids and empty spaces represent the deleted 
portions of VP8. Interaction of VP8 with STAT1 is shown by the + sign and lack of interaction is 
indicated by the – sign. The first and last amino acids of each VP8 mutant are indicated. The red 
lines indicate STAT1-interacting domains of VP8. 
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3.5.4      Effects of VP8 on STAT1 ubiquitination and degradation. 
 STAT1 is a well-known transcriptional regulator. Some viral proteins, such as SV5 V 
protein, interact with STAT1 and mediate ubiquitination and subsequent degradation of STAT1 
(375). Since BoHV-1 VP8 caused down-regulation of IFN-β signaling and interacted with 
STAT1, we investigated whether STAT1 is ubiquitinated and degraded in the presence of VP8 or 
SV5 protein V, which was used as positive control for detection of STAT1 ubiquitination. HEK 
293T cells were co-transfected with pFLAG/pHis-Ub, pFLAG-VP8/pHis-Ub and pSV5V/pHis-
Ub plasmids in the presence or in the absence of the proteasome inhibitor MG132. Since 
ubiquitin proteases cleave off ubiquitin from polyubiqutinated STAT1, His-Ub plasmid was used 
for transfection in each sample. To prevent cleavage of ubiquitin from ubiquitinated STAT1, the 
ubiquitin protease inhibitor guanidium hydrochloric acid was used at a final concentration of 6M 
in the lysis buffer. At 24 h post-transfection cell lysates were generated and incubated with His-
60 nickel beads, and protein complexes were analyzed by Western blotting with anti-STAT1 
antibody. Figure. 3.6A shows that ubiquitinated STAT1 was not pulled down in mock- and 
FLAG-VP8 transfected lysates, but was pulled down from SV5 V-transfected lysates. Input 
lysates are presented in Figure. 3.6B. In the absence of MG132 STAT1 was not detected (Figure. 
3.6D), and thus not pulled down by His-Ub (Figure. 3.6C). VP8 was precipitated by anti-
ubiquitin antibody (Figure. 3.6E), and anti-VP8 antibody pulled down ubiquitinated VP8 from 
FLAG-VP8 transfected lysates, but not from FLAG-transfected lysates (Figure. 3.6F), which 
confirms that VP8 is ubiquitinated as shown previously and validates the ubiquitin-specific 
antibody. This demonstrates that, although BoHV-1 VP8 interacts with STAT1, STAT1 is not 
ubiquitinated by the presence of VP8. This confirms that STAT1 is not degraded by the 
proteasome. Taken together these results suggest that BoHV-1 VP8 interacts with STAT1 
without mediating ubiquitination or degradation of STAT1.  
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Figure. 3.6 Cellular STAT1 is not ubiquitinated by the presence of BoHV-1 VP8.  
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Cellular STAT1 is not ubiquitinated by the presence of BoHV-1 VP8. (A to D) HEK293T cells 
were transfected with pFLAG/pHis-Ub, pFLAG-VP8/pHis-Ub, and pSV5V/pHis-Ub in the 
presence or absence of 10 µM MG132. At 24 h posttransfection, cell lysates were generated and 
incubated with His-60 nickel resin in the presence (A) or absence (C) of MG132 followed by 
Western blotting with anti-STAT1 antibody. Input lysates of pFLAG/pHis-Ub-, pFLAG-
VP8/pHis-Ub-, and pSV5V/pHis-Ub-transfected cells are shown in panels B and D. (E and F) 
HEK293T cells were transfected with pFLAG or pFLAG-VP8. At 24 h posttransfection, cell 
lysates were generated and incubated with antiubiquitin antibody (E) and anti-VP8 antibody (F), 
followed by protein G-Sepharose. Monoubiquitinated VP8 was detected by Western blotting with 
anti-FLAG antibody (E) or with anti-Ub antibody (F). 
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3.5.5      Effect of VP8 on STAT1 tyrosine phosphorylation. 
  IFN-α and -β signaling is stimulated by binding of IFN-α and -β to the cell surface 
receptors. Engagements of IFN receptors leads to phosphorylation of STAT1, STAT2 and several 
other cellular kinases (reviewed in (373)). To investigate whether VP8 impairs this stage in IFN-
β signaling, IFN-β-induced STAT1 tyrosine phosphorylation was examined (Figure. 3.7). Vero 
cells were transfected with pFLAG-EYFP or pFLAG-VP8. At 24 h posttransfection cells were 
stimulated with human IFN-β for 4 h or left untreated. Cell lysates were separated by SDS-PAGE 
and transferred to nitrocellulose membrane, and STAT1 and STAT1 phosphorylated at tyrosine 
residue Y701 were detected using anti-STAT1 and anti-pSTAT1 antibodies, respectively. As a 
loading control actin was detected by anti-actin antibody. STAT1 started to be phosphorylated 
within 10 min of IFN-β treatment compared to non-treated cells in the presence of both FLAG-
EYFP and FLAG-VP8. The total STAT1 and phosphorylated STAT1 amounts were similar in the 
presence and absence of VP8 in the cells, which indicates that the expression of VP8 does not 
reduce STAT1 phosphorylation.  
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Figure. 3.7 VP8 does not affect STAT1 tyrosine phosphorylation.  
Vero cells were transfected with pFLAG-EYFP or pFLAG-VP8. At 24 h posttransfection, cells 
were stimulated with IFN-β (2,500 units/0.5 ml) for 10, 30, and 60 min, and cell lysates were 
generated. Twenty-five micrograms of cellular protein were loaded and separated on a 10% gel 
for Western blot analysis. Phosphorylated STAT1, STAT1, and VP8 were detected by anti-
pSTAT1, anti-STAT1, and anti-VP8 antibodies, respectively. As a protein loading control, actin 
was detected by anti-actin antibody. 
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3.5.6      VP8 inhibits IFN-β induced nuclear accumulation of STAT1. 
In virus-infected cells nuclear translocation of STAT1 is stimulated by IFN-β. In the 
nucleus newly imported STAT1 together with STAT2 and IRF9 forms a multiprotein complex, 
ISGF3, which functions as transcriptional activator (reviewed in (373)). To further examine 
which step of IFN-β signaling is inhibited by VP8, we examined nuclear accumulation of STAT1 
by immunofluorescence.  Vero cells were transfected with pFLAG or with pFLAG-VP8 219-741, 
which expresses VP8 without nuclear localization signal (NLS) or with pFLAG-VP8. VP8 and 
STAT1 were detected with anti-FLAG and anti-STAT1 antibodies. As shown in Figure. 3.8A, 
IFN-β treatment of Vero cells redistributed STAT1 from the cytoplasm to the nucleus, whereas in 
non-treated cells STAT1 was cytoplasmic. Since the nuclear localization signal of VP8 was 
removed, VP8 219-741 was completely cytoplasmic and clearly prevented nuclear accumulation 
of STAT1 following IFN-β treatment (Figure. 3.8B). Without IFN-β treatment of VP8-expressing 
cells STAT1 was also cytoplasmic as expected. The translocation of STAT1 to the nucleus was 
also studied in the context of expression of full-length VP8, which is found mostly in the nucleus, 
while some if it is cytoplasmic. In most of the cells that expressed VP8, STAT1 remained 
cytoplasmic (Figure. 3.8C).  
To examine the translocation of STAT1 in the context of infection, MDBK cells were 
mock-infected or infected with BoHV-1, BoHV1-ΔUL47 or BoHV-1-UL47R for 14 h. Cells were 
left untreated or were treated with IFN-β, and incubated with anti-VP8, anti-gB and bovine anti-
STAT1 antibodies. As shown in Figure. 3.9A, IFN-β treatment of mock-infected cells resulted in 
transport of STAT1 into the nucleus, while without IFN-β treatment STAT1 was cytoplasmic. 
However, in BoHV-1 and BoHV-1-UL47R-infected cells (Figure. 3.9B) IFN-β treatment did not 
result in nuclear accumulation of STAT1. To confirm the role of VP8 in inhibition of STAT1 
nuclear translocation MDBK cells were -with BoHV1-ΔUL47 (Figure. 3.9C). Infection with 
BoHV1-ΔUL47 was confirmed by incubation with gB-specific monoclonal antibody. STAT1 was 
localized in the nucleus of BoHV1-ΔUL47-infected cells, which confirms the role of VP8 in 
inhibition of STAT1 nuclear transport. These experiments demonstrated that nuclear 
accumulation of STAT1was inhibited by the presence of VP8. 
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Figure. 3.8 VP8 prevents IFN-β-induced nuclear accumulation of STAT1.  
Vero cells were transfected with A) pFLAG, B) pFLAG-VP8 219-741 or C) pFLAG-VP8. At 24 
h post-transfection cells were stimulated with 2500 units of human IFN-β for 30 min or left 
untreated, followed by fixation with paraformaldehyde and permeabilization. Truncated and full-
length VP8 were stained with monoclonal anti-FLAG antibody and Alexa-488-conjugated goat 
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anti-mouse IgG. STAT1 was detected with rabbit anti-STAT1 antibody and Alexa-633 
conjugated anti-rabbit IgG. The nucleus was stained with Prolong gold DAPI. The cells were 
examined with a Leica SP5 confocal microscope. 
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Figure. 3.9 BoHV-1 infection prevents IFN-β-induced nuclear accumulation of STAT1.  
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MDBK cells were A) mock-infected or B) infected with BoHV-1 at a MOI of 4 or C) with 
BoHV-1ΔUL47 at a MOI of 5 and D) with BoHV-1-UL47R at a MOI of 4. At 14 h post-infection 
cells were stimulated with bovine IFN-β for 30 min or left untreated. Cells were then fixed with 
paraformaldehyde, permeabilized and stained with monoclonal anti-VP8 or anti-gB antibodies 
and Alexa-488 conjugated goat anti-mouse IgG. STAT1 was detected with anti-STAT1 
antibodies and Alexa-633 conjugated anti-rabbit IgG. DNA was labeled with Prolong gold DAPI. 
The cells were examined with a Leica SP5 confocal microscope. 
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3.5.7      Subcellular distribution of VP8 is correlated with the STAT1 translocation. 
To determine how early after infection VP8 might be able to retain STAT1 in the 
cytoplasm, the subcellular localization of VP8 at early and late time points in the context of 
STAT1 retention was determined.  MDBK cells were mock-infected or infected with BoHV-1 at 
a MOI of 4. At 2, 4, 6 or 14 h post-infection cells were stimulated with IFN-β or left untreated 
followed by VP8 and STAT1 detection (Figure. 3.10A & B). VP8 was detected as early as 2 h in 
the cytoplasm, while STAT1 was retained in the cytoplasm. As BoHV-1 infection progressed to 4 
h, some VP8 was localized to the nucleus, but VP8 was also still present in the cytoplasm, as was 
STAT1. At 6 h post-infection most of the VP8 was detected in the nucleus, while STAT1 was 
still cytoplasmic. VP8 was again observed in the cytoplasm at 14 h post-infection. Throughout 
the entire period post-infection STAT1 was detected in the cytoplasm confirming that the 
retention of STAT1 was initiated with the incoming VP8 as early as 2 h.  
To further confirm the subcellular distribution of VP8 at different stages of infection 
cytoplasmic and nuclear fractions were prepared from BoHV-1-infected MDBK cells at 2, 4, 6 
and 14 h (Figure. 3.11) and then examined by Western blotting. The cytoplasmic (tubulin) and 
nuclear (fibrillarin) markers were used to validate the fractionation procedure. In agreement with 
the microscopy data VP8 was first detected in the cytoplasm at 2 h. At 4 h post-infection, VP8 
gradually started to localize to the nucleus and at 6 h there was more VP8 in the nucleus than in 
the cytoplasm. However, at 14 h post infection most of the VP8 was present in the cytoplasm. 
According to these data incoming viral VP8 is present in the cytoplasm, and thus is capable of 
retaining STAT1 in the cytoplasm immediately after infection. Although VP8 then migrates from 
the cytoplasm to the nucleus, at late stages of infection it is again mostly in the cytoplasm. Since 
this large tegument protein is capable of STAT1 retention immediately after infection it explains 
the ability of VP8 to inhibit IFN signaling at the onset of BoHV-1 infection.  
                
 
         
 
 
		
	 81	
                     
 
Figure. 3.10A Subcellular localization of BoHV-1 VP8 at different times post-infection. 
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Figure. 3.10B Subcellular localization of BoHV-1 VP8 at different times post-infection.  
MDBK cells were infected with BoHV-1 at an MOI of 4 for 2, 4, 6, and 14 h. The infected cells 
were left untreated (A) or stimulated with bovine IFN-β for 30 min (B). Cells were then fixed 
with paraformaldehyde, permeabilized, and incubated with monoclonal anti-VP8 and Alexa Fluor 
488-conjugated goat anti-mouse IgG. STAT1 was detected with anti-STAT1 antibodies and 
Alexa Fluor 633-conjugated anti-rabbit IgG. DNA was labeled with Prolong gold DAPI. The 
cells were examined with a Leica SP5 confocal microscope. 
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Figure. 3.11 Subcellular fractionation of BoHV-1 VP8 at different times during infection.  
MDBK cells were mock infected or infected with BoHV-1 at an MOI of 4 for 2, 4, 6, and 14 h. 
The cells were collected by trypsinization at the indicated time points, followed by cytoplasmic 
and nuclear fractionation of proteins isolation as described in Materials and Methods. The 
resulting fractionations were analyzed by SDS-PAGE followed by detection of VP8 with anti-
VP8 antibody. The fractionation procedure was validated by incubation with antibodies specific 
for the cytoplasmic and nuclear proteins tubulin and fibrillarin, respectively. 
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3.6         Discussion. 
In response to viral infection, cells establish an antiviral state through type I IFN 
signaling; however, many viruses have evolved unique mechanisms to evade this response. With 
this study, we demonstrated that VP8 of BoHV-1 plays an important biological function by down-
regulating IFN-induced responses. Transient expression of BoHV-1 VP8 inhibited IFN-β-induced 
transcriptional responses in transfected cells. Inhibition of IFN signaling was also observed in 
BoHV-1-infected cells, while BoHV1-ΔUL47-infected cells showed partial recovery of IFN 
signaling compared to BoHV-1-infected cells. The presence of bICP0 and possibly bICP27 can 
also down-regulate the IFN responses(207, 379, 380), which might explain the incomplete 
recovery of IFN signaling in BoHV1-ΔUL47-infected cells. To test this, ActD was added during 
BoHV-1 infection, which prevented immediate early gene expression. In ActD-treated cells, down-
regulation of IFN signaling was observed in BoHV-1- or BoHV1-UL47R-infected cells, but not in 
mock- or BoHV1-ΔUL47-infected cells, which further confirmed the role of VP8 in down-
regulation of IFN signaling.	
Despite some homology between the BoHV-1 and human herpesvirus 1 (HHV-
1) UL47 gene products, they differ in several respects. The HHV-1 UL47 gene product, VP13/14, 
interacts with polyadenylate-binding protein (PABP) and disrupts the association of PABP with 
PABP-interacting protein 2 (Paip2) jointly with its binding partner, ICP27 (193). Since Paip2 
remains in the cytoplasm, Dobrikova et al. (193) mentioned that it was unclear whether the Paip2 
dissociation is a primary event that happens in the cytoplasm after HHV-1 infection. Shu et al. 
demonstrated that the HHV-1 UL47 interacts with vhs-RNase and attenuates the degradation of all 
kinetic classes of viral mRNA and thereby regulates the expression of β and γ genes by controlling 
the expression of α gene products (194). Thus far, these functions have not been investigated for 
BoHV-1 VP8. Liu et al. presented data suggesting that HHV-1 VP13/VP14 forms a complex with 
UL31, UL34, and US3, which are critical for viral nuclear egress, and plays a regulatory role in 
HHV-1 primary envelopment (161). However, deletion of BoHV-1 UL47 did not result in 
impaired nuclear egress (179). HHV-1 UL47 (VP13/14) interacts with VP16 or alpha-transinducing 
factor (αTIF), and UL47-deleted HHV-1 demonstrated impaired ability to induce immediate early 
promoter-regulated expression of a reporter gene (96, 383), but this effect was not observed for 
BoHV-1 VP8, as immediate early bICP4 mRNA transcripts were detected at similar levels in wild-
type (WT), BoHV1-ΔUL47, and BoHV1-UL47R infected cells (179). In addition, when expressed 
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in Escherichia coli or insect cells, HHV-1 VP13/14, but not BoHV-1 VP8, bound directly to RNA 
(189). In contrast, VP8 expressed in mammalian cells interacts with bICP0, gB, gC, and gD 
mRNAs (188). 
We identified cellular STAT1 as an interacting partner of BoHV-1 VP8 in both VP8-
transfected and BoHV-1 infected cells. The domains of VP8 that interact with STAT1 were found 
to be located in two different regions, VP8 259-482 and 632-686. BLAST sequence analysis of 
BoHV-1 VP8 demonstrated high homology of amino acids 280 to 735 with UL47-encoded proteins 
of human herpesvirus 1 and other herpesviruses and much less sequence similarity in the N-
terminal region of amino acids 1 to 259 (Figure. 3.3) Furthermore, the predicted secondary 
structure for amino acids 280 to 735 was mostly alpha-helical, a feature that has previously been 
implicated in protein-protein interactions (188, 384). The crystal structure of STAT1 revealed that 
it has an alpha-helical coiled-coil domain starting at residue 130 and a DNA binding domain that is 
in the center of the STAT1 protein. The coiled-coil domain presents extensive possibilities for 
protein-protein interaction and, indeed, has been documented as interacting with other proteins 
(reviewed in reference (385)). For example, although the rabies virus P protein binding site on 
STAT1 could not be precisely determined, the P protein-interacting domain resides in the coiled-
coil and DNA binding domain of STAT1 (374). This suggests that the BoHV-1 VP8 binding site 
on STAT1 may be present on the coiled-coil or DNA-binding domain. 
Viruses have evolved different mechanisms to antagonize the IFN signaling pathway 
through STAT1 or STAT2 interaction with viral proteins. For example, several paramyxovirus 
family members such as human parainfluenza virus-2 and SV5 induce polyubiquitination and 
degradation of STAT1 to block IFN signaling through the P and V proteins, respectively (386). 
The C protein of Sendai virus down-regulates IFN signaling by inhibiting STAT1 phosphorylation 
and STAT1 degradation (387). The V protein of measles virus, also belonging to Paramyxoviridae 
family, blocks IFN signaling by reducing STAT1 and STAT2 phosphorylation (388). In contrast, 
mumps virus V protein antagonizes IFN-induced antiviral effects by both degradation of STAT1 
and prevention of nuclear translocation of STAT1 (378). Similarly, the V protein of Nipah virus 
and Hendra virus, members of the Henipa virus genus, inhibit IFN-α/β and IFN-γ signaling by 
preventing both STAT1 phosphorylation and nuclear translocation (389, 390). The P protein of 
rabies virus, belonging to the Rabdoviridae, neither induces STAT1 degradation nor inhibits 
STAT1 phosphorylation, but prevents STAT1 nuclear accumulation (374). The viral protein pM27 
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of mouse CMV (MCMV) inhibits IFN signaling by inducing proteasomal degradation of STAT2 
(123). These examples show that viral proteins antagonize the IFN-induced host antiviral effects 
through the JAK-STAT signaling pathway in different ways.  
VP8 is the first BoHV-1 protein identified as interacting with STAT1, thus contributing to 
prevention of IFN signaling. Although the expression of BoHV-1 VP8 inhibited IFN signaling, 
VP8 induced neither ubiquitination nor degradation or phosphorylation of STAT1. However, 
translocation of STAT1 to the nucleus following IFN-β treatment was inhibited by full-length VP8 
as well as a truncated form of VP8, which contains the domains for interaction with STAT1. After 
exposure to IFN, ligand-dependent tyrosine phosphorylation and STAT1 dimerization take place 
followed by the accumulation of STAT1s to the nucleus (391). The transport of the large protein 
complexes to the nucleus is facilitated by binding of importin-α with the NLS of STAT1 (392). 
Other residues in the coiled-coil domain are also responsible for nuclear import of some STAT 
proteins (263). A mutation in the STAT1 leucine residue at 407 (L407A) located in the DNA 
binding domain inhibited nuclear translocation of STAT1 (392). Similarly, McBridge et al. showed 
that STAT1 protein defective in DNA binding failed to accumulate in to the nucleus (392). 
Integrity of the DNA binding domain also determines nuclear retention of STAT1 (393). Since 
point mutations in the arginine and lysine-rich-residues in the DNA binding domain resulted in 
defective nuclear import of STAT1 (394), a lack of DNA binding is possibly associated with 
cytoplasmic retention of STAT1. Thus, an interaction between VP8 and the DNA-binding domain 
or coiled-coil domain of STAT1 could impede the nuclear transport machinery as well as the DNA 
binding function. The NLS of VP8, amino acids 51-54 (RRPR), regulates nuclear localization of 
VP8 (182). A truncated version of VP8 consisting of amino acids 219-741, which lacks the NLS 
but contains two VP8-STAT1 interacting domains, was completely cytoplasmic and also able to 
retain STAT1 in the cytoplasm.  
Accumulation of STAT1 to the nucleus was not observed in BoHV1 and BoHV1-UL47R-
infected cells, while BoHV1-ΔUL47 allowed translocation of STAT1 to the nucleus. BoHV1 VP8 
is the most abundant tegument protein of the virion. Previously, the full-length VP8 was observed 
in the cytoplasm as early as 2 h and was visualized in the nucleus at 5 h post-infection (187). Thus, 
interaction of VP8 with STAT1 in the cytoplasm might interfere with the nuclear import of STAT1 
early after initiation of infection. We demonstrated that VP8 is present in the cytoplasm at 2 h 
post-infection, at which time STAT1 was retained in the cytoplasm. Since VP8 is a late protein, 
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this suggests that viral VP8 released into the cytoplasm immediately after initiation of infection 
counteracts the establishment of an antiviral state by interacting with STAT1 to inhibit IFN 
signaling.   
In summary, our data provide evidence that BoHV-1 VP8 inhibits IFN signaling early 
after initiation of infection in the absence of immediate early protein synthesis. Inhibition of IFN 
signaling appeared to occur through interference with nuclear translocation of STAT1 in both 
VP8-transfected and BoHV-1 infected cells. This is the first BoHV-1 protein shown to interact 
with cellular STAT1 to inhibit IFN-β signaling before the onset of virus replication. These results 
provide a new functional role for VP8 in BoHV-1 infection and a potential explanation for the lack 
of viral replication of the UL47 deletion mutant in cattle. 
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                                                               CHAPTER 4 	
LINKER BETWEEN CHAPTER 3 AND CHAPTER 5 
               In chapter 3, we demonstrated a function of incoming virion and cytoplasmic VP8 in the 
establishment of an anti-viral state to facilitate BoHV-1 replication. Upon virus infection, the 
cellular STAT1 must accumulate in the nucleus in order to trigger IFN-β production. We 
determined that BoHV-1 VP8 interacts with cellular STAT1 protein to prevent its translocation 
from the cytoplasm to the nucleus. The inhibition of STAT1 translocation was observed in 
BoHV-1- and BoHV-1UL47R-infected but not in BoHV-1ΔUL47-infected cells.  Thus, the IFN-β 
production was significantly lower in BoHV-1-infected cells when compared to BoHV-1ΔUL47-
infected cells, suggesting that VP8 contributed to inhibition of IFN-β signaling and in turn, 
promoted BoHV-1 replication. This is in agreement with the previously demonstrated fact that 
UL47-deleted virus has a 100-fold reduced titer in cell culture and is avirulent in cattle. Therefore, 
the interference with IFN-β signaling by VP8 may benefit BoHV-1 replication. 
 Due to the presence of NLS and NES, VP8 is a nuclear-cytoplasmic shuttling protein. In 
chapter 5 we investigated pro-viral function of nuclear VP8. Virus interaction with the host cells 
promotes DDR response. We determined that VP8 formed a complex with DDR proteins, and 
this interaction revealed function of nuclear VP8 in the modulation of the DDR pathway. 
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5.1         Abstract. 
  VP8, the ul47 gene product in bovine herpes virus-1 (BoHV-1), is a major tegument 
protein, essential for virus replication in vivo. The major DNA damage response protein, ataxia 
telangiectasia mutated (ATM), phosphorylates Nijmegen breakage syndrome (NBS1) and 
structural maintenance of chromosome-1 (SMC1) proteins during the DNA damage response. 
VP8 was found to interact with ATM and NBS1 during transfection and BoHV-1 infection. 
However, VP8 did not interfere with phosphorylation of ATM in transfected or BoHV-1-infected 
cells. In contrast, VP8 inhibited phosphorylation of both NBS1 and SMC1 in transfected cells, as 
well as in BoHV-1-infected cells, but not in cells infected with a VP8 deletion mutant (BoHV-
1ΔUL47). Inhibition of NBS1 and SMC1 phosphorylation was observed at 4 h post infection by 
nuclear VP8. Furthermore, ultraviolet light (UV)-induced cyclobutane pyrimidine dimer (CPD) 
repair was reduced in the presence of VP8, and VP8 in fact enhanced etoposide or UV-induced 
apoptosis. This suggests that VP8 blocks the ATM/NBS1/SMC1 pathway and inhibits DNA 
repair. VP8 induced apoptosis in VP8-transfected cells through caspase-3 activation. The fact that 
BoHV-1 is known to induce apoptosis through caspase-3 activation is in agreement with this 
observation. The role of VP8 was confirmed by the observation that BoHV-1 induced 
significantly more apoptosis than BoHV-1ΔUL47. These data reveal a potential role of VP8 in the 
modulation of the DNA damage response pathway and induction of apoptosis during BoHV-1 
infection. 
 
5.2         Importance. 
	 To our knowledge, the effect of BoHV-1 infection on the DNA damage response has not 
been characterized. Since BoHV-1ΔUL47 was previously shown to be avirulent in vivo, VP8 is 
critical for the progression of viral infection. We demonstrated that VP8 interacts with DNA 
damage response proteins and disrupts the ATM-NBS1-SMC1 pathway by inhibiting 
phosphorylation of DNA repair proteins, NBS1 and SMC1. Furthermore, interference of VP8 
with DNA repair was correlated to decreased cell viability and increased DNA damage-induced 
apoptosis. These data show that BoHV-1 VP8 developed a novel strategy to interrupt the ATM 
signaling pathway and to promote apoptosis. These results further enhance our understanding of 
the functions of VP8 during BoHV-1 infection and provide an additional explanation for the 
reduced virulence of BoHV-1ΔUL47. 
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5.3         Introduction. 
Upon DNA damage, a variety of cellular responses are induced in eukaryotic cells. 
Damaged DNA poses a continuous threat to genomic stability, which results in the activation of a 
network of sensors, transducers, and activator proteins. These proteins conduct different 
physiological responses including the arrest of cell cycle progression and activation of DNA 
repair or if the damage is too severe, induction of apoptosis or cell death (395, 396) Immediately 
after exposure to genotoxic stress, the cellular regulatory mechanism is triggered. At the 
recognition of damaged DNA, highly conserved cellular checkpoint proteins are rapidly induced 
to prevent cellular replication and damaged DNA propagation before the repair is completed. The 
major DNA damage response-signaling network includes ataxia telangiectasia mutated protein 
(ATM) and ataxia telangiectasia and Rad3 related protein (ATR). ATM and ATR respond to a 
variety of abnormal DNA structures leading to the initiation of a signaling cascade (265). In 
undamaged cells, ATM exists as a catalytically inactive dimer. After recognition of damaged 
DNA, ATM undergoes auto- or transphosphorylation at Serine-1981 that leads to catalytically 
active ATM monomers (263). Consequently, ATM activates downstream proteins including the 
Nijmegen breakage syndrome (NBS1) and structural maintenance of chromosome-1 (SMC1) 
proteins to signal checkpoint control (265). ATM activation by double-strand breaks (DSBs) 
facilitates the recruitment of DNA repair protein NBS1 (397), which leads to checkpoint 
activation through phosphorylation of NBS1 and SMC1. SMC1 functions as a downstream 
effector of the ATM/NBS1 pathway to activate the S-phase checkpoint, which is deficient in 
ataxia telangiectasia (A-T) and NBS patients (398). 
Immediately after infection, cellular antiviral responses are aimed at preventing viral 
replication and spread. Host cells are exposed to large amounts of exogenous materials or 
abnormal DNA structures such as DNA ends, or unusual structures during viral replication. Thus, 
viral replication is recognized as DNA damage stress by the infected cells and triggers DNA 
damage signal transduction as a part of host immune-surveillance (399).  
Herpesviruses are enveloped double-stranded DNA viruses containing ~150 kbp 
genomes (400, 401). Upon infection, the viral genome is replicated, producing highly branched 
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replication intermediates. During herpes simplex virus-1 (HSV-1) infection DSBs are generated 
(402). Consequently, HSV-1 induces cellular DNA damage responses through activation of ATM 
and its downstream effector molecules (274). Similarly, other herpesviruses such as Kaposi’s 
sarcoma-associated herpesvirus (KSHV) induce ATM activation in primary endothelial cells 
(309). Murine gamma herpesvirus-68 (gammaHV68) also induces ATM activation (403). 
Although gamma herpesvirus M2 protein activates ATM, downstream signaling of the ATM 
pathway was inhibited by M2 protein (404). Thus, herpesviruses modulate the DNA damage 
response to favor viral replication in different ways. 
Bovine herpesvirus-1 (BoHV-1) is an important pathogen in cattle, responsible for a 
variety of clinical symptoms, in particular respiratory and genital infections. VP8, the UL47 gene 
product, is the most abundant tegument protein in BoHV-1. BoHV-1 VP8 contains a nuclear 
localization signal and a nuclear export signal and thereby shuttles between the nucleus and 
cytoplasm (182). A UL47-deleted virus (BoHV-1ΔUL47) replicates less efficiently in cell culture 
and is avirulent in cattle supporting the importance of VP8 in the establishment of BoHV-1 
infection (179). Although the precise role of VP8 in viral infection remains mostly unknown, 
some functions of VP8 are being elucidated. VP8 interacts with a cellular DNA damage binding 
protein-1, DDB1 (187). The signal transducer and activator of transcription (STAT1) is also an 
interacting partner of VP8. However, while the interaction of the paramyxovirus family V protein 
with DDB1 and STAT1 targets STAT1 for degradation (405), VP8 does not degrade STAT1 or 
interfere with STAT1 phosphorylation, but prevents translocation of STAT1 to the nucleus, thus 
inhibits interferon-β (IFN-β) signaling (405). Human cytomegalovirus (HCMV) also contributes 
to DDR activation by interacting with DDB1 (406), and the gamma herpesvirus M2 protein 
regulates the DNA damage response (DDR) pathway through interaction with DDB1 and ATM 
(404).  
Since VP8 interacts with DDB1 (187), it was of interest to investigate whether VP8 
interacts with other DNA damage response proteins, and plays a role in the modulation of the 
DDR during BoHV-1 infection. The data shown here reveal that VP8 interacts with ATM and 
NBS1, and prevents phosphorylation of NBS1 and SMC1. Thus, VP8 disrupts the 
ATM/NBS1/SMC1 pathway and inhibits DNA repair. Furthermore, VP8 increased DNA 
damage-induced apoptosis. 
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5.4         Materials and Methods. 
5.4.1      Cells, viruses, and plasmids. 
  HeLa, MDBK, and HEK 293T cells were grown in Eagle’s minimum essential medium 
(MEM, Sigma-Aldrich Canada Ltd, Oakville, ON, Canada). The medium was supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Gibco, Life Technologies, Burlington, ON, 
Canada), 1% antibiotic-antimycotic (Life Technologies) and 10 mM HEPES buffer (Life 
Technologies). Cells were cultured with 5% CO2 in a 37°C incubator.  BoHV-1 108, BoHV-
1ΔUL47 and BoHV-1UL47R were propagated in MDBK cells (179). MDBK cells were infected 
with BoHV-1 at different multiplicities of infection (MOI) as mentioned elsewhere. The plasmids 
pFLAG and pFLAG-VP8 were previously described by Labiuk et al, 2009 (184) and Afroz et al, 
2016 (405), respectively. EYFP was amplified from pEYFP by using forward primer 5′-	
CACAAGCTTCCACCGGTCGCCACCAT-3′ and reverse primer 5′-	 
AGACTCGAGCGTGGGAGGTTTTTTAAAGCAAG-3′. The pFLAG-VP8 and the amplified 
EYFP were digested with HindIII and XhoI followed by ligation to generate pFLAG-EYFP. 
 
5.4.2      Antibodies and chemical reagents. 
VP8-specific murine monoclonal and glycoprotein C-specific rabbit polyclonal antibodies 
were used as previously described (405). ATM-, pATM-, NBS1-, pNBS1-, SMC1, and pSMC1 - 
specific antibodies were purchased from Abcam (Toronto, ON, Canada). Murine monoclonal 
actin- and FLAG-specific antibodies were purchased from Sigma-Aldrich Canada Ltd. Mouse 
monoclonal CPD-specific antibody was obtained from Cosmobio, Tokyo. Japan. Rabbit caspase-3-
specific antibody was obtained from New England Biolabs. Etoposide was purchased from Sigma-
Aldrich Canada Ltd.  
 
5.4.3      Preparation of cell lysates.  
HEK 293T and HeLa cells were transfected at 60-80% confluency with different 
plasmids. Lipofectamine and Plus reagents (Invitrogen, Life Technologies) were used for 
transfection. At 24 h post transfection, HEK 293T cells were washed with ice-cold PBS (pH 7.4). 
Cells were treated with lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 
pH 7.4) supplemented with mammalian cell and tissue extract protease inhibitor cocktail (Sigma-
Aldrich) and gently rocked on a nutator for 5 min followed by incubation on ice for 30 min. The 
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samples were centrifuged at 12,000 × g for 15 min at 4°C. The supernatants were collected in 1.5 
ml Eppendorf tubes and kept at −80°C for future use. MDBK cells were lysed as described 
above.  
 
5.4.4      Immunoprecipitation and Western blotting.  
For immunoprecipitation cell lysates were generated as described above. Cell lysates 
were added to anti-FLAG M2 affinity gel (Sigma-Aldrich) and the mixtures were incubated 
overnight at 4°C; alternatively, cell lysates were incubated at 4°C overnight with primary 
antibodies, followed by incubation for 3 h at 4°C with Protein G Sepharose Fast Flow beads (GE 
Health Care, Niskayuna, NY, USA). The immune complexes were washed with wash buffer (50 
mM Tris-HCl, 250 mM NaCl, 2% Triton X-100, pH 7.4) and subsequently boiled in SDS-PAGE 
sample buffer for 5 min. The immune complexes were then separated on 10% or 8 % SDS-PAGE 
gels followed by transfer to nitrocellulose membranes.  The nitrocellulose membranes were 
blocked with 5% skim milk or 5% bovine serum albumin (BSA) in PBS containing Tween-20 
(PBST; 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 0.1% Tween 20, pH 
7.4) for 2 h followed by incubation with primary antibodies overnight at 4°C.  The membranes 
were washed three times with PBST followed by incubation with IRDye680-conjugated anti-
mouse IgG or IRDye-800CW-conjugated anti-rabbit IgG (LI-COR Bioscience, Lincoln, NE, 
USA). An Odyssey CLx Infrared Imaging system (LI-COR Bioscience) was used for protein 
detection and the images were processed using the Odyssey 3.0.16 application software (LI-COR 
Bioscience). 
 
5.4.5      Immunofluorescence.  
HeLa cells were plated at a concentration of 2 × 105 cells per well in two-chamber 
Permanox slides (Lab-Tek, Naperville, IL, USA). Cells were mock-transfected or transfected 
with pFLAG-EYFP or pVP8-EYFP. At 24 h post transfection, cells were either left untreated or 
treated with etoposide for 30 min. Subsequently, cells were fixed with 4% paraformaldehyde 
(Sigma-Aldrich) for 20 min at room temperature (RT) and permeabilized, followed by blocking 
with 1% goat serum and 0.1% Triton X-100 in PBS. The cells were incubated with primary 
antibodies for 2 h at RT.  MDBK cells were infected with BoHV-1 or BoHV1-UL47R at a MOI of 
4 or with BoHV1-ΔUL47 at a MOI of 5 for 14 h. The cells were either left untreated or treated 
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with etoposide for 30 min, followed by fixation and antibody incubations as described above. For 
the time course experiment, MDBK cells were infected with BoHV-1 at a MOI of 4, and the cells 
were fixed at indicated time points and blocked overnight followed by incubation with primary 
antibodies. Subsequently, the cells were incubated with AlexaFluor 488 goat anti-mouse IgG or 
AlexaFluor 633 goat anti-rabbit IgG (Invitrogen, Life Technologies) for 1 h. Mounting medium 
containing 4′,6-diamino-2-phenylindole (DAPI) was used to identify the nucleus, and the slides 
were air-dried for 24 h at RT. The cells were examined by using laser excitation at 488 nm 
(Alexa 488), 633 nm (Alexa 633) and 461 nm (DAPI). Confocal images were taken with a Leica 
SP5 confocal microscope (Leica Microsystems Inc., Concord, ON, Canada). Image J software 
was used to process the images. 
 
5.4.6      Cyclobutane Pyrimidine Dimer identification.  
HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h 
post transfection cells were irradiated with 10 J/m2 UV-C.  Cells were treated according to the 
manufacturer’s instructions. Briefly, cells were either fixed with 4% formalin immediately after 
UV irradiation at 0 h or incubated for 24 h before fixation. The cells were permeabilized with 
0.5% Triton X-100 followed by blocking with 20% FBS. The cells were then incubated with 
murine monoclonal anti-CPD antibody (Cosmo Bio Co, Japan) for 1.5 h at 37°C. The cells were 
washed 5 times with PBS and were then incubated with Alexa-Fluor 633 goat anti-mouse IgG.  
The images were captured with a Leica SP5 confocal microscope (Leica Microsystems Inc.) and 
processed with Image J software. A biological image-processing program, Fiji (407), was used to 
quantify the relative fluorescent intensities. The mean intensity within defined areas was shown 
as procedure defined unit (PDU). 
 
5.4.7      Apoptosis assay.  
   HeLa cells at 60-70% confluency were mock-transfected or transfected with pFLAG or 
pFLAG-VP8. At 24 h post transfection cells were left untreated, treated with etoposide or 
exposed to UV and incubated for another 12 h. Cells were then harvested by trypsinization and 
were fixed with 1% paraformaldehyde followed by addition of 70% ethanol, and stored at -20°C 
overnight. The cells were analyzed by using an APO-BrdU TUNEL assay Kit (Molecular Probes, 
Thermofisher Scientific) according to the manufacturer's instructions. Briefly, the cells were 
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washed with the washing buffer before incubation with terminal deoxynucleotidyl transferase and 
BrdUTP at 37°C for 2 h. Cells were washed three times followed by incubation with Alexa Fluor 
488 dye-labeled anti-BrdU antibody. After subsequent washes, the cells were analyzed by flow 
cytometry on a flow cytometry cell sorting (FACS) Calibur (BD Biosciences, Franklin Lakes, NJ, 
USA). All data were analyzed with Kaluza Software (v1.2) (Beckman Coulter Inc., Pasadena, 
CA, USA).  Similarly, MDBK cells were mock-infected or infected with BoHV-1 or BoHV-
1ΔUL47 at indicated MOI’s and the TUNEL assay was performed as described above. 
 
5.5         Results. 
5.5.1      VP8 is an interacting partner of ATM and NBS1.   
 To identify a potential interaction between VP8 and ATM, human embryonic kidney 
(HEK) 293T cells were mock-transfected or transfected with pFLAG-EYFP or pFLAG-VP8. At 
24 h post transfection cell lysates were incubated with anti-FLAG beads and immune complexes 
were detected by anti-FLAG and anti-ATM antibodies. As shown in Figure. 5.1A, anti-FLAG 
beads precipitated EYFP and VP8 from pFLAG-EYFP- and pFLAG-VP8-transfected cells, 
respectively. ATM was precipitated from VP8-transfected cells, but not from mock- or EYFP-
transfected cells, suggesting that VP8 interacts with ATM. To investigate the interaction of VP8 
with ATM during infection, Madin-Darby bovine kidney (MDBK) cells were mock-infected or 
infected with BoHV-1 or BoHV-1ΔUL47. Incubation with VP8-specific antibody followed by 
Protein G Sepharose Fast Flow beads resulted in precipitation of VP8 and ATM from BoHV-1-
infected cells, but not from BoHV-1ΔUL47-infected cells (Figure. 5.1B). Conversely, VP8 was 
precipitated with ATM-specific antibody from BoHV-1-infected cells, but not from mock- and 
BoHV-1ΔUL47-infected cells (Figure. 5.1C), indicating interaction of VP8 with ATM during 
BoHV-1 infection. 
 Since ATM forms a complex with NBS1 (397), we investigated whether VP8 also 
interacts with NBS1. HEK 293T cells were mock-transfected or transfected with pFLAG-EYFP 
or pFLAG-VP8. Cell lysates were incubated with anti-FLAG resin followed by detection of 
immune complexes by anti-FLAG and anti-NBS1 antibodies. As demonstrated in Figure. 5.1D, 
anti-FLAG beads precipitated EYFP and VP8 from pFLAG-EYFP- and pFLAG-VP8-transfected 
cells, respectively. NBS1 was precipitated by anti-FLAG beads from VP8-transfected cells, but 
not from mock- and pFLAG-EYFP-transfected cells, suggesting that VP8 interacts with NBS1. 
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To demonstrate the interaction of VP8 with NBS1 during infection, MDBK cells were mock-
infected or infected with BoHV-1 or BoHV-1ΔUL47. Cell lysates from infected cells were 
incubated with an anti-VP8 antibody followed by Protein G Sepharose Fast Flow beads. VP8-
specific antibody precipitated VP8, as well as NBS1, from BoHV-1-infected cells, but not from 
mock- or BoHV-1ΔUL47-infected cells (Figure. 5.1E). Furthermore, incubation of BoHV-1-
infected cell lysates with anti-NBS1 antibody followed by Protein G Sepharose Fast Flow beads 
precipitated VP8 from BoHV-1-infected cells (Figure. 5.1F), confirming that NBS1 interacts with 
VP8 during BoHV-1 infection. To investigate an interaction of VP8 with ATM and NBS1 as a 
complex, mock-, BoHV-1- and BoHV-1ΔUL47-infected cell lysates were incubated with an anti-
VP8 antibody followed by Protein G Sepharose Fast Flow beads. As shown in Figure. 5.1G, anti-
VP8 antibody pulled down NBS1 as well as ATM from BoHV-1 infected cells, but not from 
mock- and BoHV-1ΔUL47-infected cells. This experiment demonstrates that VP8 forms a 
complex with both NBS1 and ATM. 
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Figure. 5.1 VP8 is an interacting partner of ATM and NBS1.  
A) HEK293T cells were mock-transfected or transfected with pFLAG-EYFP or pFLAG-VP8. Cell 
lysates were collected at 24 h post transfection and incubated with anti-FLAG resin. VP8 and 
ATM were detected by Western blotting with murine monoclonal anti-FLAG and rabbit anti-ATM 
antibodies, respectively. B) MDBK cells were mock-infected or infected with BoHV-1 or BoHV-
1ΔUL47 at a MOI of 2, and lysed after 24 h. Following incubation with anti-VP8 antibody and 
Protein G Sepharose Fast Flow beads, VP8, and ATM were detected by Western blotting with 
murine monoclonal anti-VP8 and rabbit anti-ATM antibodies, respectively. C) BoHV-1 cells were 
infected as described for Figure. 5.1B. Infected cells were lysed at 24 h post infection and 
incubated with rabbit anti-ATM antibody, followed by Protein G Sepharose Fast Flow beads. VP8 
and ATM were detected by Western blotting with murine monoclonal anti-VP8 and rabbit anti-
ATM antibodies, respectively. D) HEK293T cells were mock-transfected or transfected with 
pFLAG-EYFP or pFLAG-VP8. Cell lysates were collected at 24 h post transfection and incubated 
with anti-FLAG resin. VP8 and NSB1 were detected by Western blotting with murine monoclonal 
anti-FLAG and rabbit anti-NSB1 antibodies, respectively. E) MDBK cells were mock-infected or 
infected with BoHV-1 or BoHV-1ΔUL47 at a MOI of 2, and lysed after 24 h. Following 
incubation with anti-VP8 antibody and Protein G Sepharose Fast Flow beads, VP8, and NSB1 
were detected by Western blotting with murine monoclonal anti-VP8 and rabbit anti-NSB1 
antibodies, respectively. F) BoHV-1 cells were infected as described for Figure. 5.1E. Infected 
cells were lysed at 24 h post infection and incubated with rabbit anti-NSB1 antibody, followed by 
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Protein G Sepharose Fast Flow beads. VP8 and NSB1 were detected by Western blotting with 
murine monoclonal anti-VP8 and rabbit anti-NSB1 antibodies, respectively. G) MDBK cells were 
mock-infected or infected with BoHV-1 or BoHV-1ΔUL47 at a MOI of 2. At 24 h post infection 
cell lysates were collected and incubated with anti-VP8 antibody, followed by Protein G 
Sepharose Fast Flow beads. VP8, ATM, and NBS1 were detected by Western blotting with anti-
VP8, anti-ATM and anti-NBS1 antibodies. IRDye680-conjugated anti-mouse IgG and IRDye-
800CW-conjugated anti-rabbit IgG were used for detection. Input lysates are presented in the right 
panels.  
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5.5.2      VP8 interferes with the ATM/NBS1/SMC1 pathway by inhibiting phosphorylation 
of NBS1 and SMC1.  
 ATM, the checkpoint kinase, acts as a central signal transducer in response to ionizing 
radiation (IR) (408).	Viral proteins such as hepatitis C virus NS3 protein interact with ATM and 
contribute to increased sensitivity of cells to DNA damage (409). Since VP8 interacted with ATM, 
we investigated whether VP8 influences ATM activation by interfering with its phosphorylation.  
Human malignant epithelial cells derived from Henrietta Lacks (HeLa) cells were mock-
transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post transfection cells were left 
untreated or treated with etoposide for 30 min and were then incubated with anti-phospho ATM 
(pATM) antibody. Etoposide is a topoisomerase II inhibitor enzyme that generates DNA double-
strand breaks by inhibiting re-ligation of DNA strands (410) and activates ATM. As shown in 
Figure. 5.2A, in the absence of etoposide, pATM was not detected in mock-, pEYFP- and pVP8-
EYFP-transfected cells. As expected, the addition of etoposide enhanced the level of pATM in 
mock- and pEYFP-transfected cells. Similarly, pATM was observed in the VP8-expressing cells 
in the presence of etoposide (Figure. 5.2B). These results suggest that VP8 expression does not 
interfere with ATM phosphorylation. 
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 Figure. 5.2 BoHV-1 VP8 does not interfere with ATM phosphorylation.  
HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post 
transfection cells were A) left untreated or B) treated with etoposide. After 30 min of incubation 
cells were fixed with paraformaldehyde, permeabilized and incubated with rabbit anti-pATM 
antibody followed by incubation with Alexa-633-conjugated goat anti-rabbit IgG. Nuclei were 
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identified with Prolong gold DAPI mounting medium.  The cells were examined with a Leica SP5 
confocal microscope. 
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NBS1 is a key player of the MRE11-RAD50-NBS1 (MRN) complex and identified as a 
DNA repair protein after initial DNA damage (266). Disruption of the NBS1 function is lethal in 
mice (411).  NBS1 plays a role in the DDR pathway by acting as a downstream target of ATM 
(397). Since VP8 interacted with ATM and NBS1 without influencing ATM phosphorylation, it 
was of interest to investigate whether VP8 interferes with phosphorylation of NBS1 as a 
downstream target. HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP, 
and were left untreated or treated with etoposide for 30 min at 24 h post transfection. Without 
etoposide treatment, phosphoNBS1 (pNBS1) was not detected in mock-, EYFP- and VP8-
transfected cells (Figure. 5.3A). Although in etoposide-treated mock- and EYFP- transfected cells 
enhanced pNBS1 was detected, in VP8-expressing etoposide-treated cells no pNBS1 was 
observed (Figure. 5.3B), indicating that VP8 prevents phosphorylation of NBS1.  
SMC1 acts downstream of the ATM/NBS1 pathway to activate S-phase checkpoint 
control and initiate DNA repair (398). Since phosphorylation of NBS1 is required for 
phosphorylation of SMC1 and subsequently for S-phase checkpoint activation (398), we 
investigated whether VP8 influences phosphorylation of SMC1. Cells were mock-transfected or 
transfected with pEYFP or pVP8-EYFP and treated with etoposide as described above. In the 
absence of etoposide, no phosphoSMC1 (pSMC1) was detected in mock-, EYFP- and VP8-
transfected cells (Figure. 5.4A). However, after addition of etoposide SMC1 was phosphorylated in 
mock- and EYFP-transfected cells as expected, but not in VP8-expressing cells (Figure. 5.4B). 
These results indicate that VP8 inhibits SMC1 phosphorylation.  
To further confirm the effects of VP8 on phosphorylation of NBS1 and SMC1, HeLa cells 
were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post transfection cells 
were stimulated with etoposide as described above. EYFP-positive cells were sorted using a                           
fluorescence-activated cell sorter (FACS). Equal amounts of cell lysate were examined by Western 
blotting for the presence of pNBS1 and pSMC1 (Figure. 5.5). While NBS1 and SMC1 were 
identified, pNBS1 and pSMC1 were not detected in the presence of VP8 after addition of 
etoposide, confirming the results shown by confocal microscopy. These experiments demonstrate 
that, although VP8 does not interfere with ATM phosphorylation, it inhibited phosphorylation of 
NBS1 and SMC1. 
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Figure. 5.3 VP8 inhibits NBS1 phosphorylation.  
HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post 
transfection cells were A) left untreated or B) treated with etoposide for 30 min. After fixation 
cells were incubated with rabbit anti-pNBS1 antibody followed by Alexa-633-conjugated goat 
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anti-rabbit IgG. Nuclei were identified with Prolong gold DAPI. The cells were analyzed with a 
Leica SP5 confocal microscope.  
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Figure. 5.4 VP8 impedes SMC1 phosphorylation.  
HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post 
transfection cells were A) left untreated or B) treated with etoposide for 30 min. After fixation 
cells were incubated with rabbit anti-pNBS1 antibody followed by Alexa-633-conjugated goat 
anti-rabbit IgG. Nuclei were identified with Prolong gold DAPI. The cells were analyzed with a 
Leica SP5 confocal microscope.  
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Figure. 5.5 Detection of phosphorylated NBS1 and SMC1 in VP8 transfected cells.  
Hela cells were mock-transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post 
transfection cells were either left untreated or treated with etoposide for 30 min. EYFP-positive 
cells were sorted by FACS and cell lysates were made in buffer containing protease and 
phosphatase inhibitors. Fifty micrograms of total protein of each sample were loaded. NBS1, 
pNBS1, SMC1, pSMC1, EYFP, VP8, and actin were detected by Western blotting with rabbit 
anti-NBS1, anti-pNBS1, anti-SMC1 and anti-pSMC1 antibodies and murine monoclonal anti-
EYFP, anti-VP8 and anti-actin antibodies, respectively. IRDye-800CW-conjugated anti-rabbit IgG 
and IRDye680-conjugated anti-mouse IgG were used for detection. 
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5.5.3      VP8 does not affect ATM phosphorylation, but inhibits NBS1 and SMC1 
phosphorylation during BoHV-1 infection. 
Since VP8 did not interfere with ATM activation, but blocked phosphorylation of NBS1 
and SMC1 in transfected cells, we examined the effect of BoHV-1 infection on ATM, NBS1 and 
SMC1 phosphorylation. MDBK cells were mock-infected or infected with BoHV-1, BoHV-
1ΔUL47 or BoHV-1UL47R. At 14 h post infection cells were incubated with anti-pATM antibody. 
BoHV-1, BoHV-1ΔUL47, and BoHV-1UL47R induced similar levels of ATM phosphorylation 
(Figure. 5.6A and B). Since VP8 did not interfere with ATM phosphorylation, etoposide-treated 
BoHV-1-, BoHV-1ΔUL47-, and BoHV-1UL47R-infected cells were not examined. 
To investigate NBS1 phosphorylation in infected cells, MDBK cells were mock-infected 
or infected with BoHV-1, BoHV-1ΔUL47 or BoHV-1UL47R. At 14 h post infection cells were left 
untreated or treated with etoposide for 30 min followed by incubation with a pNBS1-specific 
antibody. As shown in Figure. 5.7A, without etoposide treatment no pNBS1 was detected, while 
the addition of etoposide induced phosphorylation of NBS1 in mock-infected cells. However, in 
BoHV-1- and BoHV-1UL47R-infected cells no pNSB1 was detected, even in the presence of 
etoposide (Figure. 5.7B and D), while in BoHV-1ΔUL47-infected cells pNBS1 was observed 
regardless of etoposide treatment (Figure. 5.7C). The lack of pNBS1 in BoHV-1- and BoHV-
1UL47R-infected cells, but not in BoHV-1ΔUL47-infected cells, was confirmed by Western blot 
analysis (Figure. 5.7E). The incoming virus particles of DNA viruses and subsequent DNA 
replication induce DNA damage responses to activate DNA repair proteins at early times post 
infection (412, 413). This explains why BoHV-1ΔUL47 infection resulted in ATM activation and 
increased phosphorylation of NBS1.  
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Figure. 5.6 VP8 does not interfere with ATM phosphorylation during BoHV-1 infection.  
A) MDBK cells were mock-infected, infected with BoHV-1 at a MOI of 4, with BoHV-1ΔUL47-
EYFP at a MOI of 5, or with BoHV-1UL47R at a MOI of 4. At 14 h post infection cells were fixed 
with paraformaldehyde, permeabilized and incubated with murine monoclonal anti-VP8- or anti-
EYFP antibodies, and rabbit pATM-specific antibodies. Cells were incubated with Alexa-488-
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conjugated goat anti-mouse IgG and Alexa-633-conjugated goat anti-rabbit IgG. Prolong gold 
DAPI was used to identify the nuclei. B) MDBK cells were mock-infected, infected with BoHV-1, 
with BoHV-1ΔUL47 or with BoHV-1UL47R as described in A). At 14 h post infection, mock-
infected cells were either left untreated or treated with etoposide for 30 min. Cell lysates were 
collected and fifty micrograms of total protein of each sample were analyzed by Western blotting. 
ATM, pATM, VP8, and actin were detected with anti-ATM, anti-pATM, anti-VP8, and anti-actin 
antibodies, respectively. 
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Figure. 5.7 Phosphorylation of NBS1 is inhibited by BoHV-1 but not by BoHV-1ΔUL47.  
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MDBK cells were A) mock-infected or infected with B) BoHV-1 at a MOI of 4, C) BoHV-
1ΔUL47-EYFP at a MOI of 5, or D) BoHV-1UL47R at a MOI of 4. At 14 h post infection cells 
were either left untreated or treated with etoposide for 30 min. Cells were then fixed with 
paraformaldehyde, permeabilized and incubated with murine monoclonal VP8- or EYFP specific 
antibodies, and rabbit pNBS1-specific antibodies. Alexa-488-conjugated goat anti-mouse IgG and 
Alexa-633-conjugated goat anti-rabbit IgG were used as secondary antibodies, respectively. 
Nuclei were identified with Prolong gold DAPI. The cells were examined with a Leica SP5 
confocal microscope. “E” represents etoposide. E) MDBK cells were mock-infected or infected 
with BoHV-1, BoHV-1ΔUL47 or BoHV-1UL47R as described above. At 14 h post infection, 
mock-infected cells were either left untreated or treated with etoposide for 30 min. Cell lysates 
were collected and fifty micrograms of total protein of each sample were analyzed by Western 
blotting. NBS1, pNBS1, VP8, and actin were detected with anti-NBS1, anti-pNBS1, anti-VP8, 
and anti-actin antibodies, respectively. 
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Figure. 5.8 BoHV-1 but not BoHV-1ΔUL47 inhibits phosphorylation of SMC1.  
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MDBK cells were A) mock-infected or infected with B) BoHV-1 at a MOI of 4, C) BoHV-
1ΔUL47-EYFP at a MOI of 5, or D) BoHV-1UL47R at a MOI of 4. At 14 h post infection cells 
were either left untreated or treated with etoposide for 30 min. The cells were fixed and incubated 
with murine monoclonal VP8- or EYFP- specific antibodies, and rabbit pSMC1-specific 
antibodies, followed by incubation with Alexa-488-conjugated goat anti-mouse IgG and Alexa-
633-conjugated goat anti-rabbit IgG, respectively. Nuclei were identified with Prolong gold DAPI. 
The cells were examined with a Leica  SP5 confocal microscope. “E” represents etoposide. E) 
MDBK cells were mock-infected or infected with BoHV-1, BoHV-1ΔUL47 or BoHV-1UL47R as 
described above. At 14 h post infection, mock-infected cells were left untreated or treated with 
etoposide for 30 min. Cell lysates were generated and fifty micrograms of total protein of each 
sample were analyzed by Western blotting. SMC1, pSMC1, VP8, and actin were detected with 
anti-SMC1, anti-pSMC1, anti-VP8, and anti-actin antibodies, respectively.  
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5.5.4      BoHV-1 infection inhibits phosphorylation of NBS1 and SMC1 early during 
infection.  
Since NBS1 phosphorylation is essential for activation of S-phase checkpoint control by 
activating SMC1 (398), it was of interest to investigate at which time during BoHV-1 infection 
VP8 interferes with NBS1 and SMC1 phosphorylation. MDBK cells were either mock-infected or 
infected with BoHV-1. At 2 h post infection VP8 was cytoplasmic due to release of virion VP8 
into the cytoplasm as previously shown (187, 405). The cytoplasmic VP8 did not inhibit 
phosphorylation of NBS1 or SMC1 (Figure. 5.9A, B). At 4 h post infection VP8 was nuclear and 
no pNBS1 was detected at this time point, or at 8 h post infection. Similarly, pSMC1 was 
observed at 2 h post infection, whereas at 4 h or 8 h post infection pSMC1 was not detected 
(Figure. 5.9B). A further analysis by Western blotting confirmed that NBS1 and SMC1 were 
phosphorylated at a low level at 2 h post infection, but were not phosphorylated at later time 
points (Figure. 5.9C). VP8 was detected as early as 2 h post infection and increased in 
concentration at later time points due to de novo synthesis, thus inhibiting NBS1 and SMC1 
phosphorylation. Collectively, these results indicate that nuclear VP8 inhibits NBS1 and SMC1 
phosphorylation from 4 h onwards during BoHV-1 infection.  
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Figure. 5.9 Nuclear BoHV-1 VP8 inhibits phosphorylation of NBS1 and SMC1.   
A) MDBK cells were infected with BoHV-1 at a MOI of 4. Cells were fixed and incubated at 
indicated time points with mouse monoclonal anti-VP8 and rabbit polyclonal anti-pNBS1 
antibodies. B) MDBK cells were mock-infected or infected with BoHV-1 at a MOI of 4. Cells 
were fixed and incubated at indicated time points with mouse monoclonal anti-VP8 and rabbit 
polyclonal anti-pSMC1 antibodies. Alexa-488-conjugated goat anti-mouse IgG and Alexa-633-
conjugated goat anti-rabbit IgG were used as secondary antibodies, respectively. Nuclei were 
identified with Prolong gold DAPI mounting medium. The cells were examined with a Leica SP5 
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confocal microscope. C) MDBK cells were mock-infected or infected with BoHV-1 at a MOI of 4.  
Mock cells were either left untreated or treated with etoposide for 30 min. BoHV-1 cell lysates 
were collected at 2, 4, 8, and 14 h post infection and fifty micrograms of total protein of each 
sample were analyzed by Western blotting. NBS1, pNBS1, SMC1, pSMC1, VP8, and actin were 
detected with anti-NBS1, anti-pNBS1, anti-SMC1, anti-pSMC1, anti-VP8, and anti-actin 
antibodies, respectively. 
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5.5.5      VP8 inhibits DNA repair.  
Checkpoints constitute the central cellular surveillance that coordinates DNA repair. 
DNA repair is controlled throughout the cell cycle (414, 415). SMC1 phosphorylation contributes 
to S-phase checkpoint activation and repair of damaged DNA (416). Since VP8 inhibited NBS1 
and SMC1 phosphorylation, which are both involved in DNA repair, we further examined the 
effect of VP8 on UV-induced cyclobutane pyrimidine dimer (CPD) repair. HeLa cells were mock-
transfected or transfected with pEYFP or pVP8-EYFP. At 24 h post transfection cells were 
irradiated with UV. Cells were then either fixed immediately after UV treatment (0 h) or further 
incubated for 24 h. CPDs were identified with a monoclonal anti-CPD antibody. Increased CPD 
intensity was observed in mock-, EYFP- and VP8-expressing cells immediately after UV 
exposure. At 24 h post UV exposure the CPDs were repaired in mock- and EYFP-transfected 
cells, but not in VP8-expressing cells (Figure. 5.10A). To perform a quantitative analysis, the CPD 
intensity was measured in 50 cells for each sample (Figure. 5.10B) by using a biological image-
processing program, Fiji (407). At 0 h a high level of UV-induced CPDs was observed in mock-, 
EYFP- and VP8-expressing cells. The UV-induced CPDs in mock- and EYFP cells were repaired 
after 24 h, while in VP8-expressing cells, the CPD intensity did not change, indicating impairment 
of DNA repair in the presence of VP8. 
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Figure. 5.10 VP8 inhibits DNA repair.   
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A) HeLa cells were mock-transfected or transfected with pEYFP or pVP8-EYFP for 24 h. Cells 
were UV irradiated at 10 J/m2. Cells were fixed immediately after UV exposure or left to recover 
for 24 h, and then fixed with paraformaldehyde. Cells were permeabilized and stained with a 
monoclonal anti-CPD antibody followed by incubation with Alexa-633-conjugated goat anti-
mouse IgG. B) CPD fluorescence intensity was measured in 50 cells in each sample using a 
biological image-processing program, Fiji (407). The values of PDU are presented as mean ± 
standard deviation (SD). Statistical significance is indicated by asterisks (***, P < 0.001).  
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5.5.6      VP8 induces apoptosis.  
Successful virus infection involves efficient production and spread of its progeny. Viral 
proteins such as HIV-1 VPr protein induce apoptosis by inhibiting DNA repair (417). Recently it 
was shown that prevention of SMC1 phosphorylation leads to a defect in the S-phase checkpoint, 
and decreased cell survival after induction of DNA damage (416). Since VP8 inhibited 
phosphorylation of SMC1, we investigated whether VP8 mediates induction of apoptosis or 
increases DNA damage-induced apoptosis.  HeLa cells were mock-transfected or transfected with 
pFLAG or pFLAG-VP8. To determine the extent of apoptosis, cells were left untreated, treated 
with etoposide or exposed to UV at 24 h post infection. After 12 h of etoposide induction or UV 
exposure cells were trypsinized and a TUNEL assay was performed. Compared to untreated 
mock- and pFLAG-transfected cells, the level of apoptosis was higher in untreated pFLAG-VP8-
transfected cells (Figure. 5.11A). DNA damage induction by etoposide increased apoptosis in 
mock- and pFLAG-transfected cells to about 3% and 6%, respectively. However, in etoposide-
treated VP8-transfected cells, apoptosis was increased to 26%, which demonstrates that VP8 
enhances DNA-damage induced apoptosis.  Furthermore, as we observed inhibition of DNA repair 
by VP8 following UV treatment (Figure. 5.10), we examined whether VP8 enhances UV-induced 
apoptosis. While UV-exposure of mock- and FLAG-transfected cells augmented apoptosis to 8% 
and 9% of cells, respectively, the percentage of apoptotic cells increased to ~55% in UV-treated 
VP8-transfected cells. This further confirms that DNA damage-induced apoptosis was increased in 
VP8-transfected cells.  
It has been reported that caspase 3 is activated in response to unrepaired UV-induced 
DNA damage (418). To determine whether VP8 expression leads to cleavage of caspase-3, cells 
were mock-transfected or transfected with pFLAG-VP8 or pFLAG. An antibody that detects both 
the pro-caspase-3 and cleaved caspase-3 was used for detection. In VP8-expressing cells as well as 
in mock-transfected cells treated with etoposide cleaved caspase-3 was detected. However, 
cleaved caspase-3 was not detected in mock- and FLAG- transfected cells (Figure. 5.11B). This 
indicates that VP8 can activate caspase-3, and is in agreement with the fact that BoHV-1 infection 
activates caspase-3 to induce apoptosis (358, 362). 
 We also examined the role of VP8 in the induction of apoptosis in virus-infected cells. 
MDBK cells were mock-infected or infected with BoHV-1 or BoHV-1ΔUL47.  Cells were 
trypsinized, and a TUNEL assay was performed. As shown in Figure. 5.11C, in contrast to mock 
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infection, BoHV-1 infection caused apoptosis in 40% of the cells. However, the number of 
apoptotic cells was 8% in BoHV-1ΔUL47-infected cells. Expression of VP8 in BoHV-1-infected 
cells was confirmed in Figure. 5.11D. To confirm infection with the BoHV-1ΔUL47, expression of 
glycoprotein-C (gC) was demonstrated (Figure. 5.11D). The residual apoptosis in BoHV-1ΔUL47-
infected cells could be the result of the virus attachment process which was previously shown to 
induce apoptosis in BoHV-1-infected cells (356). Furthermore, gD was suggested to be involved 
in the induction of apoptosis (357), as well as the immediate early protein of BoHV-1, bICP0 
(360).  Since BoHV-1ΔUL47 contains gD and bICP0, the residual apoptotic activity in BoHV-
1ΔUL47-infected cells is likely due to one or both of these proteins. Since a significant reduction 
(~32%) of apoptosis was observed in BoHV-1ΔUL47-infected cells compared to wild type BoHV-
1 infection, this demonstrates that VP8 contributes to induction of apoptosis.    
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 Figure. 5.11 VP8 induces apoptosis in transfected and BoHV-1 infected cells. 
 A) HeLa cells were mock-transfected or transfected with pFLAG or pFLAG-VP8. At 24 h post 
transfection cells were left untreated, treated with etoposide or irradiated with UV 50 J/m2, and 
incubated for 12 h before trypsinization.  Apoptosis was detected by TUNEL assay. The cells were 
analyzed by FACS.  B) HeLa cells were mock-transfected or transfected with pFLAG or pFLAG-
VP8.  At 48 h post transfection, mock- infected cells were either left untreated or treated with 
etoposide. Cell lysates were collected and equal amount of proteins were analyzed by Western 
blotting. Caspase-3, cleaved caspase-3, VP8, and actin were detected with anti-caspase-3, anti-
VP8, and anti-actin antibodies, respectively. C) MDBK cells were mock-infected or infected with 
BoHV-1 or BoHV-1ΔUL47 at a MOI of 4. At 10 h post infection cells were trypsinized and 
apoptosis was measured by TUNEL assay. The cells were analyzed by FACS. D) Cell lysates 
were generated and VP8 and glycoprotein C (gC) were detected with murine monoclonal anti-VP8 
and anti-rabbit polyclonal gC antibodies, followed by incubation with IRDye680-conjugated anti-
mouse IgG and IRDye-800CW-conjugated anti-rabbit IgG, respectively.   
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5.6.        Discussion. 
During virus infection, host cells establish an intrinsic anti-viral defense, such as the IFN 
response and apoptosis. While some viruses counteract these responses by modulating the host 
immune responses, others manipulate the cellular machinery in favor of virus replication. In the 
present study, we demonstrated that VP8 interacts with ATM and NBS1. ATM is a central player 
in the DNA damage response and is activated immediately after DNA damage (265), by 
autophosphorylation at Serine-1981, which in turn leads to the phosphorylation of many 
downstream targets to coordinate DNA repair, cell cycle arrest and apoptosis (reviewed in (265)). 
Although VP8 interacted with ATM, VP8 did not interfere with ATM phosphorylation.  However, 
although the ATM activation was not interrupted, VP8 inhibited NBS1 phosphorylation. VP8, 
ATM and NBS1 were detected as a complex indicating that VP8 interacts with both ATM and 
NBS1. Since interaction between NBS1 and ATM is required for NBS1 phosphorylation, VP8 
might inhibit phosphorylation by blocking this interaction. Phosphorylation of SMC1 by ATM 
depends on NBS1 phosphorylation and is critical to activate the S-phase checkpoint (398). In fact, 
VP8 also inhibited SMC1 phosphorylation, which can prevent S-phase checkpoint activation (398, 
416). Overall, this shows that VP8 interacts with DNA damage response proteins and disrupts the 
ATM/NBS1/SMC1 pathway resulting in a defective DNA damage response.  
  BoHV-1, but not BoHV-1ΔUL47, inactivated the ATM/NBS1 pathway by reducing 
phosphorylation of NBS1, further supporting this function of VP8. Inhibition of NBS1 
phosphorylation was mediated by nuclear VP8 from 4 h onwards during infection. In contrast to 
BoHV-1, HSV-1 does not disrupt the ATM signaling pathway. Interestingly, Lou et al. revealed 
that in two closely related species such as white-cheeked gibbon (Nomascus leucogenys) and 
siamang (Symphalangus syndactylus), NBS1 functions differently during the establishment of 
HSV-1 infection (419), supporting the possibility of distinctive NBS1 role in the establishment of 
herpesvirus infections. Moreover, unlike HSV-1, HCMV disrupts both ATM and ATR pathways 
to subvert full activation of S-phase checkpoints (304) and Kaposi’s Sarcoma-associated 
herpesvirus inhibits the ATM signal transduction pathway by compromising the ATM/P53 DNA 
damage response checkpoint (311).  
Viruses have developed unique strategies to circumvent host-cell responses while others 
hijack cellular DNA damage response proteins for their propagation or replication. Similar to 
BoHV-1, homologous recombination repair is also inhibited during HSV-1 infection (279). 
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Furthermore, murine gamma herpesvirus 68 (γHV68) M2 protein interacts with the DNA repair 
complex, DDB1/ATM/COP9/cullin (404). Although γHV68 M2 protein induced ATM activation, 
the DNA damage response was abolished. Adenovirus E4 protein also reorganizes the MRN 
complex resulting in degradation (420). Adenovirus deregulates the host cell machinery in favor 
of viral genome processing, whereas HSV-1 activates and manipulates the DNA damage response. 
Thus, viral proteins use various distinct and overlapping mechanisms to accomplish viral 
propagation.  
Non-repaired DNA induces apoptosis in DNA repair-deficient cells (421). Similarly, 
inhibition of DNA repair has been implicated in the induction of apoptosis by HIV VPr (417). 
Previously, BoHV-1 has been shown to induce apoptosis (356, 360, 364). Interestingly, VP8 
appeared to contribute to induction of apoptosis outside the context of infection, as well as during 
BoHV-1 infection. We observed more apoptosis in BoHV-1-infected cells compared to BoHV-
1ΔUL47-infected cells. A low level of apoptosis was still observed in BoHV-1ΔUL47-infected 
cells, which can be contributed to other BoHV-1 proteins, for instance gD (357), ORF8 (364), 
and/or bICP0 (360). Since according to previous reports, prevention of SMC1 phosphorylation 
leads to a defect in the S-phase checkpoint and decreased cell survival after induction of DNA 
damage (416), prevention of SMC1 phosphorylation and abrogation of DNA repair by VP8 likely 
contributes to induction of apoptosis. Alternatively, VP8 may contribute to ATM activation, 
which can then phosphorylate p53 (thus leading to apoptosis). However, we observed activation of 
caspase 3 by VP8, and Dunkern et al, demonstrated that in repair-deficient cells UV-induced DNA 
damage triggered apoptosis independent of p53 and through caspase 3 activation (418). The fact 
that previously caspase-3-mediated apoptosis was observed in BoHV-1-infected cells (358) (362), 
further supports the contention that VP8 might function through caspase 3 activation to induce 
apoptosis.  
While some viruses express anti-apoptotic proteins to favor virus pathogenesis, others 
also exhibit pro-apoptotic properties to manipulate the cellular machinery for efficient virus 
production. For example, influenza virus upregulates pro-apoptotic factors for viral replication 
(422, 423), and HIV-1 enhances pro-apoptotic gene expression for efficient virus production 
(424). Furthermore, HSV-1 immediate early protein ICP0 triggers apoptosis during HSV-1 
infection to influence viral pathogenesis (425). Induction of apoptosis by VP8 might expedite the 
egress and progression of BoHV-1 infection. In BoHV-1ΔUL47-infected cells, the release of 
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infectious virus particles into the culture medium was reduced more than 1,000 fold compared to 
BoHV-1-infected cells which suggested reduced egress of BoHV-1ΔUL47 virions (179).  
In summary, BoHV-1 developed a novel evasion mechanism, whereby VP8 targets DNA 
damage response proteins. Without interfering with ATM activation, VP8 abrogated downstream 
signaling and thus, impaired the DNA repair mechanism. As a consequence, VP8 increased DNA 
damage-induced apoptosis. VP8 is the first BoHV-1 tegument protein reported to interfere with 
the DNA damage response pathway. These results illustrate a potential role of VP8 in the 
modulation of DNA damage response during BoHV-1 infection. 
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CHARPTER 6 
LINKER BETWEEN CHAPTER 5 AND CHAPTER 7 
 In BoHV-1-infected cells, VP8 is observed in the cytoplasm early during infection. As 
infection progresses VP8 is localized to the nucleus, followed by translocation of VP8 into the 
cytoplasm later during infection. The results in chapter 5 demonstrated that the subcellular 
localization of VP8 is associated with its function.  In the nucleus, interaction of VP8 with DDR 
proteins, ATM and NBS1, inhibited ATM-mediated DDR pathway resulting in induction of 
apoptosis.   
 The C-terminal domain of VP8 consists of mostly alpha-helices and is homologous to 
other herpesviruses ul47 gene products. However, there is no structural information available for 
any of the herpesvirus ul47 gene products. Therefore, we set out to determine the structure of 
VP8 by expressing it in different expression systems. 
 
6.1         Expression and purification of VP8.  
  VP8 was first expressed in baculovirus by using the Bac-to-Bac baculovirus expression 
system (Invitrogen). Briefly, VP8 was cloned into pFast-Bac donor plasmid. The recombinant 
donor plasmid was transformed into competent DH10Bac E. coli cells. Recombinant bacmid 
DNA was transfected into the Spodoptera frugiperda (Sf9) insect cells. The recombinant 
baculovirus passage-1 stock was secreted in the media. Following amplification of the 
baculovirus stock, the virus titer was determined and was used for subsequent infection of Sf9 
cells for large scale VP8 production. 
Secondly, to express VP8 in the mammalian secretory system, tissue plasminogen 
activator (tPA) signal and His tag were introduced at the N-terminus and C-terminus of VP8, 
respectively. VP8 was cloned into the pEB5.2 vector. Following screening of positive clones, 
HEK 293T cells were transfected with the VP8 recombinant vector. Secretion of VP8 in the 
media was screened for several days by Western blotting. 
For large scale VP8 production, VP8 was cloned into a lentivirus transfer vector, TRiP. 
VP8 was introduced with the N-terminals FLAG tag and C-terminal His tag. A VP8 positive 
clone was selected base on antibiotic selection. To generate the lentivirus, HEK 293T cells were 
transfected with the VP8 containing transfer vector, packaging vector psPAX2, and envelope 
vector pMD2. At 16 h post transfection medium was replaced with antibiotic containing medium. 
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The recombinant lentivirus was secreted into the medium. At 48 h post transfection supernatants 
were collected and screened for VP8 production. The supernatant was used for subsequent 
infection to express VP8.  
Finally, the truncated VP8 was expressed in E. coli with the addition of sumoylation-
Histidine (SUMO-His) tag at the N-terminus. VP8 was purified using affinity chromatography. 
To eliminate further contaminating proteins, truncated VP8 was subjected to size-exclusion 
chromatography. Sephadex-G-25 resin was used to pack the column followed by passing the 
purified VP8 through the column. The eluted protein was collected in multiple fractions. The 
collected fractions were analyzed by SDS-PAGE gel (Figure. 6.2A). Nonetheless, pure VP8 was 
not obtained through gel filtration chromatography.  
Ion exchange chromatography was performed with the truncated VP8 to separate other 
non-specific contaminating proteins. Q-Sepharose anion resin was used to incubate the purified 
protein. Following incubation of protein with the beads and subsequent washes, the proteins were 
eluted with a salt gradient. For cation exchange chromatography, the purified VP8 was incubated 
with sulphopropyl (SP) Sepharose. After multiple washes the proteins were eluted with the 
different salt concentrations. However, the unknown protein was not separated from VP8 by 
using on exchange chromatography (Figure. 6.2B).  
 
6.2         Results and Discussion. 
 In this study, we expressed VP8 in multiple expression systems. First, we chose to 
express VP8 in baculovirus expression system. However, the expression of VP8 was too low for 
large scale VP8 production. Secondly, VP8 recombinant lentivirus was generated. However, VP8 
was not expressed in the lentivirus expression system. Thirdly, since VP8 was transiently 
expressed in mammalian cells, we cloned VP8 in the mammalian secretory system with addition 
of tPA signal peptide. Nonetheless, VP8 was not secreted in the mammalian secretory system. 
The effort to express full length VP8 in E. Coli was also unsuccessful (demonstrated by a 
previous researcher form our lab). Therefore, since the C-terminal domain of VP8 is enriched 
with alpha-helices (Figure. 6.1A), we attempted to express the C-terminal domain in E. coli. 
Addition of the SUMO tag, which is responsible for increasing solubility of any protein, to VP8 
enhanced its expression in E. Coli. Nonetheless, VP8 formed a strong complex with another 
bacterial protein. 
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Figure. 6.1 Predicted secondary structure of VP8. 
A) BoHV-1 VP8 amino acid sequences were analyzed with PSIPRED. Pink colour rods represent 
helical structures, Yellow arrows represent strand and the black lines indicate coil structures. 
Blue colour represents conf: confidence of prediction, pred: predicted secondary structure and 
AA: amino acids. B) The Phyre 2 analysis was used for the prediction of transmembrane helices 
in VP8 (426). 
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Figure. 6. 2 Expression and purification of VP8. 
A) SUMO-His-VP8 219-741 was VP8 was expressed in E. coli. VP8 was purified by using a 
Nickel column. Size-exclusion chromatography was used for further purification of VP8. 
Fractions (F) were collected and analyzed by SDS-PAGE. F14-F23 are presented. B) VP8 was 
purified by using a cation resin (Left panel) and an anion resin (Right panel). The purified protein 
was analyzed by SDS-PAGE.  
 
 
 
 
 
 
 
A)	
B)	
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 For structural analysis we proceeded further for crystallization screening of VP8 and the 
unknown bacterial protein complex.  However, crystallization screening of VP8 and the unknown 
bacterial protein complex did not reveal any condition suitable for VP8 crystallization. 
Furthermore, concentrating VP8 at a concentration higher than 1 mg/ml was not possible as it 
precipitated at higher concentration. Recent predicted secondary structural analysis suggested that 
VP8 contains some transmembrane domains (Figure. 6.1B). This might explain the difficulties in 
expressing, purifying, and crystallizing VP8. Thus, in the future, modifying the crystallization 
screening approach might facilitate VP8 crystallization. 
 In the process of VP8 expression and purification, we identified a novel mitochondrial 
interacting partner of VP8. In the following chapter, we demonstrate another potential function of 
VP8 associated with the mitochondrial function. 
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7.1         Abstract 
  The ul47 gene product, VP8, is a major tegument protein of BoHV-1. While VP8 is not 
essential for virus replication in cell culture, a UL47-deleted virus exhibits a smaller tegument 
structure and is avirulent in cattle. To elucidate the structure of VP8, we expressed an N-
terminally truncated version of VP8 in E. coli.  However, the recombinant VP8 consistently co-
purified with a tightly associated bacterial protein; this protein was identified by mass 
spectrometry as GroEL, which has considerably homology with mammalian HSP60, thus 
suggesting a new role for VP8 in virus/host interaction. A physical interaction of HSP60 and VP8 
in both VP8-transfected and BoHV-1-infected cells was demonstrated by immunoprecipitation. 
Analysis of different truncated VP8 constructs revealed that amino acids 259-482 and 632-741 
are involved in binding to HSP60. Full-length VP8 and VP8 219-741 (containing both interacting 
domains, 259-482 and 632-741) co-localized with HSP60 and mitochondria. VP8 was localized 
in the mitochondria at 2-14 h post infection in BoHV-1-infected cells. The mitochondrial 
membrane potential (MMP) was reduced in both VP8-transfected and BoHV-1-infected cells and 
was further reduced by overexpression of HSP60 in the presence of VP8.  In addition, VP8 
expression also decreased the ATP concentration during transfection, as well as BoHV-1 
infection. Thus, VP8 may play a role in the deregulation of mitochondrial function through 
interaction with HSP60. This is consistent with the fact that BoHV-1 infection is known to 
promote mitochondrial dysfunction.  
 
7.2        Introduction. 
Bovine herpesvirus (BoHV-1) is an alpha herpesvirus and a major pathogen in cattle 
(11, 427), causing several diseases, including conjunctivitis, infectious bovine rhinotracheitis 
(IBR), balanoposthitis and abortions in cattle. Thus, BoHV-1 contributes significantly to 
economic losses of the North American cattle industry (11). BoHV-1 is a double-stranded DNA 
virus with a ~140kb genome. It contains four different compartments; a DNA core enclosed 
within a capsid, a thick tegument layer and an outer envelope with glycoproteins (428). The 
tegument of the BoHV-1 virion is the most complex structure containing ~ 20 virus-encoded 
proteins. The functions of the proteins in the tegument are not well understood. Immediately after 
fusion of the glycoproteins to the host cell membrane, herpesviruses release their tegument 
proteins into the cytoplasm (66). Thus, the tegument proteins are the first proteins to get into 
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contact with the intracellular environment, possibly to promote virus infection. Besides the 
structural role of the tegument proteins, these proteins contribute to multiple regulatory functions 
including DNA replication, transcriptional regulation, capsid transport, and kinase activity (106). 
Hence, the tegument proteins play a significant role during the establishment of virus infection. 
The ul47 gene product, VP8, is the most abundant tegument protein (176). VP8 is not 
essential for viral replication in vitro. However, a UL47-deleted BoHV-1 mutant has a smaller 
tegument structure and does not replicate in cattle (179). VP8 contains a nuclear localization 
signal (NLS) and a nuclear export signal (NES). These signals are responsible for shuttling of 
VP8 between the cytoplasm and nucleus (182). Early during infection the virion VP8 and the de 
novo synthesized VP8 can be detected in the cytoplasm. With the progression of infection VP8 
localizes to the nucleus and later during infection VP8 is again observed in the cytoplasm (181, 
187). VP8 has also been detected in the cisternae of the Golgi and found to interact with gB, gC, 
and gD mRNAs (181, 188).  
Mitochondria play a pivotal role in supplying energy and regulating apoptotic cell death 
processes, which are crucial for cell mortality. Human herpes simplex virus-1 (HSV-1) infection 
has been associated with deregulation of mitochondrial function. During HSV infection 
mitochondrial protein synthesis is progressively reduced (429, 430). HSV-1 infection also 
induces mitochondrial membrane disruption (431). Murata et al, demonstrated that mitochondria 
migrate to the perinuclear region with the tegument proteins UL41 and UL46 during HSV-1 
infection (432). Similarly, some tegument proteins accumulate in the perinuclear region of the 
cytoplasm (433, 434). The tegument protein UL16 also contains a mitochondrial localization 
signal and interacts with mitochondria (435). Likewise, BoHV-1 infection induces mitochondrial 
dysfunction and is associated with the stimulation of apoptosis (358, 362). Moreover, BoHV-1 
infection leads to mitochondrial dysfunction through induction of reactive oxygen species (363). 
Since some viral proteins targeted to mitochondria are also meant to subvert host defenses 
(reviewed in (436)), the de-regulation of mitochondrial functions by tegument proteins might be 
correlated to the establishment of virus infection. 
Several functions of VP8 are mediated by interaction with other host or other viral 
proteins, indicating that VP8 is a multifunctional protein and is extensively involved in host-
pathogen interactions. BoHV-1 VP8 interacts with cellular CK2 and viral US3 kinase (184). 
Furthermore, VP8 interacts with DNA damage-binding protein-1 (DDB1) (187), and with the 
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cellular signal transducer and activators of transcription (STAT1) to down-regulate interferon- β 
(IFN-β) signaling (405). Homologues of VP8 are present in different herpesviruses. The C-
terminal domain of VP8 is enriched with alpha-helical structures and is conserved among some 
herpesviruses (405).  
VP8 may exert more functions by interacting with additional viral or cellular proteins. 
The C-terminal domain of VP8 contains mostly α-helical structures (24), which mediate protein-
protein interactions (437). While expressing and purifying an N-terminal truncated VP8 for 
structural analysis in Escherichia coli, we observed a strongly interacting protein that co-purified 
with VP8. By mass spectrometry this bacterial protein was identified as GroEL, which shows 
conserved homology with mammalian heat shock protein-60 (HSP60). HSP60 is a molecular 
chaperone located in the cytoplasm and mitochondria and implicated in correct folding and 
transport of proteins to the mitochondrial matrix. We demonstrated that VP8 interacts with 
HSP60 in both VP8-transfected and BoHV-1-infected cells. Furthermore, we determined that 
VP8 localized to mitochondria resulting in deregulation of mitochondrial functions. 
 
7.3         Materials and Methods.  
7.3.1      Cells, viruses and plasmids. 
Madin-Darby bovine kidney (MDBK) and HeLa cells were maintained in Eagle’s 
minimum essential medium (MEM, Sigma-Aldrich Canada Ltd, Oakville, ON, Canada) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Life Technologies, 
Burlington, ON, Canada), 10 mM HEPES buffer (Life Technologies) and 1% antibiotic-
antimycotic (Life Technologies). A 37°C incubator with 5% CO2 was used to culture the cells. 
BoHV-1, BoHV1-ΔUL47 and BoHV-1UL47R were generated previously, (179) and were 
propagated in MDBK cells. The plasmid pFLAG-VP8 which allows expression of VP8 with a N-
terminal FLAG tag from a cytomegalovirus (CMV) promoter was described previously (Labiuk 
et al., 2009) The bacterial expression vector pET His6 Sumo TEV LIC was a gift from Scott 
Gradia (Addgene plasmid # 29659). A HSP60 expression plasmid was obtained from Sino 
Biologicals Inc., Wayne, PA, USA.  
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7.3.2      Antibodies and other reagents. 
BoHV-1 VP8-specific mouse monoclonal antibody was raised and used as previously 
described (181). HSP60 rabbit polyclonal antibody was obtained from Cell Signaling 
Technology, Beverly, MA, USA. Murine monoclonal anti-FLAG antibody was purchased from 
Sigma-Aldrich Canada Ltd, (Oakville, ON, Canada). A mitochondria detection kit, MITO-ID 
Red detection kit, was obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). ATPlite 
1step Luminescence Assay system was purchased from PerkinElmer (Waltham, MA, USA). 
 
7.3.3      Cell lysates, immunoprecipitation, and Western blotting. 
HeLa cells were seeded one day before transfection and grown to 60-70% confluency.  
The cells were transfected with different plasmids with Lipofectamine and Plus reagents 
(Invitrogen, Life Technologies). At 24 h post transfection ice-cold phosphate-buffered saline 
(PSB, pH 7.4) was used to wash the cells followed by incubation with lysis buffer (50 mM Tris, 
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 7.4). The lysis buffer was supplemented with 
mammalian cell and tissue extract protease inhibitor cocktail (Sigma-Aldrich). The cell and lysis 
buffer mixture was incubated on ice for 30 min followed by centrifugation at 12,000 × g for 15 
min at 4°C. The cell lysates were collected and stored at −80°C for future use. MDBK cells were 
infected with different viruses, and cell lysates were collected as described above.  
For immunoprecipitation, the cell lysates were incubated with anti-FLAG resin 
overnight. Alternatively, the cell lysates were incubated with anti-HSP60 antibody overnight 
followed by incubation with G-Sepharose Fast Flow beads (GE HealthCare, Niskayuna, NY, 
USA). The protein complexes were washed, and the bound proteins were eluted by adding SDS-
PAGE sample buffer followed by boiling. The protein samples were analyzed on 10% or 8-16% 
gradient gels.  The proteins were transferred to a nitrocellulose membrane followed by incubation 
with blocking buffer (5% skim milk in PBS containing Tween-20). The membrane was incubated 
with an appropriate primary antibody followed by incubation with IRDye680-conjugated anti-
mouse IgG or IRDye-800CW-conjugated anti-rabbit IgG (LI-COR Bioscience, Lincoln, NE, 
USA). The images were detected with an Odyssey Infrared Imaging system (LI-COR 
Bioscience).  
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7.3.4  Expression and purification of truncated VP8. 
A truncated ORF of VP8 (amino acids 219 – 741) was PCR amplified using the primers 
GAGGGATCCGAGCGGCTGTCGGAAGGGCCCCCGCTCCTCAAC and 
CACCTCGAGCTACCGGCCGCCCAGGCGCGGGCCCCGCCCATC, and then cut with 
BamHI and XhoI and cloned into a modified version of pET His6 Sumo TEV LIC. This allowed 
for expression of truncated VP8 with an N terminal SUMO together with his tag. A N-terminal 
SUMO has been shown to enhance expression and solubility of proteins (438); previous attempts 
to express VP8 in E. coli without SUMO were unsuccessful (results not shown). A Tobaco Etch 
Virus (TEV) protease site between the SUMO-his and VP8 allows for removal of the N-terminal 
tag from the purified protein. Recombinant protein was expressed in transformed BL21 (DE3) 
cells by inducing mid-log phase cells with Isopropyl β-D-1-thiogalactopyranoside (IPTG) at a 
final concentration of 250 mM and further incubation at 37˚C for 5 h. The cells were harvested 
by centrifugation at 10,000 x g for 15 min. and resuspended in 20 mM imidazole, 200 mM 
sodium phosphate buffer, supplemented with a SIGMAFAST Protease Inhibitor Cocktail tablet. 
The cells were lysed with a cell disruptor (Constant system, LTD. USA) and purified with a GE 
Healthcare His-Trap column. The purified protein was digested with Ac-TEV protease to cleave 
SUMO-His from the truncated VP8 and was re-purified on the Nickel column. The pure 
truncated VP8 was concentrated with an Amicon concentrator tube. Proteins were analyzed by 
SDS-PAGE followed by Coomassie Brilliant Blue staining and destaining.   
 
7.3.5				Mass	spectrometry.		
SUMO-His tagged truncated VP8 expressed in bacteria was purified using a Nickel 
column. The purified protein was analyzed by SDS-PAGE and stained with Coomassie Brilliant 
Blue in 10 % acetic acid, 40 % methanol. After destaining the gel, the proteins bands were excised 
and treated for in-gel trypsin digestion. The protein samples were then analyzed using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in the 
Alberta Proteomics and Mass Spectrometry Facility, University of Alberta, Edmonton, Canada. 
Briefly, the excised protein bands were destained (100 mM ammonium bicarbonate/acetonitrile 
(50:50)); reduced (10 mm BME in 100 mm bicarbonate), alkylated (55 mM iodoacetamide in 100 
mm bicarbonate) and dehydrated.  The dehydrated samples were trypsinized with 6 ng/µl trypsin 
(Promega Sequencing grade) overnight at room temperature (RT). 97% water/2% acetonitrile/1% 
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formic acid was used for extraction of the tryptic peptides. The second extraction was performed 
using 50% of the first extraction buffer and 50% acetonitrile. Nanoflow HPLC (Easy-nLC II, 
Thermo Scientific) coupled to a LTQ XL-Orbitrap hybrid mass spectrometer (Thermo Scientific) 
was used to resolve the tryptic peptide fractions. The peptide mixtures were injected onto the 
column, and the mass spectrometer data were obtained. The data processing was performed with 
Proteome Discoverer 1.4 (Thermo Scientific) and UniProt (uniprot.org) bovine, E. coli and VP8 
databases.  The data was searched with SEQUEST (Thermo Scientific).   
 
7.3.6      Immunofluoresence. 
HeLa or MDBK cells were seeded in two-chamber Permanox slides (Lab-Tek, 
Naperville, IL, USA) in MEM supplemented with 5% FBS. Lipofectamine and Plus reagents 
were used for mock transfection or transfection with pFLAG-VP8. At 24 h post transfection cells 
were fixed with 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100. 
The cells were blocked with 1% goat serum in PBS. Subsequently, the cells were incubated with 
primary antibodies for 2 h at RT. MDBK cells were mock-infected or infected with BoHV-1. The 
infected cells were fixed, permeabilized and incubated with primary antibodies. Following 
subsequent washes, the cells were incubated with Alexa Fluor 488 goat anti-mouse IgG or Alexa 
Fluor 633 goat anti-rabbit IgG (diluted 1:500; Invitrogen, Life Technologies). The nuclei were 
incubated with 4′,6-diamino-2-phenylindole (DAPI) containing mounting medium. For detection 
of mitochondria, a MITO-ID red detection kit (Farmingdale, NY, USA) was used. The cells were 
treated with MITO-ID red dye according to the manufacturer’s instruction. Green laser excitation 
at 488 nm (Alexa 488), red laser excitation at 633 nm (Alexa 633), and 461 nm for DAPI were 
used to analyze the confocal images. A Leica SP5 confocal microscope (Leica Microsystems 
Inc., Concord, ON, Canada) was used to obtain immunofluorescence images. 
 
7.3.7      Measurement of cellular ATP levels. 
The cellular ATP level was determined with an ATPLite 1step Luminescence assay 
system (PerkinElmer, Waltham, MA, USA). HeLa cells were cultured in 96-well plates and 
mock-transfected or transfected with pFLAG or pFLAG-VP8. At 48 h post transfection, the ATP 
level was measured according to the manufacturer’s instruction. Briefly, the ATPLite substrate 
was added to the wells followed by incubation for 5 min at RT with shaking. Luciferase signals 
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emitting at 560 nm were detected with a VICTOR X light luminescence plate reader 
(PerkinElmer). ATP concentration was determined from the standard curve. MDBK cells were 
mock-infected or infected with BoHV-1, BoHV1-ΔUL47 or BoHV1-UL47R. At 24 h post-
infection the ATP level was detected as described above. 
 
7.3.8      Mitochondrial membrane potential detection.  
A NIR mitochondrial membrane potential kit (Sigma-Aldrich) was used to detect 
mitochondrial membrane potential. HeLa cells were mock-transfected or transfected with pFLAG 
or pFLAG-VP8. At 48 h post-transfection cells were stained with the cationic membrane 
potential dye according to the manufacturer’s instruction.  MDBK cells were mock-infected or 
infected with BoHV-1, BoHV1-ΔUL47 or BoHV1-UL47R.  At 24 h post infection the cells were 
trypsinized and processed to examine the mitochondrial membrane potential.  Briefly, 
mitochondrial membrane potential dye, Near Infrared (NIR), was added to trypsinized cells 
followed by incubation for 15-30 min. After subsequent washes, the cells were resuspended in 
assay buffer and were analyzed by FACS. Fluorescence intensity was monitored with a flow 
cytometer equipped with a 635 nm red diode laser and a 661 nm filter. 
 
7.3.9      RNA interference.  
HeLa cells were seeded in 6-well plates one day before transfection. The cells were 
transfected with control and HSP60 siRNA (SMART-pool ON-TARGETplus HSP60 siRNA, 
Dharmacon, USA). At 24 h post transfection cells were transfected again with HSP60 siRNA 
together with the pFLAG-VP8. At 48 h post transfection of HSP60 siRNA and 24 h post 
transfection of pFLAG-VP8, the cell lysates were collected. The protein concentration was 
measured, and 50 µg of each protein sample were analyzed by Western blotting. 
 
7.4      Results. 
7.4.1    Identification of an in vitro interacting partner of BoHV-1 VP8.  
 BoHV-1 VP8 consists of 741 amino acids. Multiple sequence alignment and secondary 
structure prediction searches demonstrated that the C-terminal domain of VP8 is conserved 
between different herpesviruses and is rich in alpha-helical structures (405). SUMO-His-VP8 
219-741 was purified by Nickel affinity chromatography (Figure 7.1A).  As shown in Figure. 1A, 
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VP8 with an apparent molecular weight of 75 kDa co-purified with a 60 kDa bacterial protein. 
Some other minor contaminating proteins were also present with VP8 after the first round of 
purification. After cleavage of SUMO-His with Ac-TEV protease (Figure. 7.1A), we observed 
nearly complete digestion, which resulted in 52 kDa VP8 and 25 kDa SUMO-His (Figure. 7.1A). 
However, the bacterial protein of 60 kDa remained present even after an additional round of 
Nickel column affinity purification (Figure. 7.1A); Western blotting confirmed that the 60 kDa 
protein was not a truncated form of VP8 (Figure. 7.1B) as polyclonal VP8-specific antibody 
recognized the 52 kDa VP8, but not the 60 kDa protein.  This suggested that VP8 specifically and 
strongly associated with a bacterial protein, which consistently co-purified with VP8.   
 The identity of the co-purified 60 kDa protein was determined by mass spectrometry of 
the protein bands excised from the gels before TEV digestion and after final purification (Figure. 
7.1A); in both cases the mass spectrometry analysis showed high hit scores with E. coli  GroEL 
(Figure. 7.1C). GroEL, a 60 kDa chaperonin protein, is required to maintain proper folding of 
many proteins. Alignment analysis (Figure. 7.1D) demonstrated considerable sequence similarity 
between bacterial GroEL and bovine and human HSP60. The bacterial GroEL lacks the N-
terminal sequences that are responsible for targeting HSP60 to mitochondria in bovine and 
human cells. The fortuitous observation that recombinant VP8 strongly associated with bacterial 
GroEL led to the hypothesis that VP8 interacts with host HSP60 during viral infection 
contributing to virulence; the HSP60 may serve to stabilize VP8 or translocate the VP8 to the 
mitochondria leading to impairment of mitochondrial function. 
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Figure. 7.1.  Identification of a bacterial protein co-purifying with recombinant VP8.  
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A) SUMO-His-VP8 219-741 was expressed in BL21 cells. Nickel column-purified VP8 was 
digested with Ac-TEV protease and was analyzed by SDS-PAGE followed by Commassie 
Brilliant Blue staining. B) Final purified VP8 and purified SUMO-His were analyzed by Western 
blotting. L represents protein molecular weight ladder in kDa. C) Purified VP8 was analyzed by 
SDS-PAGE followed by Coomassie Brilliant Blue staining. The upper 60kDa band (from Figure. 
7.1A) was excised and analyzed by MALDI-TOF-MS. The identified peptides were used to 
search Uniprot data bases and the sum of the score of peptides is presented in the table. D) 
Sequence homology between bacterial GroEL and bovine and human HSP60 was analyzed by 
ClustalW. The gray boxes represent homologous sequences. 
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7.4.2      Interaction of BoHV-1 VP8 with HSP60 in vivo.  
    Interaction between cellular HSP60 and VP8 was determined by immunoprecipitation 
following transfection of HeLa cells with plasmid expressing FLAG-tagged VP8; cell lysates 
were collected at 24 h post transfection (Figure. 7.2A left panel). Anti-FLAG resin precipitated 
VP8 and EYFP from VP8- and EYFP-transfected cells, respectively, whereas HSP60 was 
precipitated with FLAG-VP8, but not with FLAG-EYFP. This shows that VP8 interacts with 
HSP60 in transfected cells. Similarly, mock-, pFLAG- and pFLAG-VP8-transfected cell lysates 
were analyzed by reverse immunoprecipitation with an anti-HSP60 antibody (Figure. 7.2B). 
HSP60-specific antibody precipitated HSP60 from mock-, FLAG- and FLAG-VP8-transfected 
cells. However, HSP60 precipitated only FLAG-VP8, and not FLAG-EYFP, confirming 
interaction of VP8 with HSP60. 
To demonstrate interaction of VP8 with HSP60 in BoHV-1-infected cells, MDBK cells 
were mock-infected or infected with BoHV-1 or BoHV-1ΔUL47. At 24 h post infection cell 
lysates were collected and incubated with a VP8-specific antibody (Figure. 7.2C). Anti-VP8 
antibody precipitated VP8 from BoHV-1-infected cells, but not from mock- or BoHV-1ΔUL47-
infected cells. The precipitated VP8 pulled down HSP60 from BoHV-1-infected cells, but not 
from mock- or BoHV-1ΔUL47-infected cells, thus demonstrating that VP8 interacts with HSP60 
during BoHV-1 infection. This was validated by reverse precipitation of VP8; mock-, BoHV-1- 
and BoHV-1ΔUL47-infected cell lysates were incubated with an anti-HSP60 antibody (Figure. 
7.2D) followed by Protein G Sepharose. HSP60-specific antibody pulled down HSP60 from 
mock-, BoHV-1- and BoHV-1ΔUL47-infected cell lysates, while VP8 was precipitated only from 
BoHV-1-infected cells. This confirms that HSP60 interacts with VP8 in BoHV-1-infected cells. 
Altogether, these experiments demonstrate interaction of VP8 with HSP60 in both VP8-
transfected and BoHV-1-infected cells. 
 To determine the domain of VP8 interacting with HSP60, five different FLAG-tagged, 
N-terminally truncated VP8 versions (VP8 121-741, VP8 219-741, VP8 343-741, VP8 538-741, 
and VP8 632-741) were analyzed for precipitation of HSP60 (Figure. 7.2E). Anti-FLAG resin 
pulled down all N-terminally truncated VP8 versions and HSP60 indicating that a region between 
amino acids 632-741 of VP8 is sufficient for interaction with HSP60. In addition, cells were 
transfected with C-terminally truncated VP8 versions (VP8 1-120, VP8 1-258, VP8 1-482, VP8 
1-631) and incubated with anti-FLAG resin. Only two C-terminally truncated VP8 versions (VP8 
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1-482 and VP8 1-631) precipitated HSP60. This experiment revealed that amino acids 259-482 of 
VP8 were sufficient to precipitate HSP60. Collectively, this suggests that regions within amino 
acids 259-482 and 632-741 of VP8 are involved in binding of VP8 to HSP60.  
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       Figure. 7.2 Interaction of BoHV-1 VP8 with HSP60 in eukaryotic cells.  
A) HeLa cells were mock-transfected or transfected with pFLAG-EYFP or pFLAG-VP8. Cell 
lysates were collected at 24 h post transfection and incubated with anti-FLAG beads. Precipitated 
proteins (left panel) and input lysates (right panel) were detected with anti-FLAG and anti-
HSP60 antibodies. B) HeLa cells were mock-transfected or transfected with pFLAG-EYFP or 
pFLAG-VP8. Cell lysates were collected at 24 h post transfection and incubated with rabbit anti-
HSP60 antibody, followed by with protein G Sepharose. The left panel represents precipitated 
proteins and the right panel represents input lysates. A) and B) precipitated proteins and input 
lysates were detected with anti-FLAG and anti-HSP60 antibodies. C) MDBK cells were mock-
infected or infected with BoHV-1 or BoHV-1ΔUL47 at an MOI of 3, and at 24 h post infection 
cell lysates were collected and incubated with mouse anti-VP8 antibody followed by protein G 
Sepharose. Precipitated proteins (left panel) and input lysates (right panel) were detected with 
anti-VP8 and anti-HSP60 antibodies. D) MDBK cells were mock-infected or infected with 
BoHV-1 or BoHV-1ΔUL47 as described above. At 24 h post infection cell lysates were collected 
and incubated with anti-HSP60 antibody followed by protein G Sepharose. Precipitated proteins 
(left panel) and input lysates (right panel) were detected with anti-VP8 and anti-HSP60 
antibodies. E) HeLa cells were mock-transfected or transfected with five N-terminally truncated 
VP8 versions. Cell lysates were collected at 24 h post transfection and incubated with anti-FLAG 
beads. Precipitated proteins were detected with anti-FLAG and anti-HSP60 antibodies. Left panel 
and right panels represent precipitated proteins and input lysates, respectively. F) HeLa cells were 
mock-transfected or transfected with pFLAG or pFLAG-VP8 or four different C-terminally 
truncated VP8 versions. Cell lysates were collected at 24 h post transfection and incubated with 
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anti-FLAG beads. Precipitated proteins were detected with anti-FLAG and anti-HSP60 
antibodies. Left panel and right panels show precipitated proteins and input lysates, respectively.  
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7.4.3      HSP60 co-localizes with VP8 but does not alter VP8 expression. 
Since VP8 interacts with HSP60 in mammalian cells, we investigated whether VP8 co-
localized with HSP60. HeLa cells were mock-transfected or transfected with pFLAG-VP8 or 
pFLAG-VP8 219-741. At 24 h post transfection cells were incubated with anti-FLAG or anti-
HSP60 antibodies. FLAG-VP8 219-741 contains the domains involved in binding to HSP60, but 
it lacks a nuclear localization signal. As demonstrated in Figure. 7.3A, VP8, as well as VP8 219-
741 co-localized with HSP60. To demonstrate co-localization of HSP60 with VP8 in BoHV-1-
infected cells, MDBK cells were mock-infected or infected with BoHV-1. At 14 h post infection 
the cells were incubated with anti-VP8 and anti-HSP60 antibodies. As indicated in Figure. 7.3B, 
some VP8 was also co-localized with HSP60 in BoHV-1-infected cells. These experiments 
demonstrate VP8 is partially co-localized with HSP60. 
          HSP60 is known to regulate the folding and maintain the stability of mitochondria- 
imported proteins (439). Since VP8 interacted and co-localized with HSP60, we investigated 
whether HSP60 was required for VP8 stability. HeLa cells were transfected with control or 
HSP60-specific siRNA, and 24 h later the cells were again transfected with HSP60-specific 
siRNA and with pFLAG-VP8. At 24 h after transfection with pFLAG-VP8 cell lysates were 
collected, and equal amounts of the cell lysates were analyzed by Western blotting. The HSP60 
level was similar in mock- and control siRNA-transfected cells (Figure. 7.3C), but was 
substantially reduced in cells transfected with HSP60-specific siRNA. However, the level of 
VP8, as detected by Western blotting, was not notably altered by the silencing of HSP60 
suggesting, that HSP60 does not play a major role in maintaining VP8 protein levels.  
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Figure. 7.3 HSP60 co-localizes with VP8, but does not alter VP8 expression. 
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A) HeLa cells were mock-transfected or transfected with pFALG-VP8 or pFLAG-VP8 219-741. 
At 24 h post transfection cells were incubated with mouse anti-FLAG and rabbit anti-HSP60 
antibodies followed by incubation with Alexa Fluor 488-conjugated goat anti-mouse and 633-
conjugated goat anti-rabbit IgG. Nuclei were identified with DAPI.  Yellow boxes represent 
higher magnifications of the selected areas. B) MDBK cells were infected with BoHV-1 at a MOI 
of 3 for 14 h. The infected cells were incubated with monoclonal anti-VP8 and polyclonal anti-
HSP60 antibodies followed by incubation with Alexa Fluor 488-conjugated goat anti-mouse and 
Alexa Fluor 633-conjugated goat anti-rabbit IgG. Nuclei were identified with DAPI. Yellow box 
represents higher magnifications of the selected area. C). HeLa cells were mock-transfected or 
transfected with control siRNA or with HSP60 siRNA for 24 h before transfecting again with 
control siRNA or with HSP60 siRNA together with FLAG-VP8 or with only FLAG-VP8. At 24 
h post transfection cell lysates were collected, and 50 µg protein of each sample were analyzed 
by SDS-PAGE and Western blotting.  HSP60, VP8 and actin were detected with anti-HSP60, 
anti-FLAG and anti-actin antibodies, respectively.  
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7.4.4      Localization of HSP60 and VP8 to mitochondria.  
HSP60 is a mitochondrial protein and contains a mitochondrial localization signal (440). 
We confirmed the localization of HSP60 to the mitochondria by incubating HeLa cells with anti-
HSP60 antibody and mito-tracker red dye (Figure. 7.4A). Since VP8 interacts with HSP60, and 
HSP60 localizes to mitochondria, we anticipated that VP8 might be localized with the 
mitochondria. HeLa cells were mock-transfected or transfected with pFLAG-VP8 or pFLAG-
VP8-219-741. At 24 h post transfection the cells were incubated with anti-FLAG antibody and 
with mito-tracker red dye. The full-length VP8 and VP8 219-741 were both partially localized to 
mitochondria (Figure. 7.4B), which indicates that like HSP60, VP8 is targeted to the 
mitochondria and that the C-terminal domain of VP8, VP8 219-741, mediates the mitochondrial 
localization of VP8. To investigate localization of VP8 to the mitochondria during BoHV-1 
infection, MDBK cells were mock-infected or infected with BoHV-1. At 14 h post infection cells 
were incubated with anti-VP8 antibody and mito-tracker red dye. As shown in Figure. 7.4C, VP8 
partially localized to mitochondria in BoHV-1-infected cells. These experiments confirm partial 
localization of VP8 to mitochondria in both VP8-transfected and BoHV-1-infected cells.    
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Figure. 7.4 Localization of HSP60 and VP8 to mitochondria.  
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A) HeLa cells were incubated with polyclonal anti-HSP60 antibody followed by Alexa Fluor 
488-conjugated goat anti-mouse IgG. Mitochondria were identified with mitotracker red dye 
followed by nuclear staining with DAPI. B) HeLa cells were mock-transfected or transfected 
with pFLAG-VP8 or pFLAG-VP8 219-741. At 14 h post transfection cells were incubated with 
monoclonal anti-FLAG antibody followed by Alexa Fluor 488-conjugated goat anti-mouse IgG. 
Mito-tracker red dye was used to identify mitochondria. Nuclei were incubated with DAPI. C) 
MDBK cells were infected with BoHV-1 at a MOI of 3 for 14 h. The infected cells were 
incubated with a monoclonal anti-VP8 antibody followed by Alexa Fluor 488-conjugated goat 
anti-mouse IgG. Mitochondria were incubated with mito-tracker red dye. DAPI was used to 
identify the nucleus. Yellow boxes represent higher magnifications of selected areas. 
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7.4.5      Localization of VP8 to mitochondria at different time points during BoHV-1 
infection.  
Since VP8 localized to mitochondria in both VP8-transfected and BoHV-1-infected 
cells, it was of interest to investigate at which time point this occurs during infection. MDBK 
cells were mock-infected or infected with BoHV-1, and at different times post infection the cells 
were fixed and incubated with an anti-VP8 antibody and mito-tracker red dye. As shown in 
Figure. 7.5, VP8 was cytoplasmic at 2 h post infection, as previously demonstrated (187, 405), 
and some VP8 was localized to the mitochondria at this time. As the infection progressed, at 4 h 
post infection VP8 was observed in the nucleus, the peri-nuclear region, and the cytoplasm. Some 
of the peri-nuclear VP8 co-localized with the mitochondria. At 6 h post infection most of VP8 
was nuclear, but some peri-nuclear VP8 located to the mitochondria. Later during infection, VP8 
is exported to the cytoplasm. At 14 h post infection, VP8 was localized in the cytoplasm and 
some VP8 was observed in the mitochondria. This experiment illustrates that VP8 partially 
localized to mitochondria at different time points throughout BoHV-1 infection. 
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Figure. 7.5 Localization of VP8 to mitochondria during BoHV-1 infection at different time points.  
MDBK cells were mock-infected or infected with BoHV-1 at a MOI of 3. Cells were fixed at 2, 
4, 6 h and 14 h, and then incubated with a monoclonal anti-VP8 antibody followed by Alexa 
Flour 488-conjugated goat anti-mouse IgG. Mitochondria were identified with mito-tracker red 
dye. DAPI was used to identify the nucleus. 
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7.4.6      Effect of VP8 on mitochondrial function.  
  During HSV-1 and BoHV-1 infection mitochondrial dysfunction is caused by the 
reduction of mitochondrial membrane potential (363, 432).  Since VP8 interacted with HSP60 
and localized to the mitochondria, we examined whether VP8 causes mitochondrial dysfunction. 
To detect the mitochondrial membrane potential in VP8-transfected cells in the absence of any 
other viral protein, HeLa cells were mock-transfected or transfected with pFLAG, pFLAG-VP8 
or pFLAG-VP8 219-741. At 48 h post transfection the MMP was determined with the NIR MMP 
dye and was analyzed by FACS (Figure. 7.6A). The MMP was reduced from approximately 98% 
in mock- or pFLAG- transfected cells to about 78% in pFLAG-VP8 or pFLAG-VP8 219-741-
transfected cells.  
               To determine the involvement of VP8 and HSP60 in reduction of the MMP, we 
analyzed the cellular MMP in the presence of exogenous HSP60 and VP8. HeLa cells were 
mock-transfected or transfected with pFLAG, pFLAG-VP8, pFLAG-VP8 219-741 or pFLAG-
VP8 1-219 (the domain that does not interact with HSP60) together with empty vector or HSP60 
(Figure. 7.6B). At 48 h post transfection, cells were incubated with NIR MMP dye, and the MMP 
was determined by FACS. As demonstrated in Figure. 7.6B, transfection of cells with empty 
vector together with pFLAG-VP8 or pFLAG-VP8 219-741 significantly reduced the MMP (~ 68-
71%) when compared to mock transfection or transfection with pFLAG together with empty 
vector (~ 95%). However, in the cells co-transfected with pFLAG-VP8 1-219 and empty vector 
the MMP was maintained at ~ 91%. In addition, when cells were co-transfected with pFLAG-
VP8 or pFLAG-VP8 219-741 and HSP60, the MMP significantly declined (~ 49-53%) when 
compared to cells co-transfected with or pFLAG-VP8 1-219 and HSP60 (~ 88%).  Introduction 
of HSP60 and pFLAG did not reduce the MMP. This experiment demonstrates that 
overexpression of VP8 and HSP60 contributes to the reduction of MMP, and that VP8 219-741 
causes reduction of MMP at a similar level as VP8.     
               Since we observed loss of MMP in VP8-transfected cells, we determined the effect of 
VP8 on MMP in BoHV-1-infected cells. For this experiment, MDBK cells were mock-infected 
or infected with BoHV-1, BoHV-1ΔUL47 or BoHV-1UL47R. At 24 h post infection the cells 
were processed for MMP detection, and were evaluated by FACS. As indicated in Figure. 7.6C, 
in mock- and BoHV-1ΔUL47-infected cells the MMP was maintained in approximately 90% of 
the cells, whereas the MMP was retained in approximately 70% of the BoHV-1 and BoHV-
		
	 156	
1UL47R-infected cells. Since the BoHV-1ΔUL47 infection retained MMP in a higher percentage 
of cells compared to BoHV-1- and BoHV-1UL47R-infection, VP8 can reduce the MMP during 
BoHV-1 infection.  
             VP8 was localized to mitochondria early post infection. To determine whether the 
localization of VP8 to mitochondria at these early time points reduces the MMP, we determined 
the MMP at 2 h and 4 h post infection (Figure.  7.6D). MDBK cells were mock-infected or 
infected with BoHV-1, BoHV-1ΔUL47 or BoHV-1UL47R. The cells were collected at 2 h and 4 h 
post infection and then incubated with NIR MMP dye. The cellular MMP was analyzed by 
FACS. As indicated in Figure. 7.6D, the MMP was maintained at these time points of the 
infection. This experiment demonstrates that the localization of VP8 to mitochondria at early 
infection does not cause reduction of MMP. 
               Mitochondria are associated with the energy metabolism by generation of ATP. Proper 
mitochondrial membrane potential maintains maximal ATP production. Many viruses modulate 
mitochondrial function for infection. HSV-1, as well as BoHV-1, reduce ATP production during 
productive infection (363, 432). Since we observed reduction of MMP in the presence of VP8, to 
further confirm mitochondrial dysfunction by VP8, we evaluated the total cellular ATP level in 
VP8-transfected cells HeLa cells were mock-transfected or transfected with pFLAG, pFLAG-
VP8, or pFLAG-VP8 219-741. At 48 h post transfection the total ATP concentration was 
measured. As demonstrated in Figure. 7.7A, the total ATP concentration was significantly 
decreased in VP8- and VP8 (VP8 219-741)-transfected cells when compared to mock- and 
FLAG-transfected cells. Thus, this experiment suggests that the presence of VP8 reduced the 
total ATP level in transfected cells. To determine the effect of VP8 on the total ATP level during 
BoHV-1 infection, MDBK cells were mock-infected or infected with BoHV-1, BoHV-1ΔUL47 or 
BoHV-1UL47R. At 24 h post infection, the cellular ATP concentration was evaluated (Figure. 
7.7B). The amount of total ATP was reduced significantly in cells that were infected with BoHV-
1 or BoHV-1UL47R. However, in BoHV-1ΔUL47-infected cells the ATP concentration was not 
affected. Hence, VP8 contributes to the reduction of ATP levels during BoHV-1 infection.  
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Figure. 7.6 Effect of VP8 on mitochondrial membrane potential.  
A) HeLa cells were mock transfected or transfected with pFLAG, pFLAG-EYFP, pFLAG-VP8 
or pFLAG-VP8 219-741. At 48 h post transfection cells were trypsinized and incubated with NIR 
MMP dye. The cells were analyzed by FACS.  B) Hela cells were transfected with empty vector 
together with pFLAG, pFLAG-VP8, pFLAG-VP8 219-741, pFLAG-VP8 1-218, or pHSP60, or 
transfected with pHSP60 together with pFLAG-VP8, pFLAG-VP8 219-741 or pFLAG-VP8 1-
218. At 48 h post transfection the cells were trypsinized and then incubated with NIR MMP dye. 
The cells were analyzed by FACS. C) MDBK cells were mock-infected or infected with BoHV-
1, BoHV-1ΔUL47 or BoHV-1UL47R at a MOI of 3 for 24 h. The MMP was detected with the 
NIR dye and the cells were analyzed by FACS. D) MDBK cells were mock-infected or infected 
with BoHV-1 at a MOI of 3. At 2 h and 4 h post infection, the cells were trypsinized and then 
incubated with MMP dye. The cells were analyzed by FACS. Statistical significance is indicated 
by asterisks (****, P < 0.0001). 
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Figure. 7.7. Reduction of ATP production by BoHV-1 VP8.  
A) HeLa cells were mock-transfected or transfected with pFLAG, pFLAG-EYFP, pFLAG-VP8 
or pFLAG-VP8 219-741. The ATP concentration was determined at 48 h post transfection. B) 
MDBK cells were mock-infected or infected with BoHV-1, BoHV1-ΔUL47 or BoHV1-UL47R at 
an MOI of 3. ATP concentrations were determined 24 h post infection. Statistical significance is 
indicated by asterisks (*, P < 0.05; ***, P < 0.01). 
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7.5       Discussion. 
 To obtain purified protein for structural characterization purposes, we expressed VP8 in 
E.coli. Since the C-terminal domain of VP8 is enriched with alpha-helices (405), we expressed 
this C-terminal VP8 (amino acids 219-741) in E. coli. The addition of a SUMO tag, which often 
enhances production and solubility of recombinant proteins, permitted substantial expression of 
soluble VP8 in E. coli. However, the recombinant VP8 consistently co-purified with a strongly 
associated bacterial protein, which was identified by mass spectrometry as GroEL protein, which 
shows substantial homology with mammalian HSP60, a mitochondrial chaperone protein. VP8 
was subsequently shown to interact with mammalian HSP60 in eukaryotic cells both after 
transfection with VP8-expressing plasmids and infection with BoHV-1, to further confirm 
mitochondrial dysfunction by VP8-1virus. Domains in the C-terminal region of VP8, amino acids 
259-482 and 632-741, were identified to be involved in the binding of VP8 with HSP60. Like 
HSP60, VP8 localized to the mitochondria. The localization of VP8 to the mitochondria led to 
mitochondrial dysfunction as determined by the reduction of mitochondrial membrane potential 
and ATP levels.  
 MASCOT analysis of MALDI-TOF-MS revealed that bacterial GroEL was tightly 
associated with VP8 with a high score. GroEL is a homolog of mammalian HSP60. Among the 
three structural domains of GroEL or HSP60, apical, intermediate and equatorial, the equatorial 
domain contains the most α-helical structures and facilitates interactions with other proteins 
(441). BoHV-1 VP8 might bind to this equatorial domain of HSP60 in a similar manner as other 
substrates of HSP60. GroEL substrates usually contain two or more domains with α-helices or β-
sheets (442). According to the predicted secondary structure, the VP8 C-terminal domain is 
enriched with α-helical structures (405). Interestingly, analysis of VP8 showed that sequences in 
its C-terminal domain, amino acids 259-482 and 632-741, were involved in interaction of VP8 
and HSP60. Hence, the presence of α-helices at the C-terminus of VP8 might facilitate 
association of HSP60 and VP8. As HSP60 is a chaperone protein that promotes proper protein 
folding and stability (439), we speculated that HSP60 might promote VP8 stability. However, the 
knock down of HSP60 by using HSP60-specific siRNA, did not alter the VP8 levels suggesting 
that HSP60 does not play a major role in maintaining the level of VP8 expression, but may serve 
to guide VP8 to mitochondria or VP8 moves to the mitochondria to interact with HSP60 and thus 
disturb mitochondrial functions.  
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 HSP60 is a predominantly mitochondrial protein. The 26 amino acids at the N-terminus 
of HSP60 drive this protein to the mitochondria (440). Mitochondria are vital organelles to 
regulate cellular functions. Targeting mitochondria is a widely known strategy that viruses use 
for their survival, replication, and escape from the cells. For instance, hepatitis C (HCV) proteins 
localize to mitochondria where their function is impaired through reduction in MMP and increase 
of reactive oxidative stress (ROS) during productive infection (443). Similarly, HIV Vpr is 
targeted to mitochondria and facilitates reduction of MMP (444). Other viral proteins, such as 
hepatitis B virus X (HBx) protein, interact with HSP60 as well as with mitochondria (445), cause 
mitochondrial aggregation and reduce mitochondrial membrane potential (446). HBx-mediated 
cell death through association with HSP60 was also observed (445). Moreover, hepatitis C virus 
(HCV) protein also associates with mitochondria to promote the reduction of MMP during 
productive infection (443).  
 During BoHV-1 infection, VP8 was detected in the mitochondria at 2 h and continued to 
be localized to the mitochondria till 14 h post infection. HSV-1 tegument proteins, UL41 and 
UL46, are associated with mitochondria, and the authors suggested that these tegument proteins 
migrate to the peri-nuclear region with mitochondria (432). In the present study, we demonstrated 
that VP8 reduces MMP and ATP concentration. This was mediated by the full-length VP8, or a 
C-terminal domain containing HSP60 binding sites. HSP60 maintains MMP, since down-
regulation of HSP60 reduces cellular MMP (447). Thus, the interaction with HSP60 and VP8 in 
the mitochondria might facilitate down-regulation of the function of HSP60 in maintaining MMP 
and subsequently reduction of MMP. Proper maintenance of MMP is associated with a normal 
level of ATP production. Any changes in the MMP level reduces ATP production (448). In 
agreement with the fact that VP8 expression decreased cellular MMP, a reduction in the ATP 
production was also observed in presence of VP8.  Additionally, we observed that during BoHV-
1 infection, VP8 reduced MMP and ATP concentrations, whereas BoHV-1ΔUL47 did not 
influence MMP and the ATP levels. These observations suggest a role of VP8 in perturbing 
mitochondrial function during infection by reducing mitochondrial membrane potential and ATP 
levels. In agreement with these results, BoHV-1 infection is known to induce mitochondrial 
dysfunction through reducing MMP, increasing oxidative stress and reducing ATP levels (363), 
which can be (partially) ascribed to VP8. As mentioned above, different viral proteins localize to 
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mitochondria to deregulate mitochondrial functions. Therefore, it is plausible that BoHV-1 VP8 
targets mitochondria to interfere with mitochondrial functions. 
  In conclusion, we report a new role for the multifunctional VP8 of BoHV-1. VP8 
interacts with HSP60, which may facilitate translocation of VP8 to mitochondria. In addition, or 
alternatively, the interaction of HSP60 with VP8 may prevent it from maintaining the MMP 
which results in reduce ATP production and mitochondrial dysfunction during BoHV-1 infection. 
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CHAPTER 8 	
GENERAL CONCLUSIONS AND DISCUSSION 
8.1       General conclusions. 
§ After fusion of the BoHV-1 envelope with the host cell membrane, VP8 from the 
tegument region of incoming virions are released into the host cytoplasm. At 2 h post 
infection, VP8 is observed in the cytoplasm. VP8 then interacts with cellular STAT1 in 
the cytoplasm using its two domains amino acids 259-482 and 632-741. 
 
§ The interaction of VP8 with STAT1 does not interfere with phosphorylation or 
degradation of STAT1. However, this interaction prevents nuclear accumulation of 
STAT1. 
 
§ Since VP8 inhibited IFN expression, the inhibition of STAT1 nuclear accumulation by 
VP8 is likely associated with the inhibition of STAT1-mediated transcription of 
interferon-inducible genes.  
 
§ With the progression of BoHV-1 infection, the DDR pathway gets activated. We 
demonstrated that VP8 interacts with the DDR pathway proteins, ATM and NBS1.  
 
§ The interaction of VP8 with ATM does not interfere with ATM phosphorylation. 
However, the interaction of VP8 with NBS1 inhibits NBS1 phosphorylation, and NBS1-
depended SMC1 phosphorylation. 
 
§ As a result, DNA repair is inhibited in the presence of VP8. This inhibition prevents DNA 
repair, which eventually leads to the activation of apoptotic pathway. Thus, VP8 increases 
DNA damage-induced apoptosis through caspase-3 activation. 
 
§ During infection, some VP8 interacts with mitochondrial chaperonin protein HSP60 and 
localizes to mitochondria.  
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§ The mitochondrial localization of VP8 induces mitochondrial dysfunction by reducing 
mitochondrial membrane potential or by decreasing ATP production.  	
8.2         General discussion. 
 Type I IFN response is one of the host defense mechanisms against virus infection. 
Virus infection triggers activation of transcription factors, IRFs, leading to transcriptional 
activation of IFN genes. However, IFN signaling is modulated by viruses to establish infection. 
During virus infection, the cellular antiviral state is established through type I IFN signaling. 
Nonetheless, viruses counteract these anti-viral responses through multiple mechanisms, such as 
modulation of IFN response or alteration of the DDR pathway. Here we observed that like other 
viruses, BoHV-1 infection down-regulates IFN-β signaling. Inhibition of IFN-β signaling is 
associated with the interaction of VP8 and STAT1. 
 In the first section, we demonstrated that during BoHV-1 infection, IFN-β signaling was 
significantly reduced in the presence of VP8. Conversely, in BoHV-1ΔUL47 infected cells the 
luciferase signal indicating IFN production was increased. Even though incomplete recovery was 
observed in BoHV-1ΔUL47-infected cells, the induction of IFN-β signaling was significantly 
higher in comparison to BoHV-1-infected cells. The residual luciferase activity in BoHV-
1ΔUL47-infected cells could be attributed to the presence of bICP0, which is involved in down-
regulation of IFN-β signaling (207, 379). To preclude the involvement of bICP0 in the regulation 
of IFN-β signaling, the transcription inhibitor, ActD was used to treat the cells. As expected, 
treatment of cells with ActD mediated complete recovery of luciferase signaling in BoHV-1Δ
UL47-infected cells, whereas inhibition of luciferase signaling was observed in BoHV-1- and 
BoHV-1UL47R-infected cells. Hence, we speculate that in the absence of newly synthesized 
protein, incoming virion VP8 functions to down-regulate IFN-β signaling. A similar function of 
the HSV-1 UL47 gene product, VP13/14, is not known. Although BoHV-1 VP8 is a homologue 
of HSV-1 VP13/14, there are some functional differences between these two protein functions. 
For instance, HSV-1 VP13/14 interacts with US3, UL13 and UL14, which are crucial for nuclear 
egress (161). In contrast, UL47-deleted BoHV-1 was not defective in nuclear egress (179). 
Moreover, HSV-1 VP13/14 forms a complex with VP16 or alpha-transducing factor (α-tTIF), and 
VP13/14-deleted HSV-1 was unable to induce immediate early promoter-mediated reporter gene 
expression (96, 383). However, BoHV-1 VP8 is did not have such function, as mRNA transcript 
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of bICP4 was detected at a similar level in BoHV-1-, BoHV-1ΔUL47- and BoHV-1UL47R-
infected cells (179).     
 Next we demonstrated the mechanism by which VP8 down-regulates IFN-β signaling. 
Binding of IFN-α/β to its corresponding receptors, IFNAR1 and IFNAR2 subunits activates the 
JAK/STAT signaling pathway. This binding initiates cascades of signaling responses to 
phosphorylate STAT1 and STAT2. A STAT1/2 homodimer then translocates to the nucleus to 
form a heterotrimeric complex. The heterotrimeric complex associates with the interferon 
response element to stimulate IFN production (373). With the entrance of BoHV-1 into host cells, 
the viral tegument proteins including VP8 and capsid are dissociated in the cytoplasm (66). This 
dissociation brings VP8 in contact with the host cytoplasmic proteins. We observed that VP8 
interacted with cellular STAT1 in both VP8-transfected and BoHV-1-infected cells. VP8 
interacted with STAT1 using two domains, amino acids 259-482 and 632-686. The predicted 
secondary structure of VP8 revealed that the VP8 C-terminal domain is enriched with alpha-
helical structures. The alpha-helical structures of a protein are associated with protein-protein 
interactions (384). Hence, the domain of VP8 containing alpha-helices facilitates VP8 and STAT 
interaction. Association of VP8 with STAT1 did not interfere with ubiquitination or degradation 
of STAT1. However, the interaction of VP8 with STAT1 prevented nuclear translocation of 
STAT1 in BoHV-1- and BoHV-1UL47R-infected cells, whereas STAT1 was localized to the 
nucleus in BoHV-1ΔUL47-infected cells. Importantly, the inhibition of STAT1 translocation is 
mediated through the interacting domains of VP8, amino acids 259-482 and 632-.686. With 
regards to cytoplasmic retention of STAT1 by VP8, subcellular fractionation of BoHV-1-infected 
cells at different time points also supported that VP8 and STAT1 are localized in the cytoplasm. 
 Viruses adapt multiple strategies to antagonize type I IFN signaling through interactions 
with the cellular proteins, STAT1 or STAT2. For instance, simian virus 5 (SV5) targets STAT1 
for ubiquitination and degradation to inhibit IFN signaling (386). Conversely, mumps virus V 
protein exhibits its antiviral activity through STAT1 degradation, as well as through prevention 
of STAT1 translocation into the nucleus (378).  Consequently, mumps virus V protein impedes 
IFN-β signaling. Similarly, VP8 alters the translocation of STAT1 to interfere with the IFN-β 
signaling. However, the mechanism whereby VP8 retains STAT1 remains unclear. STAT1 
contains a DNA binding domain and a coiled-coil domain. Previously, it was shown that the 
mutation or alteration in the integrity of the DNA binding domain or coiled-coil domain was 
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associated with the retention of STAT1 in the cytoplasm (393). Moreover, preventing binding of 
STAT1 NLS with importin-α disrupts STAT1 accumulation into the nucleus (392). Similarly, the 
rabies virus P protein binds with the coiled-coil or DNA-binding domain and subsequently, 
prohibits STAT1 translocation into the nucleus. Conceivably, binding of VP8 with STAT1 either 
interferes with the importin-α and STAT1 binding or with the coiled-coil or DNA binding 
domain function of STAT1. Thus, VP8 might alter the nuclear transport mechanism of STAT1 to 
interfere with STAT1 translocation. In macrophages and dendritic cells, activation of the 
JAK/STAT signaling pathway prevents HSV-1 replication. However, blocking this pathway 
supports HSV-1 replication (449). Thus, impeding IFN signaling promotes HSV-1 replication 
(449). Likewise, since BoHV-1ΔUL47 is defective in replication in cell culture and unable to 
replicate in cattle (179), VP8 promotes BoHV-1 replication by preventing IFN signaling. VP8 
was observed in the cytoplasm as early as 2 h post infection and prevented nuclear accumulation 
of STAT1. Thus, the prevention of nuclear import of STAT1 by VP8 at early infection 
counteracted the establishment of the antiviral state to promote BoHV-1 replication. This is in 
agreement with the fact that a VP8-deleted mutant is avirulent in vivo (179). 
 Another potential function of VP8 that we determined is the interference in the DDR 
pathway during BoHV-1 infection. VP8 interacted with DDR proteins, ATM and NBS1. ATM is 
the key player in the DDR pathway. Upon detection of the presence of DNA damage, ATM is 
activated by phosphorylation at serine-1981. The activated ATM, in turn, triggers 
phosphorylation of the DDR downstream targets, such as NBS1 or SMC1 to coordinate DNA 
repair, cell cycle arrest, or apoptosis (265). We observed that the interaction VP8 with ATM did 
not interfere with ATM phosphorylation. However, the interaction of VP8 with NBS1 blocked 
NBS1 phosphorylation. SMC1 is another downstream target of ATM, and also gets 
phosphorylated by ATM. However, the phosphorylation of SMC1 is dependent on NBS1 
phosphorylation (398). As VP8 impeded NBS1 phosphorylation, the SMC1 phosphorylation was 
also inhibited by VP8. Since VP8 immunoprecipitates both ATM and NBS1 as a complex, VP8 
might block ATM and NBS1 interaction to inhibit the phosphorylation of NBS1 and thereby, 
prevent SMC1 phosphorylation. Inhibition of NBS1 and SMC1 phosphorylation was observed in 
both BoHV-1- and BoHV-1UL47R-infected cells but not in BoHV-1ΔUL47-infected cells, clearly 
indicating the involvement of VP8 in the prohibition of NBS1 and SMC1 phosphorylation. At the 
beginning of infection, at 2 h post infection, NBS1 and SMC1 were phosphorylated. At this pint 
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VP8 was present in the cytoplasm. VP8 contains a NLS, with the progression of infection VP8 
was localized to the nucleus. VP8 was observed in the nucleus at 4 h post infection. Researchers 
reported that with the incoming HSV-1 virus genome, the DDR pathway gets activated (271).  
Phosphorylation of NBS1 or SMC1 at early infection can be the result of incoming virus 
particles. However, at 4 h post infection when VP8 was localized to the nucleus, no 
phosphorylation of NBS1 or SMC1 was observed, indicating an involvement of nuclear VP8 in 
the inhibition of NBS1 and SMC1 phosphorylation. Some viruses evolved unique strategies to 
counteract host cell responses, while others hijack and manipulate DDR pathway for viral 
propagation and replication. HSV-1 infection activates the ATM pathway (274), which is 
different from BoHV-1 infection.  However, the ATR pathway, another major DDR signaling 
component is inhibited by HSV-1 infection (281). Besides, murine gamma herpesvirus 68 
(γHV68) M2 protein interacts with ATM. Although this interaction triggers ATM activation, it 
blocks ATM downstream signaling (403).  Adenovirus also deregulates the DDR machinery by 
reorganizing the MRN complex to favor viral genome processing (420). Hence, different viral 
proteins manipulate distinct or overlapping mechanisms for the accomplishment of virus 
propagation. 
 SMC1 phosphorylation contributes to S-phase checkpoint activation to facilitate DNA 
repair (416). Since VP8 prevented SMC1 phosphorylation, UV-induced damaged DNA repair 
was inhibited by VP8. Similarly, homologous recombination-mediated DNA repair was 
abrogated during HSV-1 infection (273). Since reduced cell viability is associated with inhibition 
of SMC1 phosphorylation and DNA repair (416), VP8-induced apoptotic cell death was observed 
in VP8-expressing cells. Moreover, UV- or etoposide-induced DNA damage increased DNA 
damage-induced apoptosis in VP8-expressing cells. Consequently, the BoHV-1-infected cells 
were more apoptotic than BoHV-1ΔUL47-infected cells. Researchers demonstrated that UV-
induced DNA damage triggered the intrinsic apoptosis pathway through activation of caspase 3 
in repair-deficient cells (418). Likewise, VP8 prevented DNA repair and triggered cleavage of 
procaspase 3 and activation of caspase 3 to induce apoptosis. Moreover, multiple researchers 
demonstrated that BoHV-1 induced apoptosis through caspase 3 activation (355, 359, 362), 
supporting the contention that VP8 triggers apoptosis through caspase 3 activation. These 
findings are in line with increased apoptosis in BoHV-1-infected cells, where cells are exposed to 
a large amount of replicating viral DNA or abnormal DNA structures. While different viruses 
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express some anti-apoptotic proteins to promote viral pathogenesis, some viruses encode pro-
apoptotic proteins to manipulate the cellular machinery for efficient virus production. For 
instance, human immune deficiency virus (HIV) stimulates pro-apoptotic gene expression for 
maximal virus production (424), and influenza virus triggers pro-apoptotic factors for efficient 
virus replication. Moreover, HSV-1 ICP0 induces apoptosis during infection (422, 423). 
Furthermore, BoHV-1 is known to induce apoptosis through multiple protein functions (355, 359, 
364). Because of the fact that BoHV-1ΔUL47 infection demonstrated 1000-fold reduced 
extracellular infectious virus particles compared to BoHV-1 infection, VP8 might contribute to 
the release of virus particles through induction of apoptosis. The purpose of reshaping the DDR 
pathway by VP8 might be to block ATM signaling and thus, circumvent host surveillance. For 
instance, during HSV-1 infection the ATR pathway is impaired in order to facilitate 
recombination-dependent repair and to promote virus replication (280, 282). Eventually, the 
inhibition of DDR by VP8 triggers apoptosis possibly to expedite the release of infectious virions 
into the extracellular environment. Although BoHV-1 is released into the extracellular 
environment by exocytosis (450), in BoHV-1ΔUL47 infected cells the extracellular virus titer was 
reduced to approximately 1000-fold (179). This suggests that the induction of apoptosis by VP8 
might accelerate infectious virion release. 
 Since VP8 is involved in carrying out multiple functions during productive infection, 
and its homologous proteins are present in other herpesviruses, we attempted to crystalize VP8. 
However, the challenge resided with the large-scale full-length or truncated VP8 production in 
both prokaryotic and mammalian expression systems. The predicted secondary structure revealed 
that VP8 is a large protein with mostly alpha-helical structures at its C-terminal domain. The 
alpha-helical structures of a protein are predominantly involved in protein-protein interaction 
(437). With the notion that VP8 is involved in multiple functions via protein-protein interaction, 
we aimed to get the crystal structure of the C-terminal domain of VP8 (amino acid 219-741). 
Finally, modification of C-terminal VP8 with the SUMO-His tag facilitated prokaryotic 
expression. However, VP8 was complexed with the bacterial GroEL protein during bacterial 
expression that led us to identify another interacting partner of VP8, HSP60. With the aim of 
obtaining the structure of VP8 and GroEL as a complex, we proceeded for crystallization 
screening with the method suitable for soluble protein crystallization. Nevertheless, no suitable 
condition for VP8 crystallization was observed. There could be one plausible explanation of not 
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getting crystal structure of VP8. Recent predicted secondary structure analysis of VP8 showed 
that VP8 has some hydrophobic domains. This may explain the difficulties in expression and 
subsequent purification of VP8. Notably, a membrane protein crystallization approach instead of 
soluble protein crystallization might promote VP8 crystallization. 
 Subsequently, we determined that VP8 interacts with a mitochondrial protein, HSP60. In 
both VP8-transfected and BoHV-1-infected cells, VP8 interacted with HSP60 and localized to 
mitochondria. The amino acids 219-741 of the C-terminal domain of VP8 were required for 
interaction with HSP60, as well as mitochondrial localization. During BoHV-1 infection, VP8 
was localized to mitochondria at 2 h post infection. The localization of VP8 to mitochondria at 2 
h post infection can be attributed to two facts. First, some viral proteins localize to mitochondria 
at early stages of infection to be transported to the nucleus. The HSV-1 tegument protein UL41 
also localizes to mitochondria and is transported to the perinuclear region (432).  Likewise, early 
during BoHV-1 infection, VP8 likely migrates to the perinuclear region through localization to 
mitochondria. Second, HSP60 functions as a chaperone protein and is involved in protein folding 
(451). Given the role of HSP60 in protein folding, it is conceivable that the interaction of VP8 
with mitochondrial HSP60 might regulate VP8 folding or expression. Nonetheless, the later 
explanation can be eliminated since knocking down of HSP60 does not alter VP8 expression 
pattern. With the progression of infection, VP8 is exported from the nucleus to the cytoplasm. At 
2-6 h post infection, VP8 is translocated to the mitochondria.  Zhang, 2017 (PhD thesis) indicated 
that around 6 h post infection VP8 was localized to a distinct compartment before accumulation 
in the Golgi apparatus (452). This may correlate with mitochondrial localization of VP8 at 6 h 
post infection. Upon investigation into the mitochondrial function in the presence of VP8, we 
observed that VP8 reduced MMP. Since proper maintenance of MMP is associated with proper 
mitochondrial function and ATP production (125), we observed that VP8 also reduced ATP 
production. Additionally, BoHV-1 infection significantly reduced MMP and ATP production, 
whereas BoHV-1ΔUL47 infection did not influence the MMP or ATP production. BoHV-1 and 
HSV-1 are known to decrease mitochondrial membrane potential and to reduce ATP production, 
which is in line with our observations (363, 432). Hence, during BoHV-1 infection, 
mitochondria-localized VP8 contributed to the deregulation of mitochondrial function. Different 
viruses are known target mitochondria for their replication, survival, and escape from the cells. 
HCV proteins localized to mitochondria deregulate mitochondrial function by reducing MMP 
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and increasing ROS (443). Similarly, HIV Vpr localized to mitochondria and decreased MMP 
(444). Therefore, it is plausible that BoHV-1 VP8 targets mitochondria for deregulation of 
mitochondrial functions. Impaired mitochondrial functions such as reduced MMP, increased ROS 
production, and decreased ATP production are involved in induction of apoptosis (453). Since 
VP8 induces apoptosis, dysregulation of mitochondrial function by VP8 might promote induction 
of apoptosis during virus infection.  
 Overall, this research demonstrated that BoHV-1 VP8 is involved in multiple functions 
that were associated with the subcellular localization of VP8. After fusion of BoHV-1 
glycoproteins with the host cell membrane receptors, VP8 from the tegument region of BoHV-1 
is released into the host cytoplasm. The cytoplasmic VP8 then interacts with cellular STAT1 to 
retain it in the cytoplasm. This interaction of VP8 with STAT1 during early infection inhibits 
IFN-β signaling possibly to create an environment suitable for virus infection. As the infection 
progresses, VP8 translocates to the nucleus. In the nucleus, VP8 interacts with ATM and NBS1 
to modulate the DDR pathway. The interaction of VP8 with ATM and NBS1 does not influence 
ATM activation but prohibits NBS1 and SMC1 phosphorylation, which eventually blocks DNA 
repair. This inhibition of DNA repair increases the accumulation of unrepaired DNA, which 
eventually led to the activation of the apoptotic pathway. Upon completion of the nuclear 
function, VP8 is exported out of the nucleus. During infection, VP8 is also localized to the 
mitochondria. Localization of VP8 to mitochondria is mediated through interaction with 
mitochondrial chaperone protein HSP60. The interaction of VP8 with mitochondrial HSP60 
induces mitochondrial dysfunction by reducing MMP and by decreasing ATP production. 
Eventually, VP8 activates apoptotic pathway through caspase-3 activation to induce apoptosis. 
Finally, VP8 accumulates in the Golgi apparatus (shown in a separate study by Zhang et al 
Thesis, 2017), where packaging of VP8 into the virus particles takes place. With the final 
incorporation of VP8 into the virion, the virus leaves the host cell for subsequent infection. 
During subsequent infection, the incorporated VP8 will function as incoming VP8 to modulate 
the cellular environment.  
 In summary, we have demonstrated that VP8 functions to down-regulate IFN-β 
signaling, and to promote apoptosis in addition to its already identified essential roles in virus 
DNA encapsidation and virion incorporation. It is evident that VP8 is capable of carrying out 
multiple pro-viral functions. Continued functional characterization of VP8 may aid in 
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understanding its role in BoHV-1 pathogenesis. Additionally, structural characterization of VP8 
may provide molecular detail into the function of VP8 or other homologous proteins, as well.  
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Figure. 8.1 Summary of VP8-assocatied functions during BoHV-1 infection 
VP8-associated functions during BoHV-1 infection are outlined here. The cellular cytoplasm, 
nucleus, mitochondria, and Golgi apparatus are illustrated. Firstly, the BoHV-1 envelope is fused 
with the host cell plasma membrane. Following fusion, the capsid and tegument proteins 
including VP8 referred to as incoming VP8, are released into the host cell cytoplasm. Incoming 
VP8 in the cytoplasm binds to STAT1 to block IFN-β signaling. Some VP8 also localizes to 
mitochondria. During BoHV-1 infection de novo VP8 is synthesized and translocated to the 
nucleus. In the nucleus, VP8 has the potential to disrupt the ATM/NBS1/SMC1 pathway, inhibit 
DNA repair, leading to accumulation of unrepaired DNA. Subsequently, this triggers apoptosis. 
Later during infection, VP8 is exported to the cytoplasm. In the cytoplasm, VP8 is localized to 
the mitochondria to deregualte mitochondrial function. In addition, VP8 is accumulated in the 
Golgi apparatus to be incorporated into the progeny virus. Finally, the complete virions with 
abundantly incorporated VP8 are released into the extracellular environment. The infectious 
virions are ready for subsequent infection.   
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8.3      Future Directions. 
 In BoHV-1-infected cells, the fusion of the viral envelope with the host cell membrane 
releases the tegument proteins into the cytoplasm. Thus, at the pre-immediate-early stage of 
BoHV-1 infection VP8 is released into the cytoplasmic compartment. Following initiation of the 
infection, VP8 interacts with STAT1 to retain it in the cytoplasm to counteract IFN response. 
However, the mechanism of STAT1 retention by VP8 remains unknown. STAT1 contains coiled-
coil and DNA-binding domains, which have been found to be necessary for the navigation of 
STAT1 into the nucleus (394, 454). Viral proteins, for instance, rabies virus P protein, binds to 
the coiled-coil and DNA-binding domains of STAT1 to inhibit its translocation into the nucleus 
(374). In the future, the introduction of mutations in the coiled-coil or DNA binding domain of 
STAT1 would help us to explore the possible mechanism of STAT1 retention in the cytoplasm 
by VP8. Besides, nuclear import of STAT1 is also associated with the NLS-dependent binding 
with importin-α. Any interference with the STAT1 NLS and importin-α binding prohibits nuclear 
accumulation of STAT1 (392). Hence, the interaction of VP8 with STAT1 can disrupt binding of 
STAT1 and importin-α to keep STAT1 in the cytoplasm. Future experiments can be planned to 
investigate the association of STAT1 with importin-α in the presence or in the absence of VP8. 
 VP8 is known to interact with cellular DDB1 and STAT1 (187). Thus, VP8 tends to 
interact with several proteins including DDR proteins, ATM and NBS1, to modulate the DDR 
pathway. DDB1 has been found to be associated with a complex with DDR protein, ATM and 
viral protein (404). However, during BoHV-1 infection, whether the interaction of VP8 with 
these multiple proteins is DDB1-dependent or -independent remains to be determined. Therefore, 
future research in DDB1-knockout bovine cell lines will resolve this issue. In this regard, the 
crisper/cas9 system can be used to knockout DDB1. The DDB1-knockout cell lines can be tested 
for VP8-associated interactions and functions during BoHV-1 infection. Besides, similar 
strategies can be used to knock out cellular STAT1. STAT1-knockout cell lines can be tested for 
VP8-mediated functions, such as VP8 and DDB1 or ATM interaction, or inhibition of NBS1 or 
SMC1 phosphorylation. Thus, these experiments will determine whether these VP8-associated 
functions are STAT1-dependent or -independent.  
               Previous and current research demonstrates that VP8 is involved in protein-protein 
interaction for its functions. The C-terminal domain of VP8 is enriched with alpha-helical 
structures, which promotes protein-protein interactions (405). Therefore, in this study, we 
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attempted to crystallize the C-terminal domain of VP8 using soluble protein crystallization. 
However, given the fact that there was no condition suitable for VP8 crystallization, we obtained 
information that can be implemented in future crystallization approaches. For example, recent 
predicted secondary structure analysis revealed that VP8 contains some transmembrane domains. 
This might explain the difficulties in expression and purification of VP8, as well as in obtaining 
highly concentrated VP8. Thus, future research can focus on crystallization of VP8 using 
membrane protein crystallization instead of soluble protein crystallization approach. Finally, the 
tertiary structure of VP8 will provide information towards synthesizing a potential inhibitor. 
               Following BoHV-1 challenge or immunization with purified VP8, T cell proliferation 
and antibody production were stimulated (181). Recent research also demonstrated that HSV-1 
VP13/14, the homolog of BoHV-1 VP8, is a tegument antigen recognized by CD8+T cells. 
Epitope mapping and subsequent immunological analysis indicated that the C-terminal domain of 
HSV-1 VP13/14 is immunogenic (455).  However, the antigenic properties of various BoHV-1 
VP8 domains remain to be determined. In this regard, the full-length and truncated VP8 versions 
can be tested for VP8 domain-specific immunogenic properties. Therefore, in future, the 
combination of structural analysis of truncated VP8, and the use of different truncated VP8 
versions as vaccine candidates will provide information towards vaccine development against 
BoHV-1 infection.  
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